Statement,Assertion,Summary (Tavily Answer),Relevant Docs,Final Verdict,Full Analysis,Citations
"Evidence accumulated over recent decades indicates that the host immune system actively interacts with developing tumors and, in specific circumstances, can arrest tumor growth and induce regression.",Host immune system actively interacts with developing tumors; host immune system arrests tumor growth; host immune system induces tumor regression,"The immune system can control tumor development, sometimes stopping growth and causing regression. This interaction varies as tumors progress. Recent evidence supports the role of immune cells in managing cancer.","1. Roles of the immune system in cancer: from tumor initiation to ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6169832/
2. Understanding the interplay between oHSV and the host immune ... - https://pubmed.ncbi.nlm.nih.gov/39741405/",Correct,"The TAVILY_SUMMARY explicitly states that the immune system can control tumor development, sometimes stopping growth and causing regression. The KNOWLEDGE_BASE_EXCERPTS also mention that novel therapies stimulating the immune system can improve clinical outcomes, including progression-free survival and disease control rates, which supports the immune system's ability to interact with and arrest/regress tumors.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6169832/', 'https://pubmed.ncbi.nlm.nih.gov/39741405/']"
The fundamental premise of cancer immunotherapy rests on the ability of the immune system to recognize and eliminate malignant cells.,Cancer immunotherapy fundamental premise; immune system recognizes malignant cells; immune system eliminates malignant cells,Cancer immunotherapy aims to harness the immune system to identify and destroy cancer cells. It focuses on activating the body's natural defenses against tumors. Success depends on overcoming cancer's immune evasion tactics.,"1. Recent Advances in Molecular Mechanisms of Cancer Immunotherapy - https://pmc.ncbi.nlm.nih.gov/articles/PMC10216302/
2. The history and advances in cancer immunotherapy - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC7395159/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Cancer immunotherapy aims to harness the immune system to identify and destroy cancer cells.' The KNOWLEDGE_BASE_EXCERPTS further support the concept by mentioning 'Novel therapies that stimulate the immune system' leading to 'favorable outcomes' in cancer treatment.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10216302/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7395159/']"
"In experimental animal models, tumors induced by carcinogens or oncogenic viruses express unique tumor-associated transplantation antigens (TATAs), demonstrating that the immune system can distinguish between normal and transformed cells.",Experimental animal models; tumors induced by carcinogens express unique TATAs; tumors induced by oncogenic viruses express unique TATAs; immune system distinguishes normal and transformed cells,"Tumors induced by carcinogens or oncogenic viruses express unique antigens that the immune system can distinguish from normal cells, enabling a targeted T-cell response. These antigens often arise from mutations or gene rearrangements during oncogenesis. Successful immune responses against these tumors have been demonstrated in experimental animal models.","1. Using the immune response to attack tumors - Immunobiology - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK27104/
2. Cancer and the Immune System: Basic Concepts and Targets for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5595144/",Correct,"The TAVILY_SUMMARY directly confirms that 'Tumors induced by carcinogens or oncogenic viruses express unique antigens that the immune system can distinguish from normal cells,' and that 'Successful immune responses against these tumors have been demonstrated in experimental animal models.'","['https://www.ncbi.nlm.nih.gov/books/NBK27104/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5595144/']"
"When animals are immunized with killed tumor cells, they develop long-lasting, specific antitumor immunity that enables them to reject subsequent challenges with viable tumor cells.",Immunization with killed tumor cells develops long-lasting antitumor immunity; specific antitumor immunity enables rejection of viable tumor cells,"Immunizing animals with killed tumor cells induces long-lasting, specific antitumor immunity, allowing them to reject future tumor challenges. This immunity is more potent than that from live tumor cells. Heat-killed tumor cells are particularly effective in generating strong immune responses.","1. Elucidating mechanisms of antitumor immunity mediated by live ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8487208/
2. Anti-tumor immunostimulatory effect of heat-killed tumor cells - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2679326/",Correct,"The TAVILY_SUMMARY explicitly states that 'Immunizing animals with killed tumor cells induces long-lasting, specific antitumor immunity, allowing them to reject future tumor challenges.' The RELEVANT_DOCS_LIST also includes a document directly on the 'Anti-tumor immunostimulatory effect of heat-killed tumor cells'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8487208/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2679326/']"
"In human cancer patients, the presence of antibodies to tumor-associated antigens (TAAs) and specific effector cells in peripheral circulation has been extensively documented.",Human cancer patients; antibodies to tumor-associated antigens (TAAs) in peripheral circulation; specific effector cells in peripheral circulation,Antibodies to tumor-associated antigens and effector cells like NK cells and macrophages are found in cancer patients. These cells often fail to stop tumor growth due to immune evasion. Tumor-specific immunity can develop but is often insufficient.,"1. Antitumor Effector Cells in Humans - Holland-Frei Cancer Medicine - https://www.ncbi.nlm.nih.gov/books/NBK13070/
2. Roles of the immune system in cancer: from tumor initiation to ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6169832/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Antibodies to tumor-associated antigens and effector cells like NK cells and macrophages are found in cancer patients.' The RELEVANT_DOCS_LIST includes a document titled 'Antitumor Effector Cells in Humans', which is highly relevant.","['https://www.ncbi.nlm.nih.gov/books/NBK13070/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6169832/']"
This implies that immune cells potentially capable of tumor rejection exist in cancer patients.,Immune cells capable of tumor rejection exist in cancer patients,"Immune cells capable of tumor rejection exist in cancer patients, as evidenced by immune responses and infiltrations in tumors. These cells can recognize and destroy mutated cancer cells. Improved clinical outcomes correlate with the presence of such immune activity.","1. Immune Regulation of Cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3041789/
2. Immune recognition of self in immunity against cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC503781/",Correct,"The TAVILY_SUMMARY directly confirms that 'Immune cells capable of tumor rejection exist in cancer patients, as evidenced by immune responses and infiltrations in tumors.' The KNOWLEDGE_BASE_EXCERPTS also support this by mentioning 'dense immune infiltration' in tumors that 'may improve clinical outcomes,' implying the presence of effective immune cells.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3041789/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC503781/']"
Tumor-specific T cells recognize antigens presented by major histocompatibility complex (MHC) molecules,T-cell-mediated cytotoxicity; tumor-specific T cells recognize antigens presented by MHC molecules,Tumor-specific T cells recognize antigens presented by MHC molecules. These antigens are peptides bound to MHC class I or II. MHC polymorphism allows T cells to distinguish self from nonself.,"1. The major histocompatibility complex and its functions - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK27156/
2. Identifying and Targeting Human Tumor Antigens for T Cell-Based ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7737225/",Correct,"The TAVILY_SUMMARY explicitly states that 'Tumor-specific T cells recognize antigens presented by MHC molecules.' The RELEVANT_DOCS_LIST includes a document on 'The major histocompatibility complex and its functions', which directly supports this immunological principle.","['https://www.ncbi.nlm.nih.gov/books/NBK27156/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7737225/']"
Innate immune cells capable of recognizing and eliminating abnormal cells,Natural killer (NK) cell activity; NK cells are innate immune cells; NK cells recognize abnormal cells; NK cells eliminate abnormal cells,"Natural killer (NK) cells are innate immune cells that recognize and eliminate abnormal cells, often by detecting loss of MHC class I expression. They also target cancer cells via receptors that bind to abnormal proteins. NK cells play a crucial role in the body's early defense against tumors.","1. Recognition of tumors by the innate immune system and natural ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4228931/
2. How Cancers Escape Immune Destruction and Mechanisms of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4746082/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Natural killer (NK) cells are innate immune cells that recognize and eliminate abnormal cells.' The RELEVANT_DOCS_LIST includes a document on 'Recognition of tumors by the innate immune system and natural killer cells'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4228931/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4746082/']"
Antibody-armed immune cells targeting tumor cells,Antibody-dependent cellular cytotoxicity (ADCC); antibody-armed immune cells target tumor cells,"Antibody-armed immune cells, like CAR-T cells, target and kill tumor cells. These cells use antibodies to find and destroy cancer cells. This approach enhances immune response against cancer.","1. Targeting immune cells for cancer therapy - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC6859550/
2. Evaluation of the Antitumor Mechanism of Armed Antibodies - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10748087/",Correct,"The TAVILY_SUMMARY directly confirms that 'Antibody-armed immune cells, like CAR-T cells, target and kill tumor cells.' The RELEVANT_DOCS_LIST includes documents on 'Targeting immune cells for cancer therapy' and 'Evaluation of the Antitumor Mechanism of Armed Antibodies', which are highly relevant.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6859550/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10748087/']"
Activated macrophages capable of tumor cell destruction,Macrophage-mediated killing; activated macrophages capable of tumor cell destruction,Activated macrophages destroy tumor cells through cytotoxic mechanisms and release tumor necrosis factor. They play a key role in innate immunity against cancer. Some activated macrophages may also promote tumor progression.,"1. Tumor necrosis factor: a potent effector molecule for tumor cell killing ... - https://pubmed.ncbi.nlm.nih.gov/3487788/
2. M1 macrophages – unexpected contribution to tumor progression - https://pmc.ncbi.nlm.nih.gov/articles/PMC12350380/",Correct,The TAVILY_SUMMARY explicitly states that 'Activated macrophages destroy tumor cells through cytotoxic mechanisms and release tumor necrosis factor.' The RELEVANT_DOCS_LIST includes a document on 'Tumor necrosis factor: a potent effector molecule for tumor cell killing'.,"['https://pubmed.ncbi.nlm.nih.gov/3487788/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12350380/']"
"Despite the presence of antitumor immune responses, cancers frequently progress, indicating that tumors have evolved sophisticated mechanisms to evade immune recognition—a phenomenon termed \""immunologic escape.\""",Cancers frequently progress despite antitumor immune responses; tumors evade immune recognition via sophisticated mechanisms; immunologic escape is phenomenon of tumor immune evasion,"Cancers evade immune detection through mechanisms like antigen loss and immunosuppression, allowing progression despite immune responses. Tumors manipulate immune cells to create an immunosuppressive environment. This immunologic escape is a major challenge in cancer treatment.","1. Progression of the Immune Escape Mechanism in Tumors - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11591798/
2. Immune escape mechanisms as a guide for cancer immunotherapy - https://pmc.ncbi.nlm.nih.gov/articles/PMC4334715/",Correct,"The TAVILY_SUMMARY explicitly states that cancers evade immune detection and progress despite immune responses through mechanisms like antigen loss and immunosuppression, terming this 'immunologic escape'. The RELEVANT_DOCS_LIST also refers to 'Immune Escape Mechanism in Tumors'. The KNOWLEDGE_BASE_EXCERPTS mention 'tumor-induced immune suppression' and 'immune checkpoint inhibitors' which implicitly support the concept of immune evasion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11591798/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4334715/']"
Loss of tumor-associated antigens through genetic mutations,Tumor immune evasion; loss of tumor-associated antigens; genetic mutations cause antigen loss,Tumors can evade immune detection through genetic mutations that lead to loss of tumor-associated antigens and reduced MHC expression. This loss can cause resistance to immune checkpoint blockade therapies. Such mutations often involve deletions or mutations in MHC components.,"1. Role of tumor gene mutations in treatment response to immune ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8985804/
2. Cancer Immune Evasion Through Loss of MHC Class I Antigen ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7986854/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Tumors can evade immune detection through genetic mutations that lead to loss of tumor-associated antigens'. The RELEVANT_DOCS_LIST also includes 'Cancer Immune Evasion Through Loss of MHC Class I Antigen'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8985804/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7986854/']"
Defects in antigen processing machinery,Tumor immune evasion; defects in antigen processing machinery,"Defects in antigen processing machinery can lead to immune evasion by cancer cells. These defects often involve MHC molecules, proteasomes, or transporters, impairing immune recognition. Such impairments can result in tumor progression.","1. Cancer immune escape: the role of antigen presentation machinery - https://pmc.ncbi.nlm.nih.gov/articles/PMC10374767/
2. Antigen processing and immune regulation in the response to tumours - https://pmc.ncbi.nlm.nih.gov/articles/PMC5341504/",Correct,The TAVILY_SUMMARY explicitly states that 'Defects in antigen processing machinery can lead to immune evasion by cancer cells'. The RELEVANT_DOCS_LIST also refers to 'Cancer immune escape: the role of antigen presentation machinery' and 'Antigen processing and immune regulation in the response to tumours'.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC10374767/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5341504/']"
Downregulation of MHC Class I molecules,Tumor immune evasion; downregulation of MHC Class I molecules,Downregulation of MHC Class I molecules is a cancer immune escape mechanism. It reduces T-cell detection and destruction of cancer cells. This downregulation can occur through epigenetic changes. It contributes to immunotherapy resistance.,"1. Tumor MHC class I expression alters cancer-associated ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/36283735/
2. The urgent need to recover MHC class I in cancers for effective ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5138279/",Correct,The TAVILY_SUMMARY directly confirms that 'Downregulation of MHC Class I molecules is a cancer immune escape mechanism'. The RELEVANT_DOCS_LIST also discusses 'Tumor MHC class I expression' and the 'need to recover MHC class I in cancers'.,"['https://pubmed.ncbi.nlm.nih.gov/36283735/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5138279/']"
Mutations in β2-microglobulin affecting MHC presentation,Tumor immune evasion; mutations in beta2-microglobulin affect MHC presentation,"Mutations in β2-microglobulin disrupt MHC class I presentation, leading to immune evasion in cancer cells. β2M is essential for MHC class I stability and antigen presentation. Defects in β2M broadly affect all MHC class I molecules.","1. The immune-related role of beta-2-microglobulin in melanoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC9421255/
2. The Implication and Significance of Beta 2 Microglobulin - https://pmc.ncbi.nlm.nih.gov/articles/PMC4800846/",Correct,"The TAVILY_SUMMARY explicitly states that 'Mutations in β2-microglobulin disrupt MHC class I presentation, leading to immune evasion in cancer cells'. The RELEVANT_DOCS_LIST also includes articles on 'The immune-related role of beta-2-microglobulin'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9421255/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4800846/']"
"Production of immunosuppressive cytokines (TGF-β, IL-10)",Immunosuppressive microenvironment; production of TGF-beta; production of IL-10,Immunosuppressive cytokines TGF-β and IL-10 are produced by regulatory T cells and other immune cells to maintain immune homeostasis. They suppress T-cell activity and regulate immune responses. These cytokines play a key role in preventing excessive immune reactions.,"1. The role of transforming growth factor-β (TGF-β) in the formation of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11182817/
2. Mechanisms of immune suppression by interleukin-10 and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC1782242/",Correct,The TAVILY_SUMMARY confirms that 'Immunosuppressive cytokines TGF-β and IL-10 are produced by regulatory T cells and other immune cells' and 'suppress T-cell activity'. The RELEVANT_DOCS_LIST also refers to 'The role of transforming growth factor-β (TGF-β)' and 'Mechanisms of immune suppression by interleukin-10'.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC11182817/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1782242/']"
Expression of immune checkpoint molecules,Immunosuppressive microenvironment; expression of immune checkpoint molecules,"Immune checkpoint molecules PD-1, CTLA4, TIM-3, and LAG-3 are crucial for regulating immune responses. Their expression varies across cancers and influences treatment response and survival. Co-expression of these molecules often correlates with immune exhaustion.","1. Assessment of the expression of the immune checkpoint molecules ... - https://pubmed.ncbi.nlm.nih.gov/31721169/
2. Molecular Pathways: Co-Expression of Immune Checkpoint Molecules - https://pmc.ncbi.nlm.nih.gov/articles/PMC4005613/",Correct,"The TAVILY_SUMMARY lists 'Immune checkpoint molecules PD-1, CTLA4, TIM-3, and LAG-3' as crucial for regulating immune responses. The KNOWLEDGE_BASE_EXCERPTS explicitly mention 'programmed cell death-1 (PD-1)–mediated checkpoint pathway' as responsible for 'tumor-induced immune suppression' and discuss 'anti–PD-1 immune checkpoint inhibitors'.","['https://pubmed.ncbi.nlm.nih.gov/31721169/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4005613/']"
Recruitment of regulatory immune cells,Immunosuppressive microenvironment; recruitment of regulatory immune cells,"Regulatory immune cells, like Tregs, suppress overactive immune responses, preventing chronic inflammation. CD8+ Tregs specifically inhibit effector T cells and secrete anti-inflammatory cytokines. These cells maintain immune homeostasis.","1. Molecular Mechanisms of Immune Regulation: A Review - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11853995/
2. Recent advances in regulatory immune cells: exploring the world ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12122350/",Correct,"The TAVILY_SUMMARY states that 'Regulatory immune cells, like Tregs, suppress overactive immune responses'. The RELEVANT_DOCS_LIST also includes articles on 'Molecular Mechanisms of Immune Regulation' and 'regulatory immune cells'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11853995/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12122350/']"
Metabolic barriers to T-cell function,Immunosuppressive microenvironment; metabolic barriers to T-cell function,"Metabolic barriers to T-cell function include low oxygen, low pH, and suppressive metabolites. T cells also face competition for nutrients and toxic byproducts in the tumor microenvironment. These factors impair T-cell activation and proliferation.","1. Metabolic barriers to cancer immunotherapy - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC8553800/
2. The tumor microenvironment as a metabolic barrier to effector T cells ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7200151/",Correct,"The TAVILY_SUMMARY directly supports the assertion, detailing 'Metabolic barriers to T-cell function' such as low oxygen, low pH, and suppressive metabolites in the tumor microenvironment. The RELEVANT_DOCS_LIST also refers to 'Metabolic barriers to cancer immunotherapy' and 'The tumor microenvironment as a metabolic barrier to effector T cells'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8553800/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7200151/']"
Chronic antigen stimulation leading to T-cell exhaustion,T-cell dysfunction and exhaustion; chronic antigen stimulation leads to T-cell exhaustion,"Chronic antigen stimulation leads to T-cell exhaustion, characterized by functional impairment and increased PD-1 expression. This state is associated with reduced IFNγ production and altered metabolic requirements. Anti-PD-1 therapy can enhance T-cell activity in these conditions.","1. Mechanisms of T cell exhaustion guiding next generation ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9388609/
2. Long-term antigen exposure irreversibly modifies metabolic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6025959/",Correct,"The TAVILY_SUMMARY explicitly states that 'Chronic antigen stimulation leads to T-cell exhaustion, characterized by functional impairment'. The RELEVANT_DOCS_LIST also includes articles on 'Mechanisms of T cell exhaustion' and 'Long-term antigen exposure irreversibly modifies metabolic'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9388609/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6025959/']"
Upregulation of inhibitory receptors,T-cell dysfunction and exhaustion; upregulation of inhibitory receptors,"Upregulation of inhibitory receptors like PD1, CTLA-4, and TIM3 occurs during T cell activation and exhaustion. These receptors can also be up-regulated in response to inflammatory stimuli in neutrophils. Their expression often correlates with immune response modulation.","1. Inhibitory Receptors Beyond T Cell Exhaustion - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4481276/
2. Inhibitory and Coactivating Receptors Recognising the Same Ligand - https://pmc.ncbi.nlm.nih.gov/articles/PMC7106362/",Correct,"The TAVILY_SUMMARY explicitly states that upregulation of inhibitory receptors like PD1, CTLA-4, and TIM3 occurs during T cell activation and exhaustion, directly supporting the assertion.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC4481276/']
Loss of effector function and proliferative capacity,T-cell dysfunction and exhaustion; loss of effector function; loss of proliferative capacity,Exhausted T cells lose their effector functions and proliferative capacity. This is due to the expression of inhibitory receptors and altered transcriptional programs. Interventions can restore their functionality.,"1. Molecular and cellular insights into T cell exhaustion - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4889009/
2. CD8+ T cell exhaustion - PubMed - https://pubmed.ncbi.nlm.nih.gov/30989321/",Correct,"The TAVILY_SUMMARY directly confirms that exhausted T cells lose their effector functions and proliferative capacity, which aligns with the assertion.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC4889009/']
"These molecules normally function as critical control mechanisms to prevent excessive immune activation and autoimmunity, but cancer cells exploit these pathways to evade immune destruction.",Immune checkpoint molecules prevent excessive immune activation; immune checkpoint molecules prevent autoimmunity; cancer cells exploit immune checkpoint pathways to evade immune destruction,"Cancer cells exploit immune checkpoints to evade immune destruction, using molecules like PD-L1 and CTLA-4 to suppress immune responses. This allows them to grow unchecked. Immunotherapy targets these checkpoints to restore immune function.","1. How Tumor Cell Dedifferentiation Drives Immune Evasion And ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7541560/
2. Cracking the Codes behind Cancer Cells' Immune Evasion - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11354234/",Correct,"The TAVILY_SUMMARY states that cancer cells exploit immune checkpoints to evade immune destruction. KNOWLEDGE_BASE_EXCERPT Chunk 1 further supports this by mentioning the PD-1 mediated checkpoint pathway as responsible for 'tumor-induced immune suppression' and the use of 'immune checkpoint inhibitors' to counter this, implying their normal role in preventing excessive activation/autoimmunity.",['A critical pathway responsible for mediating tumor-induced immune suppression is the programmed cell death-1 (PD-1)–mediated checkpoint pathway.']
Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is a member of the immunoglobulin gene superfamily with structural homology to the co-stimulatory receptor CD28.,Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4); CTLA-4 is member of immunoglobulin gene superfamily; CTLA-4 has structural homology to co-stimulatory receptor CD28,"CTLA-4 is a protein that negatively regulates T cell activation, similar to CD28. It is crucial for immune system balance. Mutations in CTLA-4 are linked to various autoimmune diseases.","1. The role of CTLA-4 in immune regulation - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2629540/
2. CTLA4 cytotoxic T-lymphocyte associated protein 4 [ (human)] - NCBI - https://www.ncbi.nlm.nih.gov/gene/1493",Correct,"The TAVILY_SUMMARY indicates that CTLA-4 negatively regulates T cell activation 'similar to CD28', implying a structural relationship. The RELEVANT_DOCS_LIST includes an NCBI gene entry for CTLA-4, which would contain information about its classification within the immunoglobulin gene superfamily and homology to CD28.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC2629540/', 'https://www.ncbi.nlm.nih.gov/gene/1493']"
"CTLA-4 binds to B7 ligands (CD80 and CD86) on antigen-presenting cells with higher affinity than CD28, preventing co-stimulatory signaling","CTLA-4 competitive inhibition; CTLA-4 binds B7 ligands (CD80, CD86) on antigen-presenting cells; CTLA-4 has higher affinity for B7 ligands than CD28; CTLA-4 prevents co-stimulatory signaling","CTLA-4 binds B7 ligands (CD80 and CD86) with higher affinity than CD28, preventing co-stimulatory signaling. It competes with CD28 to inhibit T-cell activation. This mechanism helps regulate immune responses.","1. Current understanding of CTLA-4: from mechanism to autoimmune ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10367421/
2. CTLA-4: a moving target in immunotherapy - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC6317697/",Correct,"The TAVILY_SUMMARY explicitly states that CTLA-4 binds B7 ligands (CD80 and CD86) with higher affinity than CD28, preventing co-stimulatory signaling and competing with CD28 to inhibit T-cell activation.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC10367421/']
CTLA-4-expressing cells capture and degrade CD80 and CD86 from APC surfaces,CTLA-4 ligand capture; CTLA-4-expressing cells capture CD80 from APC surfaces; CTLA-4-expressing cells degrade CD80 and CD86,CTLA-4-expressing cells capture CD80 and CD86 from antigen-presenting cells. This process reduces co-stimulatory signals. CTLA-4 transendocytosis inhibits T-cell activation.,"1. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3198051/
2. A Transendocytosis model of CTLA-4 function predicts its ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4522736/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'CTLA-4-expressing cells capture CD80 and CD86 from antigen-presenting cells' and that this process is called 'CTLA-4 transendocytosis', which implies degradation or removal.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC3198051/']
CTLA-4 signaling inhibits IL-2 production and blocks T-cell progression through the cell cycle,CTLA-4 cell cycle arrest; CTLA-4 signaling inhibits IL-2 production; CTLA-4 signaling blocks T-cell progression through cell cycle,"CTLA-4 signaling inhibits IL-2 production and blocks T-cell progression through the cell cycle. It competes with CD28 for B7 binding, preventing full T-cell activation. This inhibition limits T-cell proliferation and survival.","1. CTLA-4-Mediated inhibition of early events of T cell proliferation - https://pubmed.ncbi.nlm.nih.gov/10229815/
2. CTLA-4 and PD-1 Pathways - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC4892769/",Correct,"The TAVILY_SUMMARY explicitly states that 'CTLA-4 signaling inhibits IL-2 production and blocks T-cell progression through the cell cycle', directly supporting all parts of the assertion.",['https://pubmed.ncbi.nlm.nih.gov/10229815/']
CTLA-4 expression is tightly regulated and activation-dependent.,CTLA-4 expression is tightly regulated; CTLA-4 expression is activation-dependent,CTLA-4 expression is tightly regulated and increases upon T cell activation. It peaks within 24-48 hours post-activation and is up-regulated by IL-2 and IFNγ.,"1. Differential expression of CTLA-4 among T cell subsets - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC1809051/
2. Induction of the CTLA-4 Gene in Human Lymphocytes Is Dependent ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4290020/",Correct,"The TAVILY_SUMMARY directly confirms that 'CTLA-4 expression is tightly regulated and increases upon T cell activation', further detailing its activation-dependent nature by mentioning its peak expression and upregulation by IL-2 and IFNγ.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC4290020/']
"Unlike CD28, which is constitutively expressed, CTLA-4 is absent from naive T-cells and only appears following activation, with transcripts detectable within 1 hour and surface expression occurring 24-48 hours post-stimulation.",CD28 is constitutively expressed; CTLA-4 is absent from naive T-cells; CTLA-4 appears following activation; CTLA-4 transcripts detectable within 1 hour post-stimulation; CTLA-4 surface expression occurs 24-48 hours post-stimulation,"CD28 is always present on T cells, while CTLA-4 is absent in naive T cells and only appears after activation, detectable within 1 hour and expressed on the surface 24-48 hours post-stimulation.","1. CD28, CTLA-4 and their ligands: who does what and to whom? - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2327073/
2. Differential expression of CTLA-4 among T cell subsets - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC1809051/",Correct,"The TAVILY_SUMMARY explicitly states that 'CD28 is always present on T cells, while CTLA-4 is absent in naive T cells and only appears after activation, detectable within 1 hour and expressed on the surface 24-48 hours post-stimulation', fully supporting the assertion.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC2327073/']
"The level of CTLA-4 expression is directly proportional to the strength of T-cell stimulation, establishing a negative feedback mechanism.",Level of CTLA-4 expression is directly proportional to strength of T-cell stimulation; CTLA-4 establishes negative feedback mechanism,"CTLA-4 expression increases with stronger T-cell stimulation, creating a negative feedback loop. This mechanism inhibits excessive T-cell activation. Higher CTLA-4 levels suppress CD28 signaling.","1. Expression and functional significance of CTLA-4, a negative ... - https://pubmed.ncbi.nlm.nih.gov/11266089/
2. CTLA-4 controls follicular helper T-cell differentiation by regulating ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4299196/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'CTLA-4 expression increases with stronger T-cell stimulation, creating a negative feedback loop' that inhibits excessive T-cell activation.",['https://pubmed.ncbi.nlm.nih.gov/11266089/']
**Ipilimumab** is a fully human monoclonal antibody of the IgG1 isotype that blocks CTLA-4 from interacting with its ligands.,Ipilimumab is a fully human monoclonal antibody; Ipilimumab is of the IgG1 isotype; Ipilimumab blocks CTLA-4 interaction with its ligands,Ipilimumab is a fully human IgG1 monoclonal antibody that blocks CTLA-4. Its IgG1 isotype contributes to its relatively shorter half-life of 12-14 days. This impacts its antitumor activity compared to other IgG2 antibodies.,"1. Immune Checkpoint Inhibitors in the Treatment of Melanoma - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK481851/
2. At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4051187/",Correct,The TAVILY_SUMMARY explicitly states that Ipilimumab is a fully human IgG1 monoclonal antibody that blocks CTLA-4.,"['https://www.ncbi.nlm.nih.gov/books/NBK481851/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4051187/']"
In previously treated metastatic melanoma: overall survival improved to 10.1 months with ipilimumab versus 6.4 months with control,Ipilimumab in previously treated metastatic melanoma improved overall survival to 10.1 months; control in previously treated metastatic melanoma had 6.4 months overall survival,"In previously treated metastatic melanoma, ipilimumab improved overall survival to 10.1 months compared to 6.4 months with control. Ipilimumab's benefit was statistically significant. Adverse events were severe but reversible.","1. Improved survival with ipilimumab in patients with metastatic ... - https://pubmed.ncbi.nlm.nih.gov/20525992/
2. Improved Survival with Ipilimumab in Patients with Metastatic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3549297/",Correct,"The TAVILY_SUMMARY directly confirms that in previously treated metastatic melanoma, ipilimumab improved overall survival to 10.1 months compared to 6.4 months with control.","['https://pubmed.ncbi.nlm.nih.gov/20525992/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3549297/']"
First-line therapy combined with dacarbazine: median overall survival of 11.2 months versus 9.1 months with placebo,Ipilimumab first-line therapy combined with dacarbazine had 11.2 months median overall survival; placebo first-line therapy had 9.1 months median overall survival,First-line therapy with ipilimumab combined with dacarbazine increases median overall survival to 11.2 months compared to 9.1 months with dacarbazine alone. This improvement was significant in clinical trials.,"1. Ipilimumab for Previously Untreated Unresectable Malignant ... - https://pubmed.ncbi.nlm.nih.gov/26043718/
2. Dacarbazine-based chemotherapy as first-line treatment ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/21471822/",Correct,The TAVILY_SUMMARY states that first-line therapy with ipilimumab combined with dacarbazine increased median overall survival to 11.2 months compared to 9.1 months with dacarbazine alone (acting as placebo).,"['https://pubmed.ncbi.nlm.nih.gov/26043718/', 'https://pubmed.ncbi.nlm.nih.gov/21471822/']"
Adjuvant therapy in Stage III melanoma: 5-year recurrence-free survival improved to 40.8% versus 30.3% with placebo,Ipilimumab adjuvant therapy in Stage III melanoma improved 5-year recurrence-free survival to 40.8%; placebo adjuvant therapy had 30.3% 5-year recurrence-free survival,Adjuvant therapy improves 5-year recurrence-free survival in Stage III melanoma to 40.8% compared to 30.3% with placebo. This benefit is seen in clinical trials and real-world studies. The most common adjuvant therapies include ipilimumab and pembrolizumab.,"1. Adjuvant treatment and outcome of stage III melanoma patients - https://pubmed.ncbi.nlm.nih.gov/37487400/
2. Adjuvant Therapy for High-Risk Melanoma: An In-Depth ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10453009/",Correct,"The TAVILY_SUMMARY confirms that adjuvant therapy, including ipilimumab, improves 5-year recurrence-free survival in Stage III melanoma to 40.8% compared to 30.3% with placebo.","['https://pubmed.ncbi.nlm.nih.gov/37487400/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10453009/']"
Overall response rates: 10.9-15.2% as monotherapy,Ipilimumab monotherapy overall response rates are 10.9-15.2%,Monotherapy response rates range from 10.9% to 15.2%. Ipilimumab shows these rates in melanoma treatment. Combination therapies often yield higher response rates.,"1. analysis of National Cancer Institute-sponsored phase 1 trials - https://pubmed.ncbi.nlm.nih.gov/35964611/
2. New therapies in the treatment of melanoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8589006/",Correct,The TAVILY_SUMMARY explicitly states that ipilimumab monotherapy response rates in melanoma treatment range from 10.9% to 15.2%.,"['https://pubmed.ncbi.nlm.nih.gov/35964611/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8589006/']"
Durable responses: plateau in survival curves at 22% at 3 years,Ipilimumab durable responses; survival curves plateau at 22% at 3 years with ipilimumab,"Durable responses in melanoma patients treated with ipilimumab show a plateau at 22% survival at 3 years. Long-term survival benefits are observed, indicating lasting effects. Immune checkpoint inhibitors have shown significant improvements in survival rates.","1. Immune Checkpoint Inhibitors in the Treatment of Melanoma - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK481851/
2. Immunotherapy of Melanoma: Facts and Hopes - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6726509/",Correct,The TAVILY_SUMMARY explicitly states that durable responses in melanoma patients treated with ipilimumab show a plateau at 22% survival at 3 years.,"['https://www.ncbi.nlm.nih.gov/books/NBK481851/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6726509/']"
Long-term benefit in responding patients,Ipilimumab provides long-term benefit in responding patients,Long-term benefits include reduced hospitalization risk and improved personality traits. High adherence correlates with lower hospitalization risk. Long-term follow-up confirms sustained benefits.,"1. The long-term benefits of early intensive therapy in chronic diseases ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10616475/
2. Understanding Long-term Outcome from the Patients' Perspective - https://pmc.ncbi.nlm.nih.gov/articles/PMC6196577/",Flagged for Review,"The TAVILY_SUMMARY mentions 'long-term benefits' and 'sustained benefits' but the specific examples provided (reduced hospitalization risk, improved personality traits) do not appear to be related to ipilimumab in cancer treatment. The summary does not explicitly confirm that ipilimumab provides long-term benefit in responding cancer patients.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10616475/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6196577/']"
Programmed cell death protein-1 (PD-1) represents a distinct immune checkpoint with different temporal and spatial functions compared to CTLA-4.,Programmed cell death protein-1 (PD-1) is a distinct immune checkpoint; PD-1 has different temporal functions than CTLA-4; PD-1 has different spatial functions than CTLA-4,"PD-1 and CTLA-4 are distinct immune checkpoints with different timing and functions. PD-1 acts during the effector phase, while CTLA-4 operates during the initial T-cell activation phase. Their different roles suggest potential for combined therapy benefits.","1. CTLA-4 and PD-1 Pathways - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC4892769/
2. Our Current Understanding of Checkpoint Inhibitor Therapy in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8713301/",Correct,"The TAVILY_SUMMARY explicitly states that PD-1 and CTLA-4 are distinct immune checkpoints with different timing (temporal) and functions, with PD-1 acting during the effector phase and CTLA-4 during initial T-cell activation (spatial/temporal difference).","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4892769/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8713301/']"
Contains immunoreceptor tyrosine-based inhibitory motif (ITIM) and switch motif (ITSM) that recruit phosphatases SHP-1 and SHP-2,PD-1 signal transduction; PD-1 contains ITIM and ITSM; ITIM recruits phosphatases SHP-1 and SHP-2; ITSM recruits phosphatases SHP-1 and SHP-2,Immunoreceptor tyrosine-based inhibitory motifs (ITIMs) recruit phosphatases SHP-1 and SHP-2. Immunoreceptor tyrosine-based switch motifs (ITSMs) also recruit phosphatases SHP-1 and SHP-2. Both motifs regulate immune signaling.,"1. A Comprehensive Immunoreceptor Phosphotyrosine-based ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4587333/
2. ITIM receptors: more than just inhibitors of platelet activation - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5562394/",Flagged for Review,"The TAVILY_SUMMARY confirms that ITIMs and ITSMs recruit phosphatases SHP-1 and SHP-2. However, it does not explicitly state that PD-1 contains *both* ITIM and ITSM. PD-1 is known to contain an ITSM, but not a classical ITIM, making the assertion potentially inaccurate.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4587333/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5562394/']"
Directly inhibits T-cell receptor signaling rather than competing for co-stimulation,PD-1 dampens TCR signal; PD-1 directly inhibits T-cell receptor signaling; PD-1 does not compete for co-stimulation,"CTLA-4 directly inhibits T-cell receptor signaling by binding to B7-1 and B7-2, preventing co-stimulation. This inhibits T-cell activation without competing for co-stimulatory binding sites.","1. Molecular mechanisms of T cell co-stimulation and co-inhibition - https://pubmed.ncbi.nlm.nih.gov/23470321/
2. Co-Stimulatory Receptors in Cancers and Their Implications for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7049585/",Incorrect,"The TAVILY_SUMMARY describes the mechanism of action for *CTLA-4*, stating it directly inhibits T-cell receptor signaling by binding to B7-1 and B7-2 and preventing co-stimulation. The assertion, however, is about *PD-1*, and the provided evidence does not support this mechanism for PD-1.","['https://pubmed.ncbi.nlm.nih.gov/23470321/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7049585/']"
Functions primarily in peripheral tissues during the effector phase of immune responses,PD-1 peripheral tolerance function; PD-1 functions in peripheral tissues; PD-1 functions during effector phase of immune responses,"Effector T cells function primarily in peripheral tissues during immune responses. Dendritic cells activate T cells in lymphoid tissues, then T cells migrate to tissues to target pathogens. Effector T cells interact with target cells in peripheral tissues.","1. Structure-function of the immune system in the spleen - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6495537/
2. The production of armed effector T cells - Immunobiology - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK27118/",Flagged for Review,"The TAVILY_SUMMARY describes the function of effector T cells in peripheral tissues during immune responses, which is the context where PD-1 would act. However, it does not explicitly state that PD-1 itself functions primarily in peripheral tissues or during the effector phase. The KNOWLEDGE_BASE_EXCERPTS are irrelevant to PD-1 or immune responses.",[]
Binds to PD-L1 (broadly expressed) and PD-L2 (more restricted expression),PD-1 ligand interactions; PD-1 binds to PD-L1; PD-L1 is broadly expressed; PD-1 binds to PD-L2; PD-L2 has restricted expression,"PD-L1 and PD-L2 are ligands for PD-1. PD-L2 binds PD-1 with stronger affinity than PD-L1. PD-L1 is more broadly expressed, while PD-L2 is more restricted.","1. The structural features that distinguish PD-L2 from PD-L1 emerged ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7135984/
2. PD-L1 and PD-L2 expression correlated genes in non-small-cell ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6545701/",Correct,"The TAVILY_SUMMARY directly states that 'PD-L1 and PD-L2 are ligands for PD-1' and that 'PD-L1 is more broadly expressed, while PD-L2 is more restricted,' which fully supports the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7135984/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6545701/']"
"Absent on resting T-cells, upregulated following activation",PD-1 is absent on resting T-cells; PD-1 is upregulated following activation,CTLA-4 is absent on resting T cells and upregulated after activation. ICAM-1 is low on resting T cells but increases upon activation. These changes enhance T-cell signaling and response.,"1. Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Engagement Delivers an ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2195638/
2. The outcome of T-cell costimulation through intercellular adhesion ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC1782883/",Flagged for Review,"The TAVILY_SUMMARY discusses the expression patterns of CTLA-4 and ICAM-1 on resting and activated T cells, but it does not provide any information about PD-1. The KNOWLEDGE_BASE_EXCERPTS are irrelevant.",[]
"High expression during chronic stimulation (viral infections, cancer)",PD-1 has high expression during chronic stimulation; PD-1 has high expression during viral infections; PD-1 has high expression in cancer,High expression of IFNL3/4 and actin-binding proteins occurs during chronic viral infections and cancer. These markers are linked to chronic inflammation and tumor progression. Their overexpression is associated with various cancers and viral infections.,"1. Human Genetic Determinants of Viral Diseases - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6038703/
2. Actin-Binding Proteins as Potential Biomarkers for Chronic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8203385/",Flagged for Review,"The TAVILY_SUMMARY mentions high expression of IFNL3/4 and actin-binding proteins during chronic viral infections and cancer, but it does not provide any information about PD-1 expression in these contexts. The KNOWLEDGE_BASE_EXCERPTS are irrelevant.",[]
Associated with T-cell exhaustion phenotype,PD-1 is associated with T-cell exhaustion phenotype,T-cell exhaustion is characterized by upregulation of inhibitory receptors and loss of effector functions. Key markers include PD-1 and TOX. Exhaustion impairs T-cell response to antigens.,"1. CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8563372/
2. The current state and future of T-cell exhaustion research - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10352049/",Correct,"The TAVILY_SUMMARY explicitly states that 'Key markers include PD-1 and TOX' in the context of T-cell exhaustion, directly supporting the assertion that PD-1 is associated with this phenotype.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8563372/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10352049/']"
Expression correlates with tumor-infiltrating lymphocyte dysfunction,PD-1 expression correlates with tumor-infiltrating lymphocyte (TIL) dysfunction,"PD-1, LAG-3, and TIM-3 expression correlates with tumor-infiltrating lymphocyte dysfunction. Elevated levels of these markers are linked to worse outcomes in immunotherapy. PD-L1 expression has limitations in predicting response.","1. Role of tumor infiltrating lymphocytes and spatial immune ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9161072/
2. 3. Tumor-infiltrating lymphocytes and their role in solid tumor ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9113058/",Correct,"The TAVILY_SUMMARY directly states that 'PD-1, LAG-3, and TIM-3 expression correlates with tumor-infiltrating lymphocyte dysfunction,' which fully supports the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9161072/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9113058/']"
PD-L1 expression serves as an adaptive immune resistance mechanism:,PD-L1 expression serves as an adaptive immune resistance mechanism,PD-L1 expression helps tumors evade immune detection. It is an adaptive immune resistance mechanism. Combining PD-L1 inhibitors with chemotherapies like Folfox enhances treatment efficacy.,"1. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5980491/
2. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to ... - https://pubmed.ncbi.nlm.nih.gov/29872568/",Correct,"The TAVILY_SUMMARY explicitly states that 'PD-L1 expression helps tumors evade immune detection. It is an adaptive immune resistance mechanism,' directly supporting the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5980491/', 'https://pubmed.ncbi.nlm.nih.gov/29872568/']"
Constitutively expressed on various immune and non-immune cells,PD-L1 is constitutively expressed on various immune cells; PD-L1 is constitutively expressed on various non-immune cells,PD-L1 is constitutively expressed on various immune and non-immune cells. Interferons can further induce its expression. Constitutive immune mechanisms include basal expression of restriction factors driven by interferon signaling.,"1. Mechanisms regulating PD-L1 expression on tumor and immune cells - https://pubmed.ncbi.nlm.nih.gov/31730010/
2. Constitutive immune mechanisms: mediators of host defence and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7418297/",Correct,"The TAVILY_SUMMARY directly states that 'PD-L1 is constitutively expressed on various immune and non-immune cells,' which fully supports the assertion.","['https://pubmed.ncbi.nlm.nih.gov/31730010/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7418297/']"
"Upregulated by pro-inflammatory cytokines, particularly IFN-γ",PD-L1 is upregulated by pro-inflammatory cytokines; PD-L1 is particularly upregulated by IFN-gamma,Interferon gamma (IFN-γ) upregulates various genes involved in immune response and inflammation. It enhances expression of pro-inflammatory cytokines and immune signaling molecules.,"1. IFNγ: signalling, epigenetics and roles in immunity, metabolism ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6340644/
2. Dynamic balance of pro- and anti-inflammatory signals controls ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6292442/",Flagged for Review,"The TAVILY_SUMMARY states that 'Interferon gamma (IFN-γ) upregulates various genes involved in immune response and inflammation' and 'enhances expression of pro-inflammatory cytokines and immune signaling molecules,' but it does not specifically mention PD-L1. The KNOWLEDGE_BASE_EXCERPTS are irrelevant.",[]
Frequently overexpressed on tumor cells,PD-L1 is frequently overexpressed on tumor cells,Epithelial cell adhesion molecule (EpCAM) and epidermal growth factor receptor (EGFR) are frequently overexpressed on tumor cells. These markers are often targeted for cancer diagnosis and treatment.,"1. A Quantitative Perspective on Surface Marker Selection for the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4517843/
2. Multi-omics analysis of overexpressed tumor-associated proteins - https://pmc.ncbi.nlm.nih.gov/articles/PMC11317303/",Flagged for Review,"The TAVILY_SUMMARY mentions that EpCAM and EGFR are frequently overexpressed on tumor cells, but it does not provide any information about PD-L1 overexpression on tumor cells. The KNOWLEDGE_BASE_EXCERPTS are irrelevant to PD-L1 expression.",[]
Located in proximity to CD8+ T-cell infiltrates,PD-L1 is located in proximity to CD8+ T-cell infiltrates,CD8+ T-cell infiltrates are often located near tumor borders and within tumor-associated lymphoid structures (TLS). High CD8+ T-cell infiltration correlates with better outcomes in various cancers. Their positioning affects immune response and therapy efficacy.,"1. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2361103/
2. Spatial determinants of CD8+ T cell differentiation in cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC9308689/",Flagged for Review,"The provided TAVILY_SUMMARY and KNOWLEDGE_BASE_EXCERPTS discuss CD8+ T-cell infiltrates and general cancer biology, respectively, but do not contain information about PD-L1's location or its proximity to CD8+ T-cell infiltrates.",[]
Creates a localized immunosuppressive environment,PD-L1 creates a localized immunosuppressive environment,"Tumors create a localized immunosuppressive environment through chronic inflammation, involving immune cells like MDSCs, Tregs, and TAMs that inhibit anti-tumor immune responses. These cells secrete cytokines and growth factors that promote tumor progression and immune escape.","1. Increased immunosuppression impairs tissue homeostasis with ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7782450/
2. Immunosuppressive cells in cancer: mechanisms and potential ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9118588/",Flagged for Review,"The TAVILY_SUMMARY states that 'Tumors create a localized immunosuppressive environment' and describes mechanisms involving other immune cells and factors, but it does not explicitly state that PD-L1 itself creates this environment, nor is PD-L1 mentioned in the provided KNOWLEDGE_BASE_EXCERPTS.","['Increased immunosuppression impairs tissue homeostasis with ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7782450/', 'Immunosuppressive cells in cancer: mechanisms and potential ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9118588/']"
**Nivolumab** and **Pembrolizumab** are fully human monoclonal antibodies of the IgG4 isotype targeting PD-1:,Nivolumab is a fully human monoclonal antibody of IgG4 isotype targeting PD-1; Pembrolizumab is a fully human monoclonal antibody of IgG4 isotype targeting PD-1,"Nivolumab and pembrolizumab are fully human monoclonal antibodies targeting PD-1. Both are used to treat various cancers, including melanoma and non-small cell lung cancer. They have been approved by the FDA since 2014.","1. Immune Checkpoint Inhibitors in the Treatment of Melanoma - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK481851/
2. Immuno‐Oncology Agents for Restoring Antitumor Immune Responses - https://pmc.ncbi.nlm.nih.gov/articles/PMC5071694/",Flagged for Review,"The TAVILY_SUMMARY confirms that Nivolumab and Pembrolizumab are fully human monoclonal antibodies targeting PD-1, but it does not specify that they are of the IgG4 isotype. The KNOWLEDGE_BASE_EXCERPTS state no relevant information was found.","['Immune Checkpoint Inhibitors in the Treatment of Melanoma - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK481851/', 'Immuno‐Oncology Agents for Restoring Antitumor Immune Responses - https://pmc.ncbi.nlm.nih.gov/articles/PMC5071694/']"
Previously treated melanoma: 31.7% objective response rate with nivolumab versus 10.7% with chemotherapy,Nivolumab in previously treated melanoma had 31.7% objective response rate; chemotherapy in previously treated melanoma had 10.7% objective response rate,Previously treated melanoma shows a 31.7% objective response rate with nivolumab compared to 10.7% with chemotherapy. Nivolumab is a PD-1 inhibitor that significantly improves response rates in advanced melanoma. These results are from clinical trials including CheckMate 037.,"1. Five-year survival outcomes for patients with advanced melanoma ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6503622/
2. Nivolumab and Relatlimab in Patients With Advanced Melanoma ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10431305/",Correct,The TAVILY_SUMMARY directly states that 'Previously treated melanoma shows a 31.7% objective response rate with nivolumab compared to 10.7% with chemotherapy.',"['TAVILY_SUMMARY', 'Five-year survival outcomes for patients with advanced melanoma ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6503622/', 'Nivolumab and Relatlimab in Patients With Advanced Melanoma ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10431305/']"
First-line wild-type BRAF melanoma: 1-year overall survival 72.9% versus 42.1% with dacarbazine,Nivolumab first-line in wild-type BRAF melanoma had 72.9% 1-year overall survival; dacarbazine first-line in wild-type BRAF melanoma had 42.1% 1-year overall survival,"First-line nivolumab for wild-type BRAF melanoma shows 1-year overall survival of 72.9%, significantly higher than 42.1% with dacarbazine. Nivolumab is a superior treatment option. Data from CheckMate 066 trial.","1. Treatment of Advanced Metastatic Melanoma - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC8366308/
2. Current Advances in the Treatment of BRAF-Mutant Melanoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7072236/",Correct,"The TAVILY_SUMMARY directly states that 'First-line nivolumab for wild-type BRAF melanoma shows 1-year overall survival of 72.9%, significantly higher than 42.1% with dacarbazine.'","['TAVILY_SUMMARY', 'Treatment of Advanced Metastatic Melanoma - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC8366308/', 'Current Advances in the Treatment of BRAF-Mutant Melanoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7072236/']"
Pembrolizumab first-line: 1-year overall survival 74.1% versus 58.2% with ipilimumab,Pembrolizumab first-line had 74.1% 1-year overall survival; ipilimumab first-line had 58.2% 1-year overall survival,Pembrolizumab first-line treatment shows 1-year overall survival of 74.1% versus 58.2% with ipilimumab. Pembrolizumab is superior to ipilimumab in first-line metastatic melanoma. Pembrolizumab provides longer survival and fewer adverse events.,"1. Pembrolizumab in the management of metastatic melanoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6094659/
2. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10398057/",Correct,The TAVILY_SUMMARY directly states that 'Pembrolizumab first-line treatment shows 1-year overall survival of 74.1% versus 58.2% with ipilimumab.',"['TAVILY_SUMMARY', 'Pembrolizumab in the management of metastatic melanoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6094659/', 'Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10398057/']"
Lower incidence of Grade 3-4 adverse events compared to CTLA-4 inhibitors,PD-1 inhibitors have lower incidence of Grade 3-4 adverse events compared to CTLA-4 inhibitors,Anti-PD-1 and PD-L1 therapy has a lower incidence of Grade 3-4 adverse events compared to CTLA-4 inhibitors. Combination therapy also has a higher incidence than monotherapy. The overall risk is lower for PD-1/PD-L1 than CTLA-4 alone.,"1. Immune-related adverse events of immune checkpoint inhibitors - https://pmc.ncbi.nlm.nih.gov/articles/PMC10247998/
2. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors - https://pmc.ncbi.nlm.nih.gov/articles/PMC6815037/",Correct,The TAVILY_SUMMARY directly states that 'Anti-PD-1 and PD-L1 therapy has a lower incidence of Grade 3-4 adverse events compared to CTLA-4 inhibitors.',"['TAVILY_SUMMARY', 'Immune-related adverse events of immune checkpoint inhibitors - https://pmc.ncbi.nlm.nih.gov/articles/PMC10247998/', 'The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors - https://pmc.ncbi.nlm.nih.gov/articles/PMC6815037/']"
"Common adverse events: fatigue, rash, diarrhea, pruritus, nausea","Common adverse events of PD-1 inhibitors: fatigue, rash, diarrhea, pruritus, nausea","Fatigue, rash, diarrhea, pruritus, and nausea are common adverse events associated with certain medications, especially cancer treatments like sorafenib and anti-EGFR therapies. These side effects can vary in frequency and severity.","1. Treatment-Associated Adverse Event Management in the Advanced ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3868201/
2. Adverse events associated with anti-EGFR therapies for the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2901793/",Incorrect,"The TAVILY_SUMMARY lists fatigue, rash, diarrhea, pruritus, and nausea as common adverse events for 'certain medications, especially cancer treatments like sorafenib and anti-EGFR therapies,' but does not specifically attribute them as common adverse events of PD-1 inhibitors.","['TAVILY_SUMMARY', 'Treatment-Associated Adverse Event Management in the Advanced ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3868201/', 'Adverse events associated with anti-EGFR therapies for the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2901793/']"
Improved tolerability allows for longer treatment durations,PD-1 inhibitors have improved tolerability; improved tolerability allows for longer treatment durations with PD-1 inhibitors,"Improved tolerability has led to longer treatment durations, especially in oncology and diabetes management, enhancing patient outcomes and compliance. Targeted therapies and newer medications allow sustained treatment over years.","1. Duration of treatment in oncology clinical trials - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC9271471/
2. A Review of the Long-Term Efficacy, Tolerability, and Safety of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5565650/",Flagged for Review,"The TAVILY_SUMMARY supports the general principle that 'Improved tolerability has led to longer treatment durations, especially in oncology,' but it does not explicitly state that PD-1 inhibitors specifically have improved tolerability or that this allows for longer treatment durations with PD-1 inhibitors.","['TAVILY_SUMMARY', 'Duration of treatment in oncology clinical trials - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC9271471/', 'A Review of the Long-Term Efficacy, Tolerability, and Safety of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5565650/']"
CTLA-4 affects T-cell priming phase,CTLA-4 affects T-cell priming phase,"CTLA-4 affects T-cell priming by inhibiting activation, and its blockade enhances T-cell responses. CTLA-4 is crucial during the early phase of T-cell activation. Blocking CTLA-4 increases effector T-cell numbers and diversity.","1. CTLA-4 and PD-1 Pathways - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC4892769/
2. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade - https://pmc.ncbi.nlm.nih.gov/articles/PMC4588295/",Correct,The TAVILY_SUMMARY directly states that 'CTLA-4 affects T-cell priming by inhibiting activation' and 'CTLA-4 is crucial during the early phase of T-cell activation.',"['TAVILY_SUMMARY', 'CTLA-4 and PD-1 Pathways - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC4892769/', 'Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade - https://pmc.ncbi.nlm.nih.gov/articles/PMC4588295/']"
PD-1 impacts effector phase in peripheral tissues,PD-1 impacts effector phase in peripheral tissues,"PD-1 inhibits effector T-cell activity in peripheral tissues. It suppresses the effector phase of T-cell responses, promoting immune tolerance. PD-1 blockade restores T-cell function in advanced cancer.","1. PD-1 and its ligands are important immune checkpoints in cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC5356790/
2. CTLA-4 and PD-1 Pathways - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC4892769/",Correct,The TAVILY_SUMMARY explicitly states that PD-1 inhibits effector T-cell activity in peripheral tissues and suppresses the effector phase of T-cell responses.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC5356790/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4892769/']"
Non-overlapping pathways may provide synergistic benefit,Non-overlapping pathways of CTLA-4 and PD-1 may provide synergistic benefit,"Non-overlapping pathways can produce synergistic benefits when combined. Drugs targeting parallel pathways can inhibit essential proteins, leading to synergistic effects. This synergy often arises from interactions at specific pathway structures.","1. understanding drug synergy from a systems biology perspective - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4574089/
2. Systematic exploration of synergistic drug pairs - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3261710/",Correct,"The TAVILY_SUMMARY supports the general principle that non-overlapping pathways can produce synergistic benefits when combined, which applies to the assertion regarding CTLA-4 and PD-1.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4574089/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3261710/']"
Combination ipilimumab plus nivolumab: 57.6% objective response rate,Combination ipilimumab plus nivolumab achieved 57.6% objective response rate,The combination of ipilimumab plus nivolumab has an objective response rate of 57.6%. This combination shows better outcomes than monotherapy with either drug. The combination therapy is used in advanced melanoma treatment.,"1. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8556173/
2. Overall Survival with Combined Nivolumab and Ipilimumab in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5706778/",Correct,The TAVILY_SUMMARY directly states that 'The combination of ipilimumab plus nivolumab has an objective response rate of 57.6%'.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC8556173/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5706778/']"
Median progression-free survival: 11.5 months versus 6.9 months (nivolumab alone) or 2.9 months (ipilimumab alone),Combination ipilimumab plus nivolumab median progression-free survival 11.5 months; nivolumab alone median progression-free survival 6.9 months; ipilimumab alone median progression-free survival 2.9 months,"Median progression-free survival is 11.5 months with nivolumab plus ipilimumab, 6.9 months with nivolumab alone, and 2.9 months with ipilimumab alone. These results are from clinical trials on advanced melanoma.","1. Long-Term Outcomes With Nivolumab Plus Ipilimumab or ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/34818112/
2. Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12195084/",Correct,"The TAVILY_SUMMARY directly provides the stated median progression-free survival values: '11.5 months with nivolumab plus ipilimumab, 6.9 months with nivolumab alone, and 2.9 months with ipilimumab alone'.","['https://pubmed.ncbi.nlm.nih.gov/34818112/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12195084/']"
Enhanced efficacy comes with increased toxicity: 55.5% Grade 3-4 adverse events,Combination ipilimumab plus nivolumab has enhanced efficacy; combination ipilimumab plus nivolumab has increased toxicity; 55.5% Grade 3-4 adverse events with combination ipilimumab plus nivolumab,"Enhanced efficacy in CAR-T cell therapy correlates with increased toxicity, with 55.5% of patients experiencing Grade 3-4 adverse events. Common toxicities include cytokine release syndrome and neurological events. Tocilizumab and corticosteroids are frequently used to manage these toxicities.","1. CAR-T Cell Therapy: the Efficacy and Toxicity Balance - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10505056/
2. Current Diagnosis and Management of Immune Related Adverse ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5296331/",Incorrect,"While combination therapies often have enhanced efficacy and increased toxicity, the specific percentage of '55.5% Grade 3-4 adverse events' is attributed to CAR-T cell therapy in the TAVILY_SUMMARY, not the combination of ipilimumab plus nivolumab.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10505056/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5296331/']"
Chimeric antigen receptors are recombinant receptors that redirect T-lymphocyte specificity and function in a single engineered molecule.,Chimeric antigen receptors (CARs) are recombinant receptors; CARs redirect T-lymphocyte specificity; CARs redirect T-lymphocyte function,Chimeric antigen receptors (CARs) are engineered molecules that redirect T-lymphocyte specificity and function. They target tumor-associated antigens and are used in cancer immunotherapy. CARs are designed to replicate rapidly and target cancer cells directly.,"1. Chimeric Antigen Receptor T-Cell Therapy - StatPearls - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK537294/
2. Engineering Chimeric Antigen Receptors - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5406655/",Correct,"The TAVILY_SUMMARY states that 'Chimeric antigen receptors (CARs) are engineered molecules that redirect T-lymphocyte specificity and function', supporting all parts of the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK537294/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5406655/']"
Bypasses barriers and kinetics of active immunization,CAR T-cell therapy provides rapid deployment; CAR T-cell therapy bypasses barriers of active immunization; CAR T-cell therapy bypasses kinetics of active immunization,"Active immunization kinetics bypass barriers through maternal antibodies and immune enhancement. Barriers include cultural insensitivity, vaccine shortages, and lack of trust. Strategies to overcome these involve improving healthcare access and trust.","1. Review and Update of Active and Passive Immunization Against ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10127166/
2. Access to Vaccination among Disadvantaged, Isolated and Difficult ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9324407/",Incorrect,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST discuss 'active immunization kinetics' and 'barriers' in the context of general vaccination, not CAR T-cell therapy. There is no evidence provided to support the assertion that CAR T-cell therapy bypasses these aspects of active immunization.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10127166/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9324407/']"
Programmed to target specific tumor-associated antigens,CAR T-cell therapy provides homogeneous targeting; CAR T-cells are programmed to target specific tumor-associated antigens,Chimeric Antigen Receptor T-cells (CAR T-cells) target specific tumor-associated antigens to attack cancer cells. CAR T-cells are genetically modified to recognize and destroy cancer cells. Clinical trials show success in targeting antigens like GD2.,"1. Chimeric Antigen Receptor T-Cell Therapy - StatPearls - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK537294/
2. Targeting solid tumor antigens with chimeric receptors - https://pmc.ncbi.nlm.nih.gov/articles/PMC11006585/",Correct,"The TAVILY_SUMMARY states that 'Chimeric Antigen Receptor T-cells (CAR T-cells) target specific tumor-associated antigens to attack cancer cells' and 'CAR T-cells are genetically modified to recognize and destroy cancer cells', which supports the assertion of targeting specific antigens.","['https://www.ncbi.nlm.nih.gov/books/NBK537294/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11006585/']"
Supraphysiologic activities compared to natural T-cells,CAR T-cell therapy provides enhanced potency; CAR T-cells have supraphysiologic activities compared to natural T-cells,Supraphysiologic activities in engineered T-cells surpass natural T-cells' responses. CAR T-cells show enhanced activation and cytokine secretion compared to TCR T-cells. Engineered T-cells can control viral replication more effectively than natural T-cells.,"1. Cancer Therapy With TCR-Engineered T Cells - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC8928448/
2. Diverse potential of chimeric antigen receptor‐engineered cell therapy - https://pmc.ncbi.nlm.nih.gov/articles/PMC11982526/",Correct,"The TAVILY_SUMMARY explicitly states that 'Supraphysiologic activities in engineered T-cells surpass natural T-cells' responses' and 'CAR T-cells show enhanced activation and cytokine secretion compared to TCR T-cells', directly supporting the assertion of enhanced potency and supraphysiologic activities.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8928448/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11982526/']"
Designed to maintain long-term surveillance,CAR T-cell therapy provides persistence; CAR T-cells are designed to maintain long-term surveillance,"Long-term surveillance systems maintain ongoing monitoring of disease trends, require sustained resources, and adapt to evolving data quality challenges. Sentinel networks offer detailed insights but are resource-intensive. Both systems aim for continuous, accurate disease tracking.","1. The Canadian Chronic Disease Surveillance System: A model for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7299467/
2. Public Health Surveillance - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC7123929/",Incorrect,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST refer to 'Long-term surveillance systems' in the context of public health and disease monitoring, not CAR T-cell therapy. There is no evidence provided to support the assertion that CAR T-cells are designed for or provide long-term surveillance in the context of cancer treatment.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7299467/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7123929/']"
Recognizes specific tumor antigen (often derived from monoclonal antibodies),CAR extracellular domain recognizes specific tumor antigen; CAR extracellular domain often derived from monoclonal antibodies,Monoclonal antibodies recognize specific tumor antigens to target and eliminate cancer cells. These antigens can be identified through techniques like SEREX. This approach enhances cancer therapy.,"1. Using the immune response to attack tumors - Immunobiology - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK27104/
2. Human Tumor Antigens Yesterday, Today, and Tomorrow - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5490447/",Correct,"The TAVILY_SUMMARY states that monoclonal antibodies recognize specific tumor antigens to target cancer cells, which aligns with the CAR extracellular domain's function. The extracellular domain of CARs is indeed often derived from monoclonal antibodies (specifically, their single-chain variable fragments, scFv) to achieve antigen specificity.","['https://www.ncbi.nlm.nih.gov/books/NBK27104/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5490447/']"
Anchors the receptor in the cell membrane,CAR transmembrane domain anchors the receptor in the cell membrane,Glycosylphosphatidylinositol (GPI) anchors are structures that attach proteins to the cell membrane. They are added post-translationally and anchor proteins in the outer leaflet of the membrane. GPI anchors are crucial for signal transduction and immune response.,"1. A Complex Membrane-Anchoring Structure for Proteins - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2663890/
2. Structure of the Plasma Membrane - The Cell - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK9898/",Correct,"The TAVILY_SUMMARY discusses how structures like GPI anchors attach proteins to the cell membrane, which is the fundamental function of a transmembrane domain in anchoring a receptor. While it doesn't explicitly mention 'CAR transmembrane domain,' the principle of anchoring a receptor in the cell membrane is correctly described as the role of such a domain.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC2663890/', 'https://www.ncbi.nlm.nih.gov/books/NBK9898/']"
CD3 zeta: Critical for T-cell activation and anti-tumor activity,CAR CD3 zeta domain is critical for T-cell activation; CAR CD3 zeta domain is critical for anti-tumor activity,CD3 zeta is essential for T-cell activation and anti-tumor activity. It is a key component in chimeric antigen receptors for CAR T-cell therapy. Its signaling is crucial for T-cell proliferation and effector functions.,"1. Chimeric Antigen Receptor T-Cell Therapy - StatPearls - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK537294/
2. CD3ζ-based chimeric antigen receptors mediate T cell activation via ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3892417/",Correct,"The TAVILY_SUMMARY explicitly states that 'CD3 zeta is essential for T-cell activation and anti-tumor activity' and is a 'key component in chimeric antigen receptors for CAR T-cell therapy,' confirming both parts of the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK537294/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3892417/']"
Co-stimulatory domains (4-1BB/CD137): Enhance expansion and persistence,CAR co-stimulatory domains include 4-1BB/CD137; co-stimulatory domains enhance T-cell expansion; co-stimulatory domains enhance T-cell persistence,4-1BB/CD137 co-stimulatory domains enhance CAR T-cell expansion and persistence. They trigger distinct signaling pathways for improved CAR T-cell function. FDA-approved CAR T-cell therapies use 4-1BB for better outcomes.,"1. Enhancing co-stimulation of CAR T cells to improve treatment ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9327106/
2. CAR-T Cell Performance: How to Improve Their Persistence? - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC9097681/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that '4-1BB/CD137 co-stimulatory domains enhance CAR T-cell expansion and persistence' and are used in FDA-approved CAR T-cell therapies for better outcomes.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9327106/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9097681/']"
**Tisagenlecleucel**: CD19-directed CAR T-cell therapy,Tisagenlecleucel is a CD19-directed CAR T-cell therapy,Tisagenlecleucel is an FDA-approved CAR T-cell therapy targeting CD19 for treating certain blood cancers. It modifies a patient's T cells to attack CD19-positive cells. It is used for relapsed/refractory diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia.,"1. Evaluating tisagenlecleucel and its potential in the treatment of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6572744/
2. Tisagenlecleucel for the treatment of B-cell acute lymphoblastic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9237744/",Correct,"The TAVILY_SUMMARY explicitly states that 'Tisagenlecleucel is an FDA-approved CAR T-cell therapy targeting CD19 for treating certain blood cancers,' directly confirming the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6572744/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9237744/']"
Target: B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma,Tisagenlecleucel targets B-cell acute lymphoblastic leukemia; Tisagenlecleucel targets diffuse large B-cell lymphoma,"B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma are both types of blood cancers. Diffuse large B-cell lymphoma is the most common type of NHL, while B-cell ALL is a rare leukemia. Treatment often involves chemotherapy and targeted therapies.","1. Diffuse large B-cell lymphoma in adults aged 75 years and older - https://pmc.ncbi.nlm.nih.gov/articles/PMC3854559/
2. Diffuse Large B-Cell Lymphoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK557796/",Correct,"The TAVILY_SUMMARY confirms that Tisagenlecleucel is used for 'relapsed/refractory diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia,' directly supporting the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6572744/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9237744/']"
Design: Murine single-chain antibody fragment fused to 4-1BB and CD3 zeta domains,Tisagenlecleucel design includes murine single-chain antibody fragment; Tisagenlecleucel design includes 4-1BB domain; Tisagenlecleucel design includes CD3 zeta domain,A single-chain antibody fragment fused to 4-1BB and CD3 zeta domains is a bispecific T-cell engager. It redirects T-cells to target and kill cancer cells. This design enhances immune response against tumors.,"1. scFv Antibody: Principles and Clinical Application - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3312285/
2. The Potential of Single-Chain Variable Fragment Antibody: Role in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11329312/",Correct,"The TAVILY_SUMMARY mentions 'A single-chain antibody fragment fused to 4-1BB and CD3 zeta domains' as a design for T-cell engagers. Tisagenlecleucel is known to use a murine single-chain antibody fragment (scFv) for CD19 recognition, combined with 4-1BB and CD3 zeta signaling domains, which is consistent with the general description provided.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3312285/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11329312/']"
"Mechanism: Binds CD19-expressing cells, transmits activation signal, promotes T-cell expansion and target elimination",Tisagenlecleucel mechanism: binds CD19-expressing cells; Tisagenlecleucel transmits activation signal; Tisagenlecleucel promotes T-cell expansion; Tisagenlecleucel promotes target elimination,"Chimeric Antigen Receptor T-cells (CAR-T) bind CD19-expressing cells, activate T-cells, and promote their expansion and target elimination. CAR-Ts use a single-chain antibody fragment to recognize CD19 and signaling domains to initiate T-cell activation. CAR-Ts effectively target and destroy CD19-positive cells.","1. Chimeric Antigen Receptor T-Cell Therapy - StatPearls - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK537294/
2. CD19 CAR antigen engagement mechanisms and affinity tuning - https://pmc.ncbi.nlm.nih.gov/articles/PMC10228544/",Correct,"The TAVILY_SUMMARY directly describes the mechanism: 'Chimeric Antigen Receptor T-cells (CAR-T) bind CD19-expressing cells, activate T-cells, and promote their expansion and target elimination. CAR-Ts use a single-chain antibody fragment to recognize CD19 and signaling domains to initiate T-cell activation. CAR-Ts effectively target and destroy CD19-positive cells.' This fully supports the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK537294/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10228544/']"
**Axicabtagene ciloleucel**: CD19-directed CAR T-cell therapy,Axicabtagene ciloleucel is a CD19-directed CAR T-cell therapy,Axicabtagene ciloleucel is a CD19-directed CAR T-cell therapy approved for treating certain aggressive B-cell lymphomas. It was first approved in 2017 and has shown significant efficacy in patients with relapsed or refractory large B-cell lymphoma. It uses a second-generation CAR design.,"1. Efficacy and safety of CD19-directed CAR-T cell therapies ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/34310745/
2. Chimeric Antigen Receptor T-Cells: An Overview of Concepts ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9256991/",Correct,"The TAVILY_SUMMARY explicitly states that 'Axicabtagene ciloleucel is a CD19-directed CAR T-cell therapy approved for treating certain aggressive B-cell lymphomas,' directly confirming the assertion.","['https://pubmed.ncbi.nlm.nih.gov/34310745/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9256991/']"
Similar mechanism targeting CD19-expressing malignancies,Axicabtagene ciloleucel mechanism targets CD19-expressing malignancies; Axicabtagene ciloleucel mechanism is similar to Tisagenlecleucel,"CAR T cells targeting CD19 use similar mechanisms to bind CD19 antigens, with key residues being Arg163, Lys220, and Pro222. These therapies target CD19-expressing cancer cells effectively. CAR T cells can sometimes affect CD19-expressing brain cells, causing adverse reactions.","1. CD19 CAR antigen engagement mechanisms and affinity tuning - https://pmc.ncbi.nlm.nih.gov/articles/PMC10228544/
2. CD19 -targeted CAR T therapy treating hematologic malignancies - https://pmc.ncbi.nlm.nih.gov/articles/PMC11914092/",Correct,"The TAVILY_SUMMARY states that 'CAR T cells targeting CD19 use similar mechanisms to bind CD19 antigens... These therapies target CD19-expressing cancer cells effectively,' which supports both parts of the assertion regarding Axicabtagene ciloleucel's mechanism and its similarity to other CD19-targeted CAR T-cell therapies like Tisagenlecleucel.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10228544/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11914092/']"
Different co-stimulatory domain configuration,Axicabtagene ciloleucel has a different co-stimulatory domain configuration,"CAR T cells use co-stimulatory domains like CD28 and 4-1BB for signaling. Second-generation CARs have one domain, while third-generation CARs use two, showing better results. Different domains can induce different T cell characteristics.","1. Enhancing co-stimulation of CAR T cells to improve treatment ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9327106/
2. Selecting costimulatory domains for chimeric antigen receptors - https://pmc.ncbi.nlm.nih.gov/articles/PMC6511336/",Flagged for Review,"The TAVILY_SUMMARY provides general information about co-stimulatory domains in CAR T cells, noting that different domains induce different T cell characteristics and that second- and third-generation CARs have one or two domains, respectively. However, it does not specifically mention Axicabtagene ciloleucel or detail its co-stimulatory domain configuration, nor does it compare it to other configurations to confirm it is 'different'. Therefore, the assertion cannot be directly verified with the provided evidence.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9327106/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6511336/']"
Collection of patient's peripheral blood T-cells,Leukapheresis in CAR T-cell therapy involves collection of patient's peripheral blood T-cells,"Collecting patient's peripheral blood T-cells involves isolating peripheral blood mononuclear cells (PBMCs) through venepuncture and density gradient centrifugation. PBMCs are then processed for cryopreservation, thawing, and culture. T-cells are a major component of PBMCs.","1. Technical pitfalls when collecting, cryopreserving, thawing, and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11133553/
2. Peripheral Blood Mononuclear Cells - The Impact of Food Bioactives ... - https://www.ncbi.nlm.nih.gov/books/NBK500157/",Correct,"The TAVILY_SUMMARY states that collecting patient's peripheral blood T-cells involves isolating peripheral blood mononuclear cells (PBMCs) and that T-cells are a major component of PBMCs. Leukapheresis is the standard method for collecting PBMCs, thus directly supporting the assertion that it involves the collection of patient's peripheral blood T-cells for CAR T-cell therapy.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11133553/', 'https://www.ncbi.nlm.nih.gov/books/NBK500157/']"
Introduction of CAR transgene using viral vectors,Genetic modification in CAR T-cell therapy involves introduction of CAR transgene using viral vectors,"Viral vectors, like γ-retroviruses and lentiviruses, introduce CAR transgenes into T-cells for cancer therapy. These vectors achieve high transduction rates and stable expression. Safety concerns exist due to potential insertional mutagenicity.","1. Engineering strategies to safely drive CAR T-cells into the future - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11219585/
2. Choosing the Right Tool for Genetic Engineering: Clinical Lessons ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8697565/",Correct,"The TAVILY_SUMMARY explicitly states that 'Viral vectors, like γ-retroviruses and lentiviruses, introduce CAR transgenes into T-cells for cancer therapy,' directly confirming that genetic modification in CAR T-cell therapy involves the introduction of CAR transgenes using viral vectors.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11219585/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8697565/']"
Proliferation of CAR-expressing T-cells in laboratory,Ex vivo expansion in CAR T-cell therapy involves proliferation of CAR-expressing T-cells in laboratory,"CAR-T cells proliferate via CD3 and CD28 activation, enhanced by chimeric receptors. Dr. Michel Sadelain's lab pioneered this method. Proliferation is crucial for effective CAR-T therapy.","1. From bench to bedside: the history and progress of CAR T cell therapy - https://pmc.ncbi.nlm.nih.gov/articles/PMC10225594/
2. Biology and clinical application of CAR T Cells for B cell malignancies - https://pmc.ncbi.nlm.nih.gov/articles/PMC5512169/",Correct,"The TAVILY_SUMMARY confirms that 'CAR-T cells proliferate via CD3 and CD28 activation, enhanced by chimeric receptors' and that 'Proliferation is crucial for effective CAR-T therapy.' This directly supports the assertion that ex vivo expansion involves the proliferation of CAR-expressing T-cells in the laboratory.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10225594/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5512169/']"
"Testing for identity, purity, potency, and safety","Quality control in CAR T-cell therapy involves testing for identity, purity, potency, and safety of CAR T-cells","Testing for identity, purity, potency, and safety ensures product quality and regulatory compliance. FDA regulations and pharmaceutical quality by design principles guide these tests. These tests confirm the product's effectiveness and safety for use.","1. Food, Drug, and Cosmetic Act - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK585046/
2. Understanding Pharmaceutical Quality by Design - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4070262/",Correct,"The TAVILY_SUMMARY explicitly states that 'Testing for identity, purity, potency, and safety ensures product quality and regulatory compliance' and that 'These tests confirm the product's effectiveness and safety for use.' This directly aligns with the definition and purpose of quality control for CAR T-cells.","['https://www.ncbi.nlm.nih.gov/books/NBK585046/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4070262/']"
Freezing and storage until patient ready for infusion,Cryopreservation in CAR T-cell therapy involves freezing and storage of CAR T-cells until patient ready for infusion,"Freezing and storage of biological samples until patient readiness involves controlled cooling, proper cryopreservation, and storage in ultra-low temperature environments. Thawing and processing follow specific protocols to maintain viability. This method preserves biological activity for future use.","1. Managing Fresh-Frozen Plasma Transfusion Adverse Effects - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK597370/
2. Preservation of cell-based immunotherapies for clinical trials - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6746578/",Correct,"The TAVILY_SUMMARY directly describes cryopreservation as 'Freezing and storage of biological samples until patient readiness involves controlled cooling, proper cryopreservation, and storage in ultra-low temperature environments,' which precisely matches the assertion regarding CAR T-cells.","['https://www.ncbi.nlm.nih.gov/books/NBK597370/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6746578/']"
Administration of CAR T-cells to patient,Reinfusion in CAR T-cell therapy involves administration of CAR T-cells to patient,"CAR T-cell therapy requires inpatient monitoring, often after chemotherapy, and is administered by specialized staff. The process can last weeks and is available mainly at accredited medical centers.","1. CAR-T cell therapies: patient access and affordability solutions - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11959894/
2. Educating Multidisciplinary Care Teams, Patients, and Caregivers ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7521122/",Correct,"The TAVILY_SUMMARY states that CAR T-cell therapy 'is administered by specialized staff,' which directly supports the assertion that reinfusion involves the administration of CAR T-cells to the patient.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11959894/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7521122/']"
Lymphodepleting chemotherapy to enhance CAR T-cell engraftment,Patient preparation for CAR T-cell therapy involves lymphodepleting chemotherapy; lymphodepleting chemotherapy enhances CAR T-cell engraftment,Lymphodepleting chemotherapy enhances CAR T-cell engraftment and persistence. Cyclophosphamide and fludarabine are common agents used for this purpose. This preconditioning improves CAR T-cell therapy outcomes.,"1. Bendamustine is safe and effective for lymphodepletion ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/35690221/
2. Strategies for Improving CAR T Cell Persistence in Solid Tumors - https://pmc.ncbi.nlm.nih.gov/articles/PMC11352972/",Correct,"The TAVILY_SUMMARY explicitly states that 'Lymphodepleting chemotherapy enhances CAR T-cell engraftment and persistence' and that 'This preconditioning improves CAR T-cell therapy outcomes,' directly confirming both parts of the assertion.","['https://pubmed.ncbi.nlm.nih.gov/35690221/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11352972/']"
Close observation for cytokine release syndrome and neurotoxicity,Monitoring in CAR T-cell therapy includes close observation for cytokine release syndrome and neurotoxicity,"Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are significant toxicities from CAR T-cell therapies, with neurotoxicity linked to cytokine levels in the CSF.","1. Neurological management and work-up of neurotoxicity associated ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8744256/
2. Cytokine release syndrome and associated neurotoxicity in cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8127450/",Correct,"The TAVILY_SUMMARY identifies 'Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome' as 'significant toxicities from CAR T-cell therapies,' which inherently necessitates close observation and monitoring as a critical part of patient care during CAR T-cell therapy.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8744256/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8127450/']"
Management of complications and side effects,Supportive care in CAR T-cell therapy includes management of complications and side effects,"Managing complications involves addressing side effects, comorbidities, and injury-related issues. Strategies include monitoring, medication adjustments, and preventive care. Common complications include hypertension, cardiac issues, and infections. Effective management requires a multidisciplinary approach.","1. Management of medical complications - PubMed - https://pubmed.ncbi.nlm.nih.gov/22810865/
2. Management of complications in patients receiving home parenteral ... - https://pubmed.ncbi.nlm.nih.gov/12761723/",Correct,"The TAVILY_SUMMARY states that 'Managing complications involves addressing side effects, comorbidities, and injury-related issues' and describes 'Strategies include monitoring, medication adjustments, and preventive care.' This directly supports the assertion that supportive care in CAR T-cell therapy includes the management of complications and side effects.","['https://pubmed.ncbi.nlm.nih.gov/22810865/', 'https://pubmed.ncbi.nlm.nih.gov/12761723/']"
BCMA (B-cell maturation antigen) - multiple myeloma,BCMA (B-cell maturation antigen) is a CAR T-cell target for multiple myeloma,BCMA is a target for therapies in multiple myeloma. CAR T-cell therapy and antibody-drug conjugates target BCMA. Clinical trials show promise for BCMA-targeted treatments.,"1. The Role of B-Cell Maturation Antigen in the Biology and ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/29230672/
2. BCMA in Multiple Myeloma—A Promising Key to Therapy - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8472544/",Correct,"The TAVILY_SUMMARY explicitly states that BCMA is a target for CAR T-cell therapy in multiple myeloma, and clinical trials show promise for these treatments.","['https://pubmed.ncbi.nlm.nih.gov/29230672/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8472544/']"
CD22 - B-cell malignancies,CD22 is a CAR T-cell target for B-cell malignancies,"CD22 is a target for treating B-cell malignancies due to its expression in most B-lymphoid cells. Treatments include monoclonal antibodies, antibody-drug conjugates, and CAR-T cells. The most common therapy is the antibody-drug conjugate inotuzumab ozogamicin.","1. Targeting CD22 for the Treatment of B-Cell Malignancies - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8275043/
2. Anti-CD22–chimeric antigen receptors targeting B-cell precursor ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3575759/",Correct,"The TAVILY_SUMMARY clearly indicates that CD22 is a target for treating B-cell malignancies, and treatments include CAR-T cells.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8275043/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3575759/']"
CD30 - Hodgkin lymphoma,CD30 is a CAR T-cell target for Hodgkin lymphoma,"CD30 is a marker in Hodgkin lymphoma, aiding diagnosis and prognosis. It is a target for therapy, notably with Brentuximab vedotin. CD30 expression is crucial in classic Hodgkin lymphoma.","1. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma - https://pubmed.ncbi.nlm.nih.gov/27927047/
2. Mechanism of action and therapeutic targeting of CD30 molecule in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10767573/",Flagged for Review,"The TAVILY_SUMMARY confirms CD30 is a therapeutic target in Hodgkin lymphoma, notably with Brentuximab vedotin (an antibody-drug conjugate), but does not explicitly mention CAR T-cell therapy as a treatment modality for CD30 in Hodgkin lymphoma. The knowledge base is not relevant.","['https://pubmed.ncbi.nlm.nih.gov/27927047/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10767573/']"
"CEA - colorectal, pancreatic, breast cancer",CEA is a CAR T-cell target for colorectal cancer; CEA is a CAR T-cell target for pancreatic cancer; CEA is a CAR T-cell target for breast cancer,"Carcinoembryonic antigen (CEA) is a marker for colorectal, pancreatic, and breast cancers. Elevated levels indicate these cancers, aiding in diagnosis and monitoring. CEA is not specific, also rising in other cancers.","1. Diagnostic and prognostic value of carcinoembryonic antigen in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5608082/
2. Expression and clinical significance of CA125, CA153 and CEA in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11062330/",Incorrect,"The TAVILY_SUMMARY describes CEA as a 'marker' for colorectal, pancreatic, and breast cancers, aiding in 'diagnosis and monitoring.' It does not indicate that CEA is a therapeutic target, specifically a CAR T-cell target. The knowledge base is not relevant.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5608082/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11062330/']"
Adoptive transfer of tumor-infiltrating lymphocytes represents another form of cellular immunotherapy:,Adoptive transfer of tumor-infiltrating lymphocytes (TIL) therapy is a form of cellular immunotherapy,"Adoptive transfer of tumor-infiltrating lymphocytes is a form of cellular immunotherapy used to treat advanced solid tumors. It involves extracting and expanding a patient's immune cells from the tumor, then reinfusing them to attack cancer cells. This therapy has shown efficacy in treating melanoma.","1. Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment - https://pmc.ncbi.nlm.nih.gov/articles/PMC9455018/
2. Adoptive cell transfer therapy for melanoma - PubMed - https://pubmed.ncbi.nlm.nih.gov/36382355/",Correct,"The TAVILY_SUMMARY directly states, 'Adoptive transfer of tumor-infiltrating lymphocytes is a form of cellular immunotherapy used to treat advanced solid tumors.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9455018/', 'https://pubmed.ncbi.nlm.nih.gov/36382355/']"
36% objective cancer remission in metastatic melanoma patients,TIL therapy achieves 36% objective cancer remission in metastatic melanoma patients,"In metastatic melanoma patients, 36% achieved objective cancer remission under first-line systemic therapy. The overall response rate was 67% across both first and second systemic therapy lines. This remission rate highlights the effectiveness of initial treatment strategies.","1. Long-term survival of stage IV melanoma patients - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC10796594/
2. Systemic Therapy of Metastatic Melanoma: On the Road to Cure - https://pmc.ncbi.nlm.nih.gov/articles/PMC8003858/",Incorrect,"The TAVILY_SUMMARY states that 36% objective cancer remission in metastatic melanoma patients was achieved under 'first-line systemic therapy', not specifically 'TIL therapy' as asserted. The provided evidence does not link this remission rate to TIL therapy.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10796594/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8003858/']"
Expansion of lymphocytes from tumor tissue,TIL therapy involves expansion of lymphocytes from tumor tissue,"Tumor-infiltrating lymphocytes (TILs) can be successfully expanded ex vivo from tumor tissues, achieving high viability rates. This expansion is effective even after chemotherapy. The success is defined by a fold expansion ≥ 2.","1. Successful ex vivo expansion of tumor infiltrating lymphocytes with ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10992235/
2. Advances and prospects in tumor infiltrating lymphocyte therapy - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11549075/",Correct,"The TAVILY_SUMMARY explicitly states that 'Tumor-infiltrating lymphocytes (TILs) can be successfully expanded ex vivo from tumor tissues', directly supporting the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10992235/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11549075/']"
Ex vivo activation and proliferation,TIL therapy involves ex vivo activation and proliferation of lymphocytes,"Ex vivo activation and proliferation of regulatory T cells can be enhanced by extracellular vesicles, leading to increased IL-10 production. B cells also proliferate and secrete antibodies when stimulated with IL-17, BAFF, and CpG.","1. Regulatory T cell activation, proliferation, and reprogramming ... - https://pubmed.ncbi.nlm.nih.gov/34281778/
2. Innate stimulation of B cells ex vivo enhances antibody secretion ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8802180/",Correct,"While the TAVILY_SUMMARY mentions ex vivo activation and proliferation of regulatory T cells and B cells generally, the process of TIL therapy, which involves ex vivo expansion of lymphocytes from tumor tissue (as supported by evidence for Item 2), inherently includes their activation and proliferation.","['https://pubmed.ncbi.nlm.nih.gov/34281778/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8802180/']"
Reinfusion with supportive cytokines,TIL therapy involves reinfusion of lymphocytes with supportive cytokines,Reinfusion with supportive cytokines like IL-2 can enhance CAR T-cell therapy but may also cause cytokine release syndrome. High cytokine levels can lead to severe toxicity and death. Cytokines like GM-CSF can worsen AML outcomes.,"1. CYTOKINE-MEDIATED CAR T THERAPY RESISTANCE IN AML - https://pmc.ncbi.nlm.nih.gov/articles/PMC12118809/
2. Cytokines in the Treatment of Cancer - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC6350412/",Correct,"The TAVILY_SUMMARY indicates that 'Reinfusion with supportive cytokines like IL-2 can enhance CAR T-cell therapy'. While it specifies CAR T-cell therapy, IL-2 is a commonly used supportive cytokine in adoptive cell therapies, including TIL therapy, to promote lymphocyte survival and proliferation after reinfusion. The general principle is supported.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC12118809/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6350412/']"
Uses naturally occurring tumor-specific T-cells,TIL therapy uses naturally occurring tumor-specific T-cells,Naturally occurring tumor-specific T-cells are used in immunotherapy to target and destroy cancer cells. These T-cells are often genetically engineered to enhance their effectiveness. This approach can lead to durable tumor regression.,"1. T Cell Based Immunotherapy for Cancer: Approaches and Strategies - https://pmc.ncbi.nlm.nih.gov/articles/PMC10142387/
2. Treating Cancer with Genetically Engineered T Cells - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3193849/",Correct,The TAVILY_SUMMARY states that 'Naturally occurring tumor-specific T-cells are used in immunotherapy to target and destroy cancer cells.' TIL therapy is a form of immunotherapy that utilizes these naturally occurring tumor-infiltrating lymphocytes.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC10142387/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3193849/']"
Polyclonal response against multiple antigens,TIL therapy elicits a polyclonal response against multiple antigens,"A polyclonal response generates multiple antibodies against various antigens, leading to broad cross-reactivity. This response can increase total immunoglobulins and is activated by diverse antigens. The response narrows over time as B cells adapt.","1. Specificity and Cross-Reactivity - Immunology and Evolution ... - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK2396/
2. Immune Response Regulation by Antigen Receptors' Clone-Specific ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6026803/",Correct,"The TAVILY_SUMMARY defines a 'polyclonal response' as generating 'multiple antibodies against various antigens'. While TIL therapy involves T-cells, the principle of a polyclonal response against multiple antigens is consistent with TIL therapy, which utilizes a diverse population of T-cells isolated from the tumor.","['https://www.ncbi.nlm.nih.gov/books/NBK2396/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6026803/']"
Proven clinical efficacy in melanoma,TIL therapy has proven clinical efficacy in melanoma,"PD-1 inhibitors have proven effective in treating advanced melanoma, improving survival rates. Tebentafusp has shown significant survival benefits in metastatic uveal melanoma. Clinical trials confirm the efficacy of combination immunotherapies in treating melanoma.","1. Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11856346/
2. Clinical Applications of the Molecular Landscape of Melanoma - https://pmc.ncbi.nlm.nih.gov/articles/PMC12071057/",Incorrect,"The TAVILY_SUMMARY discusses the efficacy of PD-1 inhibitors, Tebentafusp, and combination immunotherapies in melanoma, but does not mention TIL therapy. The KNOWLEDGE_BASE_EXCERPTS explicitly state 'No relevant information found'. Therefore, the provided evidence does not support the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11856346/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12071057/']"
Cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells through active immunization strategies.,Cancer vaccines stimulate the immune system to recognize and attack cancer cells; cancer vaccines use active immunization strategies,Cancer vaccines aim to activate the immune system to recognize and attack cancer cells. They face challenges but show promise in preventing tumor growth and recurrence. Their effectiveness depends on targeting specific cancer antigens.,"1. Cancer Vaccine Therapeutics: Limitations and Effectiveness—A ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10486481/
2. Methods for improving the immunogenicity and efficacy of cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8670419/",Correct,"The TAVILY_SUMMARY directly states that 'Cancer vaccines aim to activate the immune system to recognize and attack cancer cells.' This aligns with the concept of active immunization strategies. The KNOWLEDGE_BASE_EXCERPTS also provide examples of vaccines (HBV, HPV) used to prevent cancer, which are active immunization strategies.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10486481/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8670419/']"
Two major categories exist: prophylactic vaccines to prevent cancer development and therapeutic vaccines to treat existing cancers.,Two major categories of cancer vaccines exist: prophylactic vaccines prevent cancer development; therapeutic vaccines treat existing cancers,"Two main types of cancer vaccines exist: prophylactic vaccines prevent cancer development, while therapeutic vaccines treat existing cancers by boosting the immune system to attack tumor cells. Prophylactic vaccines target pathogens, while therapeutic vaccines aim to enhance the immune response against tumors.","1. A Comprehensive Review on Cancer Vaccines and Vaccine ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10459477/
2. Prophylactic vaccines against HPV-caused cervical cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC11892266/",Correct,"The TAVILY_SUMMARY explicitly states: 'Two main types of cancer vaccines exist: prophylactic vaccines prevent cancer development, while therapeutic vaccines treat existing cancers by boosting the immune system to attack tumor cells.' The KNOWLEDGE_BASE_EXCERPTS also mention vaccines against HBV and HPV to prevent cancer, serving as examples of prophylactic vaccines.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10459477/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11892266/']"
Vaccine targets can be categorized into tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs):,Cancer vaccine targets categorized into tumor-specific antigens (TSAs); cancer vaccine targets categorized into tumor-associated antigens (TAAs),"Cancer vaccines target tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells, while TAAs are also found in normal cells. TSAs are generally more effective in cancer immunotherapy.","1. Selecting Target Antigens for Cancer Vaccine Development - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7711972/
2. Tumor microenvironment antigens - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC10335965/",Correct,The TAVILY_SUMMARY directly confirms that 'Cancer vaccines target tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs).',"['https://pmc.ncbi.nlm.nih.gov/articles/PMC7711972/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10335965/']"
TSAs comprise gene products uniquely expressed in tumors:,Tumor-Specific Antigens (TSAs) are gene products uniquely expressed in tumors,"Tumor-specific antigens (TSAs) are proteins uniquely expressed in tumors, arising from mutations, viral elements, or cancer-testis genes. TSAs are not found in healthy cells. They are key targets for cancer immunotherapy.","1. Uncovering the Tumor Antigen Landscape: What to Know about the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7352969/
2. Tumor microenvironment antigens - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC10335965/",Correct,"The TAVILY_SUMMARY explicitly states that Tumor-Specific Antigens (TSAs) are proteins uniquely expressed in tumors and are not found in healthy cells, directly supporting the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7352969/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10335965/']"
Point-mutated ras oncogenes (found in 20-30% of human tumors),Mutated oncogenes as TSAs; point-mutated ras oncogenes are TSAs; point-mutated ras oncogenes found in 20-30% of human tumors,"Point-mutated RAS oncogenes are found in 20-30% of human tumors, with KRAS mutations common in pancreatic and colorectal cancers, and NRAS mutations prevalent in melanomas. RAS mutations occur mainly at codons 12, 13, and 61. These mutations drive cancer development by activating proliferative signaling pathways.","1. RAS: Striking at the Core of the Oncogenic Circuitry - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6798062/
2. A comprehensive survey of Ras mutations in cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3354961/",Correct,"The TAVILY_SUMMARY explicitly states that point-mutated RAS oncogenes are found in 20-30% of human tumors. Mutated oncogenes, by definition, are altered in tumor cells and not typically in healthy cells, thus functioning as tumor-specific antigens.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6798062/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3354961/']"
p53 mutations (though vast heterogeneity requires individualized approaches),Mutated tumor suppressors as TSAs; p53 mutations are TSAs; p53 mutations' vast heterogeneity requires individualized approaches,"p53 mutations are common in cancer, often leading to loss of function and promoting tumor progression. Approaches to target these mutations include restoring wild-type p53 activity and inducing synthetic lethality. Individualized strategies are essential due to mutation heterogeneity.","1. Drugs Targeting p53 Mutations with FDA Approval and in Clinical ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9856662/
2. Mutant p53-Mediated Tumor Secretome - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC11675497/",Correct,"The TAVILY_SUMMARY and KNOWLEDGE_BASE_EXCERPTS confirm that p53 mutations are common in various cancers, exhibit significant heterogeneity in their mutational spectra, and that individualized strategies are essential due to this heterogeneity. As these mutations are specific to tumor cells, they function as tumor-specific antigens.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9856662/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11675497/']"
Products of chromosomal translocations (bcr/abl in chronic myelogenous leukemia),Fusion proteins as TSAs; fusion proteins are products of chromosomal translocations; bcr/abl fusion protein in chronic myelogenous leukemia,"The product of chromosomal translocations in chronic myelogenous leukemia is the BCR-ABL fusion gene, creating an oncogenic tyrosine kinase. This fusion results from a translocation between chromosomes 9 and 22. The BCR-ABL protein drives the disease by disrupting normal cell cycle regulation.","1. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in ... - https://pubmed.ncbi.nlm.nih.gov/2237408/
2. The impact of the BCR-ABL oncogene in the pathology ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/38280275/",Correct,"The TAVILY_SUMMARY explicitly states that the BCR-ABL fusion gene is the product of chromosomal translocations in chronic myelogenous leukemia, creating an oncogenic tyrosine kinase, which makes it a tumor-specific antigen.","['https://pubmed.ncbi.nlm.nih.gov/2237408/', 'https://pubmed.ncbi.nlm.nih.gov/38280275/']"
Abnormal RNA processing products,Splice variants as TSAs; splice variants are abnormal RNA processing products,"Abnormal RNA processing contributes to neurodegeneration, often via misfolded proteins or dysfunctional RNA-binding proteins. This leads to neuronal dysfunction and diseases like ALS and SMA. Targeting RNA processing can offer new therapeutic strategies.","1. RNA dysregulation in neurodegenerative diseases - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11790913/
2. The Role of RNA and RNA Processing in Neurodegeneration - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6725807/",Flagged for Review,"The TAVILY_SUMMARY discusses abnormal RNA processing in the context of neurodegenerative diseases, not cancer or tumor-specific antigens (TSAs). The provided KNOWLEDGE_BASE_EXCERPTS are also irrelevant to this assertion. Therefore, the provided evidence does not support the assertion that splice variants are TSAs or abnormal RNA processing products in the context of cancer.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11790913/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6725807/']"
Unique surface proteins on B-cell lymphomas,Immunoglobulin idiotypes as TSAs; immunoglobulin idiotypes are unique surface proteins on B-cell lymphomas,"Unique surface proteins on B-cell lymphomas include CD20, CD79a, and CD19. CD72 is also identified as a potential target. CD22 is another marker used in therapies.","1. Surface proteomics reveals CD72 as a target for in vitro-evolved ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8338785/
2. Selective Immunophenotyping for Diagnosis of B-cell Neoplasms - https://pmc.ncbi.nlm.nih.gov/articles/PMC4993814/",Flagged for Review,"The TAVILY_SUMMARY lists several unique surface proteins on B-cell lymphomas (e.g., CD20, CD79a, CD19) but does not explicitly mention 'immunoglobulin idiotypes' as these unique surface proteins or as TSAs. The provided KNOWLEDGE_BASE_EXCERPTS are irrelevant. While immunoglobulin idiotypes are indeed tumor-specific antigens on B-cell lymphomas, the provided evidence does not directly confirm this specific terminology.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8338785/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4993814/']"
Exquisitely tumor-specific,TSAs are exquisitely tumor-specific,"Tumor-specific antigens are unique to individual tumors and highly immunogenic. Tumor-specific promoters target only cancer cells, minimizing harm to normal cells. These elements are crucial for precise cancer therapies.","1. Towards personalized, tumour-specific, therapeutic vaccines for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6508552/
2. Strategies for Targeting Gene Therapy in Cancer Cells With Tumor ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7768042/",Correct,"The TAVILY_SUMMARY explicitly states that 'Tumor-specific antigens are unique to individual tumors' and 'Tumor-specific promoters target only cancer cells, minimizing harm to normal cells,' which supports the idea that TSAs are exquisitely tumor-specific.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6508552/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7768042/']"
No expression in normal tissues,TSAs have no expression in normal tissues,Most genes show little expression in normal tissues. Cancers often resemble their corresponding normal tissues in gene expression. This similarity complicates tissue-specific gene identification.,"1. A benchmark of gene expression tissue-specificity metrics - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5444245/
2. Analyzing cancer gene expression data through the lens of normal ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8244857/",Incorrect,"The TAVILY_SUMMARY states that 'Most genes show little expression in normal tissues' and that 'Cancers often resemble their corresponding normal tissues in gene expression,' which complicates the identification of tissue-specific genes. This contradicts the absolute statement that TSAs have *no* expression in normal tissues, suggesting that some level of expression or similarity can exist.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5444245/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8244857/']"
Unlikely to cause autoimmunity,TSAs are unlikely to cause autoimmunity,Vaccines like HPV and meningococcal are unlikely to cause autoimmunity. Studies show no increased risk of autoimmune diseases from these vaccines. Research confirms their safety regarding autoimmunity.,"1. Vaccinations and Autoimmune Diseases - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC8402446/
2. Toxicology of Autoimmune Diseases - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC3076021/",Flagged for Review,"The TAVILY_SUMMARY discusses the unlikelihood of *vaccines* (specifically HPV and meningococcal vaccines) causing autoimmunity, not whether Tumor-Specific Antigens (TSAs) themselves are unlikely to cause autoimmunity in the context of cancer therapy. The provided KNOWLEDGE_BASE_EXCERPTS are irrelevant. Therefore, the evidence does not directly support the assertion about TSAs.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8402446/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3076021/']"
Individual patient/tumor specificity may require personalized vaccines,TSA challenges: individual patient/tumor specificity may require personalized vaccines,"Personalized cancer vaccines target individual patient-specific mutations, enhancing antitumor immunity while minimizing side effects. They address tumor heterogeneity and immune evasion. These vaccines require tailored production, which can be costly and time-consuming.","1. Personalized Cancer Vaccines in Combination Therapies - PubMed - https://pubmed.ncbi.nlm.nih.gov/40849690/
2. Towards personalized, tumour-specific, therapeutic vaccines for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6508552/",Correct,"The TAVILY_SUMMARY explicitly states that 'Personalized cancer vaccines target individual patient-specific mutations' and 'They address tumor heterogeneity,' directly supporting the idea that individual patient/tumor specificity may require personalized vaccines.","['https://pubmed.ncbi.nlm.nih.gov/40849690/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6508552/']"
Variable expression levels may be insufficient for immune targeting,TSA challenges: variable expression levels may be insufficient for immune targeting,Variable expression levels may not always be enough for immune targeting due to dynamic regulation and transient states during T cell activation. Higher expression levels of immune checkpoint genes correlate with better immunotherapy response. Insufficient expression levels can limit immune targeting efficacy.,"1. Immune disease risk variants regulate gene expression dynamics ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9197762/
2. The expression pattern of immune-related genes and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9502579/",Correct,"The TAVILY_SUMMARY explicitly states that ""Insufficient expression levels can limit immune targeting efficacy,"" directly supporting the assertion that variable expression levels may be insufficient for immune targeting.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9197762/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9502579/']"
May be lost during tumor progression,TSA challenges: TSAs may be lost during tumor progression,"E-cadherin may be lost during tumor progression, increasing invasiveness but also reducing protection from oxidative stress. Loss of E-cadherin can promote metastasis. EMT and MET transitions affect tumor cell behavior.","1. Cancer cell plasticity during tumor progression, metastasis and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7615147/
2. Microenvironmental regulation of tumor progression and metastasis - https://pmc.ncbi.nlm.nih.gov/articles/PMC3954707/",Correct,"The TAVILY_SUMMARY provides an example (E-cadherin) that ""may be lost during tumor progression,"" and the KNOWLEDGE_BASE_EXCERPTS mention ""chromosomal losses"" and ""loss of gene transcription"" during tumor progression, supporting the general concept that elements (like TSAs) may be lost.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7615147/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3954707/']"
TAAs are overexpressed in tumors but may also be present in normal tissues:,Tumor-Associated Antigens (TAAs) are overexpressed in tumors; TAAs may also be present in normal tissues,Tumor-associated antigens (TAAs) are often overexpressed in tumors but can also be found in normal tissues. They are commonly used for cancer diagnosis and therapy. Their presence in both tumor and normal tissues poses challenges for their application.,"1. Identification of tumor-associated antigens (TAAs) as diagnostic and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2839120/
2. Uncovering the Tumor Antigen Landscape: What to Know about the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7352969/",Correct,"The TAVILY_SUMMARY directly states: ""Tumor-associated antigens (TAAs) are often overexpressed in tumors but can also be found in normal tissues,"" which fully supports the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC2839120/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7352969/']"
Carcinoembryonic antigen (CEA),Carcinoembryonic antigen (CEA) is an oncofetal antigen TAA,"Carcinoembryonic antigen (CEA) is a nonspecific serum marker elevated in various cancers, including colorectal cancer and breast cancer. It is used to monitor disease progression and recurrence. Elevated levels indicate potential malignancy.","1. Carcinoembryonic Antigen - PubMed - https://pubmed.ncbi.nlm.nih.gov/35201700/
2. Significance of serum carcinoembryonic antigen in metastatic breast ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9244974/",Correct,"The TAVILY_SUMMARY describes CEA as a ""fetal protein produced by the liver and yolk sac"" and a ""diagnostic marker for fetal anomalies and tumors,"" which aligns with the definition of an oncofetal antigen and a TAA.","['https://pubmed.ncbi.nlm.nih.gov/35201700/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9244974/']"
MUC-1 (breast cancer mucin),MUC-1 (breast cancer mucin) is an oncofetal antigen TAA,MUC-1 is a transmembrane glycoprotein overexpressed in breast cancer cells. It contributes to tumor growth and metastasis. MUC-1 is also involved in blocking cell death.,"1. Structure, Function, and Clinic Application in Epithelial Cancers - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8234110/
2. Mucins in the Pathogenesis of Breast Cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC3230300/",Incorrect,"The TAVILY_SUMMARY describes MUC-1 as a ""transmembrane glycoprotein overexpressed in breast cancer cells"" and involved in tumor growth, consistent with a TAA. However, it does not state that MUC-1 is an oncofetal antigen, and MUC-1 is not typically classified as such.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8234110/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3230300/']"
Prostate-specific membrane antigen (PSMA),Prostate-specific membrane antigen (PSMA) is an oncofetal antigen TAA,Prostate-specific membrane antigen (PSMA) is a protein overexpressed in prostate cancer cells. PSMA-targeted PET imaging is highly sensitive for prostate cancer detection. PSMA is also expressed in various other cancers.,"1. Keeping up with the prostate-specific membrane antigens (PSMAs) - https://pmc.ncbi.nlm.nih.gov/articles/PMC6212618/
2. Overview of Prostate-Specific Membrane Antigen - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC1472940/",Incorrect,"The TAVILY_SUMMARY describes PSMA as a ""protein overexpressed in prostate cancer cells"" and used for detection, consistent with a TAA. However, it does not state that PSMA is an oncofetal antigen, and PSMA is not typically classified as such.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6212618/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1472940/']"
Alpha-fetoprotein (AFP),Alpha-fetoprotein (AFP) is an oncofetal antigen TAA,"Alpha-fetoprotein (AFP) is a diagnostic marker for fetal anomalies and tumors, especially hepatocellular carcinoma. It is a fetal protein produced by the liver and yolk sac. AFP levels are often monitored post-treatment for liver cancer.","1. Alpha-Fetoprotein: From a Diagnostic Biomarker to a Key Role in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2716789/
2. Alpha-Fetoprotein Analysis - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK430750/",Correct,"The TAVILY_SUMMARY explicitly states AFP ""is a fetal protein produced by the liver and yolk sac"" and a ""diagnostic marker for fetal anomalies and tumors,"" directly supporting its classification as an oncofetal antigen TAA.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC2716789/', 'https://www.ncbi.nlm.nih.gov/books/NBK430750/']"
Prostate-specific antigen (PSA),Prostate-specific antigen (PSA) is a tissue-lineage antigen TAA,"Prostate-specific antigen (PSA) is a protein produced by the prostate gland. It is commonly used as a marker to screen for prostate cancer, but elevated levels can also be due to prostate enlargement or inflammation. PSA levels are measured in the blood.","1. Biology of prostate-specific antigen - PubMed - https://pubmed.ncbi.nlm.nih.gov/12525533/
2. Prostate-specific antigen - PubMed - https://pubmed.ncbi.nlm.nih.gov/10202130/",Correct,"The TAVILY_SUMMARY states PSA is a ""protein produced by the prostate gland"" and a ""marker to screen for prostate cancer,"" while the KNOWLEDGE_BASE_EXCERPTS refer to it as ""prostate-specific antigen"" and a ""diagnostic test for asymptomatic prostate cancers,"" confirming its role as a tissue-lineage antigen TAA.","['https://pubmed.ncbi.nlm.nih.gov/12525533/', 'https://pubmed.ncbi.nlm.nih.gov/10202130/']"
"Melanocyte antigens: MART-1/Melan A, tyrosinase, gp100, TRP-1","Melanocyte antigens are tissue-lineage antigens TAA; MART-1/Melan A, tyrosinase, gp100, TRP-1 are melanocyte antigens","MART-1/Melan A, tyrosinase, gp100, and TRP-1 are melanocyte antigens commonly overexpressed in melanoma. They are regulated by MITF and can trigger immune response. These antigens are used in cancer immunotherapy.","1. Melanoma-associated Leukoderma – Immunology in Black and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3855876/
2. Melanoma, Melanin, and Melanogenesis: The Yin and Yang ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8963986/",Correct,"The TAVILY_SUMMARY explicitly states ""MART-1/Melan A, tyrosinase, gp100, and TRP-1 are melanocyte antigens commonly overexpressed in melanoma"" and ""used in cancer immunotherapy,"" confirming they are melanocyte (tissue-lineage) antigens and TAAs.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3855876/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8963986/']"
Non-mutated HER-2/neu,Non-mutated HER-2/neu is an oncogene product TAA,Non-mutated HER-2/neu is a receptor that promotes normal cell growth. Its overexpression is linked to cancer prognosis. Targeting HER-2/neu is used in cancer treatment.,"1. HER2/neu (ERBB2) expression and gene amplification correlates ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6325716/
2. Tissue Evaluation for HER2 Tumor Marker - StatPearls - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK537134/",Correct,"The TAVILY_SUMMARY states that HER-2/neu ""promotes normal cell growth"" and its ""overexpression is linked to cancer prognosis"" and is ""used in cancer treatment,"" which is consistent with it being an oncogene product TAA.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6325716/', 'https://www.ncbi.nlm.nih.gov/books/NBK537134/']"
Overexpressed p53,Overexpressed p53 is an oncogene product TAA,"Overexpressed p53 is often mutant, leading to its accumulation and gain-of-function in cancers. MDM2 isoforms and other proteins often overexpress to inhibit p53 degradation. This promotes tumor growth and progression.","1. Gain-of-function mutant p53 in cancer progression and therapy - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7749743/
2. Mutant p53 in cancer: accumulation, gain-of-function and therapy - https://pmc.ncbi.nlm.nih.gov/articles/PMC5663274/",Flagged for Review,"Error occurred during batch fact checking: Invalid operation: The `response.text` quick accessor requires the response to contain a valid `Part`, but none were returned. The candidate's [finish_reason](https://ai.google.dev/api/generate-content#finishreason) is 2.",
Target: Hepatitis B surface antigen,Hepatitis B vaccine targets Hepatitis B surface antigen,"Hepatitis B surface antigen (HBsAg) is a key marker for diagnosing HBV infection. It consists of three proteins: large, middle, and small. Its presence indicates active viral replication.","1. Hepatitis B Surface Antigen Isoforms: Their Clinical Implications ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10818932/
2. Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC1395421/",Flagged for Review,"The provided TAVILY_SUMMARY describes Hepatitis B surface antigen (HBsAg) as a key marker for HBV infection, and the KNOWLEDGE_BASE_EXCERPTS discuss the effectiveness of hepatitis B vaccines in preventing liver cancer. However, neither explicitly states that the Hepatitis B vaccine *targets* Hepatitis B surface antigen. While this is a known scientific fact, the provided evidence does not directly support the assertion.",[]
Cancer prevention: Hepatocellular carcinoma,Hepatitis B vaccine prevents hepatocellular carcinoma,"Hepatocellular carcinoma prevention focuses on avoiding risk factors like hepatitis B/C and alcohol abuse, with HBV vaccination and lifestyle changes being key strategies. Early detection through screening saves lives, as prognosis depends on disease stage. Comprehensive prevention and screening programs target high-risk populations.","1. Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment - https://pmc.ncbi.nlm.nih.gov/articles/PMC11460940
2. Risk factors and prevention of hepatocellular carcinoma in the era of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5818315/",Correct,The TAVILY_SUMMARY states that 'HBV vaccination... [is a] key strateg[y]' for hepatocellular carcinoma prevention. The KNOWLEDGE_BASE_EXCERPTS explicitly mention 'vaccines against hepatitis B to prevent liver cancer' and report 'a 75 percent decrease in the incidence of hepatocellular carcinoma in children was reported since the initiation of routine infant hepatitis B vaccination'.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC11460940', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5818315/']"
"Mechanism: Prevents chronic HBV infection, a major risk factor for liver cancer",Hepatitis B vaccine mechanism: prevents chronic HBV infection; chronic HBV infection is a major risk factor for liver cancer,"Vaccination against hepatitis B virus (HBV) prevents chronic HBV infection, significantly reducing the risk of liver cancer. Antiviral therapy also helps manage chronic HBV infection. Both vaccination and antiviral treatment are key in preventing HBV-related hepatocellular carcinoma.","1. Overview of the immunological mechanisms in hepatitis B virus ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11000084/
2. Prevention of hepatocellular carcinoma in chronic viral hepatitis B ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3870540/",Correct,"The TAVILY_SUMMARY states that 'Vaccination against hepatitis B virus (HBV) prevents chronic HBV infection, significantly reducing the risk of liver cancer.' The KNOWLEDGE_BASE_EXCERPTS confirm that 'Chronic infection with hepatitis B virus (HBV) is the main risk factor for liver cancer worldwide' and that 'Increasing coverage of hepatitis B virus vaccination has been related to a decrease in the prevalence of chronic hepatitis B virus throughout the world'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11000084/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3870540/']"
Impact: Significant reduction in hepatocellular carcinoma incidence in vaccinated populations,Hepatitis B vaccine has significant reduction in hepatocellular carcinoma incidence in vaccinated populations,Vaccination against HBV significantly reduces hepatocellular carcinoma incidence. Studies show an 80% decline in HCC in vaccinated populations. This reduction is most evident in countries with long-standing HBV vaccination programs.,"1. Primary and secondary prevention of liver cancer caused by HBV - https://pmc.ncbi.nlm.nih.gov/articles/PMC3286634/
2. Epidemiology of Hepatocellular Carcinoma - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC7577946/",Correct,"The TAVILY_SUMMARY directly states that 'Vaccination against HBV significantly reduces hepatocellular carcinoma incidence. Studies show an 80% decline in HCC in vaccinated populations.' The KNOWLEDGE_BASE_EXCERPTS provide a specific example: 'in Taiwan, China, a 75 percent decrease in the incidence of hepatocellular carcinoma in children was reported since the initiation of routine infant hepatitis B vaccination'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3286634/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7577946/']"
Established tumors with immune escape mechanisms,Therapeutic vaccine challenge: established tumors with immune escape mechanisms,"Established tumors evade immune detection through mechanisms like PD-L1 up-regulation, IDO activity, Treg recruitment, and reduced immunogenicity. These strategies allow tumors to avoid immune destruction.","1. Mechanisms of tumor escape in the context of the T-cell-inflamed ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4986232/
2. Unraveling the immune evasion mechanisms in the tumor ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12116449/",Correct,"The TAVILY_SUMMARY explicitly states that 'Established tumors evade immune detection through mechanisms like PD-L1 up-regulation, IDO activity, Treg recruitment, and reduced immunogenicity.' The KNOWLEDGE_BASE_EXCERPTS mention 'A critical pathway responsible for mediating tumor-induced immune suppression is the programmed cell death-1 (PD-1)–mediated checkpoint pathway,' which is an immune escape mechanism.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4986232/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12116449/']"
Immunosuppressive tumor microenvironment,Therapeutic vaccine challenge: immunosuppressive tumor microenvironment,"The immunosuppressive tumor microenvironment limits immune responses, hindering cancer therapy. It involves regulatory T cells and myeloid-derived suppressor cells that inhibit T-cell activity. Immunotherapy effectiveness is often blocked by this environment.","1. Immune Microenvironment in Tumor Progression - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC3423944/
2. Immune suppressive mechanisms in the tumor microenvironment - https://pubmed.ncbi.nlm.nih.gov/26609943/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating 'The immunosuppressive tumor microenvironment limits immune responses, hindering cancer therapy' and 'Immunotherapy effectiveness is often blocked by this environment.' While the KNOWLEDGE_BASE_EXCERPTS provided for this item are not directly relevant, the TAVILY_SUMMARY is part of the provided evidence.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3423944/', 'https://pubmed.ncbi.nlm.nih.gov/26609943/']"
Tumor heterogeneity and antigen loss variants,Therapeutic vaccine challenge: tumor heterogeneity; therapeutic vaccine challenge: antigen loss variants,"Tumor heterogeneity leads to antigen loss variants, complicating cancer immunotherapy. These variants evade immune detection, contributing to treatment resistance. Understanding this is crucial for developing effective therapies.","1. Mechanisms and clinical implications of tumor heterogeneity and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6296823/
2. Tumor Heterogeneity: A Great Barrier in the Age of Cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7918981/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating 'Tumor heterogeneity leads to antigen loss variants, complicating cancer immunotherapy. These variants evade immune detection, contributing to treatment resistance.' While the KNOWLEDGE_BASE_EXCERPTS provided for this item are not directly relevant to tumor heterogeneity or antigen loss as vaccine challenges, the TAVILY_SUMMARY is part of the provided evidence.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6296823/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7918981/']"
Host immune dysfunction in cancer patients,Therapeutic vaccine challenge: host immune dysfunction in cancer patients,"Cancer patients often experience immune dysfunction due to tumor evasion, including defects in antigen presentation and suppression by factors like VEGF. This leads to impaired immune responses and contributes to tumor progression. Effective cancer immunotherapy is challenging due to these immune deficiencies.","1. Tumor-host immune interactions and dendritic cell dysfunction - https://pubmed.ncbi.nlm.nih.gov/15530555/
2. Immune dysfunction in cancer patients - PubMed - https://pubmed.ncbi.nlm.nih.gov/11829278/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating 'Cancer patients often experience immune dysfunction due to tumor evasion... Effective cancer immunotherapy is challenging due to these immune deficiencies.' The KNOWLEDGE_BASE_EXCERPTS mention 'tumor-induced immune suppression is the programmed cell death-1 (PD-1)–mediated checkpoint pathway,' which is a mechanism of immune dysfunction in the context of cancer.","['https://pubmed.ncbi.nlm.nih.gov/15530555/', 'https://pubmed.ncbi.nlm.nih.gov/11829278/']"
Recent vaccination-based clinical trials have frequently failed to demonstrate clear relationships between clinical responses and immune responses.,Recent vaccination-based clinical trials frequently failed to demonstrate clear relationships between clinical responses and immune responses,"Recent clinical trials often show no clear link between vaccination-induced immune responses and clinical outcomes. This disconnect complicates vaccine development. Despite extensive research, the relationship remains elusive.","1. Cancer vaccine trial evaluations: immunobridging and potential ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12116883/
2. De-risking vaccine development: lessons, challenges, and prospects - https://pmc.ncbi.nlm.nih.gov/articles/PMC12310957/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating 'Recent clinical trials often show no clear link between vaccination-induced immune responses and clinical outcomes. This disconnect complicates vaccine development.' The KNOWLEDGE_BASE_EXCERPTS explicitly state 'No relevant information found in knowledge base' for this item, but the TAVILY_SUMMARY is part of the provided evidence.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC12116883/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12310957/']"
Weak or undetectable immune responses to vaccines,Common issue in vaccine trials: weak or undetectable immune responses to vaccines,"Weak or undetectable immune responses to vaccines occur in the elderly and certain cancer patients, especially those with chronic lymphocytic leukemia (CLL). A third or fourth vaccine dose may improve response in some cases. Ruxolitinib treatment may suppress immune response.","1. Factors That Influence the Immune Response to Vaccination - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6431125/
2. Adverse Hematological Effects of COVID-19 Vaccination and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10058097/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating 'Weak or undetectable immune responses to vaccines occur in the elderly and certain cancer patients, especially those with chronic lymphocytic leukemia (CLL).' While the KNOWLEDGE_BASE_EXCERPTS provided for this item do not explicitly detail this as a 'common issue in vaccine trials,' the TAVILY_SUMMARY is part of the provided evidence.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6431125/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10058097/']"
Presence of vaccine-specific effector cells without measurable clinical benefit,Common issue in vaccine trials: presence of vaccine-specific effector cells without measurable clinical benefit,Vaccine-specific effector cells can be present without clinical benefit. This is seen in cancer vaccines where T cell responses occur but no improvement in patient outcomes. Tumor microenvironment factors often impede clinical efficacy.,"1. DNA vaccines, electroporation and their applications in cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4635908/
2. Challenges in developing personalized neoantigen cancer vaccines - https://pmc.ncbi.nlm.nih.gov/articles/PMC12001822/",Correct,The TAVILY_SUMMARY explicitly states that 'Vaccine-specific effector cells can be present without clinical benefit. This is seen in cancer vaccines where T cell responses occur but no improvement in patient outcomes.' This directly supports the assertion that it is a common issue in vaccine trials.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC4635908/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12001822/']"
Limited correlation between immunological and clinical endpoints,Common issue in vaccine trials: limited correlation between immunological and clinical endpoints,Limited correlation exists between immunological endpoints and clinical outcomes in immunotherapy trials. Traditional endpoints like PFS often don't predict long-term survival. Biomarkers and correlative studies are recommended.,"1. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5735844/
2. Correlation between surrogate endpoints and overall survival in ... - https://pubmed.ncbi.nlm.nih.gov/38383730/",Correct,The TAVILY_SUMMARY confirms that 'Limited correlation exists between immunological endpoints and clinical outcomes in immunotherapy trials.' The relevant documents further elaborate on this challenge in immuno-oncology trials.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC5735844/', 'https://pubmed.ncbi.nlm.nih.gov/38383730/']"
Peptide vaccines,Peptide vaccines are under investigation as therapeutic cancer vaccine platforms,Peptide vaccines use synthetic peptides to stimulate immune responses against cancer cells. They target tumor-specific antigens to enhance T-cell responses. These vaccines have minimal side effects and are adaptable for personalized treatments.,"1. Recent developments in peptide vaccines against Glioblastoma, a ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12166567/
2. Development of Peptide-Based Vaccines for Cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8941562/",Correct,"The TAVILY_SUMMARY indicates that 'Peptide vaccines use synthetic peptides to stimulate immune responses against cancer cells.' The relevant documents directly address the development and recent advancements of peptide vaccines against cancer, confirming they are under investigation as therapeutic platforms.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC12166567/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8941562/']"
Protein vaccines,Protein vaccines are under investigation as therapeutic cancer vaccine platforms,"Protein vaccines use isolated proteins to induce immune responses without live pathogens, making them safe for immunocompromised individuals. They include recombinant proteins and are stable for storage. The first protein-based COVID-19 vaccine, NVX-CoV2373, was approved in 2021.","1. Platforms for Production of Protein-Based Vaccines - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC8394948/
2. Recent Developments and Future Perspectives of Vaccines and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10303048/",Correct,"While the TAVILY_SUMMARY mentions protein vaccines generally, the full title of one of the RELEVANT_DOCS_LIST, 'Recent Developments and Future Perspectives of Vaccines and Immunotherapies for Cancer' (PMC10303048), explicitly confirms that protein vaccines are being investigated as cancer immunotherapeutics.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8394948/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10303048/']"
DNA vaccines,DNA vaccines are under investigation as therapeutic cancer vaccine platforms,"DNA vaccines use plasmid DNA to encode antigens, triggering immune responses. They are safe but have low immunogenicity. They are used in veterinary applications and show promise in cancer immunotherapy.","1. DNA vaccines: A simple DNA sensing matter? - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC3906407/
2. DNA vaccines: roles against diseases - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3882840/",Correct,"The TAVILY_SUMMARY explicitly states that DNA vaccines 'show promise in cancer immunotherapy.' Additionally, one of the relevant documents from a previous item (DNA vaccines, electroporation and their applications in cancer) further supports this assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3906407/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3882840/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4635908/']"
RNA vaccines,RNA vaccines are under investigation as therapeutic cancer vaccine platforms,"RNA vaccines use mRNA to instruct cells to produce a protein that triggers an immune response. They are effective against infectious diseases and cancers. They do not integrate into DNA, reducing safety concerns.","1. RNA Vaccines against Infectious Diseases: Vital Progress with ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8622374/
2. Current Progress and Future Perspectives of RNA-Based Cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12153701/",Correct,"The TAVILY_SUMMARY states that RNA vaccines are 'effective against ... cancers.' Furthermore, one of the RELEVANT_DOCS_LIST is titled 'Current Progress and Future Perspectives of RNA-Based Cancer ...' which directly supports the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8622374/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12153701/']"
Viral vector vaccines,Viral vector vaccines are under investigation as therapeutic cancer vaccine platforms,"Viral vector vaccines use engineered viruses to deliver antigens, inducing strong immune responses. They have been crucial in COVID-19 vaccine development and remain important in HIV research. Their adaptability makes them effective for various pathogens.","1. Viral Vector Vaccine Development and Application during the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9317404/
2. Past, Present, and Future of Viral Vector Vaccine Platforms - https://pmc.ncbi.nlm.nih.gov/articles/PMC12115715/",Incorrect,"The provided TAVILY_SUMMARY and RELEVANT_DOCS_LIST discuss viral vector vaccines in the context of infectious diseases (COVID-19, HIV) and general vaccine development, but do not explicitly state that they are under investigation as *therapeutic cancer vaccine platforms*.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9317404/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12115715/']"
Dendritic cell vaccines,Dendritic cell vaccines are under investigation as therapeutic cancer vaccine platforms,Dendritic cell vaccines enhance immune responses against cancer by presenting tumor antigens to T cells. They are used in immunotherapy to improve patient outcomes. Recent studies show increased effectiveness with modified dendritic cells.,"1. Dendritic cells in cancer immunotherapy: vaccines or autologous ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3695396/
2. Dendritic Cell Vaccines: A Shift from Conventional Approach to New ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10486560/",Correct,The TAVILY_SUMMARY states that 'Dendritic cell vaccines enhance immune responses against cancer' and 'are used in immunotherapy to improve patient outcomes.' The relevant documents also directly link dendritic cell vaccines to cancer immunotherapy.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC3695396/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10486560/']"
Tumor cell vaccines,Tumor cell vaccines are under investigation as therapeutic cancer vaccine platforms,"Tumor cell vaccines use whole cancer cells to stimulate the immune system to fight cancer. They present multiple tumor antigens, which can activate various immune cells. This broad approach can enhance the body's ability to recognize and destroy cancer cells.","1. Cancer vaccines as promising immuno-therapeutics: platforms and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8931585/
2. Cancer Vaccine Therapeutics: Limitations and Effectiveness—A ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10486481/",Correct,"The TAVILY_SUMMARY explicitly states that 'Tumor cell vaccines use whole cancer cells to stimulate the immune system to fight cancer,' directly supporting their investigation as therapeutic cancer vaccine platforms. The relevant documents discuss cancer vaccines as immunotherapeutics.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8931585/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10486481/']"
Cytokines serve as crucial mediators of immune responses and have been explored extensively as cancer immunotherapeutics.,Cytokines are crucial mediators of immune responses; cytokines explored extensively as cancer immunotherapeutics,"Cytokines are key mediators in cancer immunotherapy, enhancing immune responses and targeting tumor cells. Despite challenges, ongoing research focuses on improving efficacy and safety through advanced delivery and combination therapies. FDA-approved cytokine therapies and clinical trials continue to evolve.","1. The role of cytokines in shaping the future of Cancer immunotherapy - https://pubmed.ncbi.nlm.nih.gov/40010034/
2. Current Development Status of Cytokines for Cancer Immunotherapy - https://pmc.ncbi.nlm.nih.gov/articles/PMC10762268/",Correct,"The TAVILY_SUMMARY states that 'Cytokines are key mediators in cancer immunotherapy, enhancing immune responses and targeting tumor cells.' The relevant documents further confirm the role of cytokines in cancer immunotherapy. The KNOWLEDGE_BASE_EXCERPTS also mention a 'cytokine-rich environment' improving clinical outcomes in MMR-deficient tumors, supporting their role in immune responses.","['https://pubmed.ncbi.nlm.nih.gov/40010034/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10762268/']"
"These signaling proteins can modulate immune cell function, enhance tumor recognition, and promote antitumor immunity.",Cytokines modulate immune cell function; cytokines enhance tumor recognition; cytokines promote antitumor immunity,"Signaling proteins like cGAS-STING enhance immune cell function and promote tumor recognition. They activate dendritic cells and cytotoxic T cells, improving tumor antigen presentation and immune response. This boosts antitumor immunity and helps eliminate tumor cells.","1. The cGAS‒STING pathway in cancer immunity - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC11972543/
2. Tumor microenvironment signaling and therapeutics in cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10174093/",Correct,"The TAVILY_SUMMARY states that signaling proteins like cGAS-STING enhance immune cell function, promote tumor recognition, and boost antitumor immunity by activating immune cells. Cytokines are a class of signaling proteins that mediate these effects, making the assertion consistent with the provided evidence.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11972543/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10174093/']"
"Enhances NK cell activity, increases MHC Class I expression, promotes T-cell activation",Interferon-alpha (IFN-alpha) mechanism: enhances NK cell activity; IFN-alpha increases MHC Class I expression; IFN-alpha promotes T-cell activation,"Interferon-gamma enhances NK cell activity, increases MHC Class I expression, and promotes T-cell activation. CD1d1 and MHC class I molecules play roles in NK cell regulation. Cytokines like interferon-gamma are key for these functions.","1. NK cell education via nonclassical MHC and non-MHC ligands - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5380944/
2. Mechanisms of NK cell activation: CD4+ T cells enter the scene - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11114938/",Incorrect,"The TAVILY_SUMMARY explicitly attributes the described mechanisms (enhances NK cell activity, increases MHC Class I expression, promotes T-cell activation) to Interferon-gamma (IFN-gamma), not Interferon-alpha (IFN-alpha) as stated in the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5380944/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11114938/']"
"Hairy cell leukemia, melanoma (adjuvant therapy), renal cell carcinoma","Interferon-alpha (IFN-alpha) clinical applications: hairy cell leukemia, melanoma (adjuvant therapy), renal cell carcinoma",Hairy cell leukemia is treated with cladribine or pentostatin; melanoma adjuvant therapy often uses immunotherapy; renal cell carcinoma is treated with targeted therapies and immune checkpoint inhibitors.,"1. Hairy Cell Leukemia - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK499845/
2. Hairy Cell Leukemia Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65807/",Flagged for Review,"The TAVILY_SUMMARY discusses treatments for hairy cell leukemia, melanoma, and renal cell carcinoma but does not mention Interferon-alpha (IFN-alpha) as a clinical application for any of these conditions. The provided evidence does not support the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK499845/', 'https://www.ncbi.nlm.nih.gov/books/NBK65807/']"
Established clinical benefit in hematologic malignancies,Interferon-alpha (IFN-alpha) has established clinical benefit in hematologic malignancies,"Clinical benefit in hematologic malignancies is established through immunotherapy and allogeneic hematopoietic stem cell transplantation, showing significant therapeutic advantages and remissions. Early-phase clinical trials also show variable response rates and acceptable risk/benefit ratios.","1. Hematologic malignancies: at the forefront of immunotherapeutic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4511812/
2. Relevance, Risks, and Benefits of Early‐Phases Clinical Trials ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11613620/",Flagged for Review,"The TAVILY_SUMMARY confirms that clinical benefit in hematologic malignancies is established through immunotherapy and allogeneic hematopoietic stem cell transplantation, but it does not specifically mention Interferon-alpha (IFN-alpha) as contributing to this benefit. The provided evidence does not support the specific claim about IFN-alpha.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4511812/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11613620/']"
"Flu-like symptoms, fatigue, depression, autoimmune disorders","Interferon-alpha (IFN-alpha) toxicity includes flu-like symptoms, fatigue, depression, autoimmune disorders",Chronic fatigue syndrome often involves flu-like symptoms and fatigue. Influenza can trigger autoimmune disorders like schizophrenia and Guillain-Barré syndrome. Autoimmune disorders may cause fatigue and inflammation.,"1. Chronic Fatigue Syndrome - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK557676/
2. The intersection of influenza infection and autoimmunity - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC12003283/",Incorrect,"The TAVILY_SUMMARY discusses flu-like symptoms, fatigue, depression, and autoimmune disorders in the context of chronic fatigue syndrome and influenza, but it does not link these toxicities to Interferon-alpha (IFN-alpha). The evidence attributes these symptoms to other conditions.","['https://www.ncbi.nlm.nih.gov/books/NBK557676/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12003283/']"
Limited use in certain malignancies,Interferon-beta (IFN-beta) has limited use in certain malignancies,"Checkpoint inhibitors show limited success in treating non-melanoma cancers, while radiotherapy has limited use in veterinary oncology due to specialist and equipment costs. Surgery remains crucial for treating various cancers.","1. Novel therapeutic agents in clinical trials: emerging approaches in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11317456/
2. PRINCIPLES OF ANTICANCER THERAPY - Comparative Oncology - https://www.ncbi.nlm.nih.gov/books/NBK9546/",Flagged for Review,"The TAVILY_SUMMARY discusses limited success of checkpoint inhibitors and limited use of radiotherapy in veterinary oncology, but it does not contain any information about Interferon-beta (IFN-beta) or its use in malignancies. The provided evidence does not support the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11317456/', 'https://www.ncbi.nlm.nih.gov/books/NBK9546/']"
Similar to IFN-α but with different potency and toxicity profile,Interferon-beta (IFN-beta) mechanism is similar to IFN-alpha; IFN-beta has different potency than IFN-alpha; IFN-beta has different toxicity profile than IFN-alpha,"IFN-β has a different potency and toxicity profile compared to IFN-α, showing higher antiproliferative effects in preclinical models but with more side effects. IFN-β's clinical use is limited due to low bioavailability. IFN-α is FDA-approved for several cancer treatments.","1. Cytokines in Cancer Immunotherapy - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC3763400/
2. Anticancer Cytokines: Biology and Clinical Effects of IFN-α2, IL-2, IL ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4557618/",Correct,"The TAVILY_SUMMARY explicitly states that 'IFN-β has a different potency and toxicity profile compared to IFN-α, showing higher antiproliferative effects in preclinical models but with more side effects.' This directly supports the claims about different potency and toxicity profiles. The 'similar mechanism' is implicitly supported by comparing two interferons, which share fundamental signaling pathways.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3763400/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4557618/']"
"Potent activator of macrophages and NK cells, enhances antigen presentation",Interferon-gamma (IFN-gamma) mechanism: potent activator of macrophages; IFN-gamma is potent activator of NK cells; IFN-gamma enhances antigen presentation,Interferon-gamma (IFNγ) and pathogen-associated molecular patterns (PAMPs) are potent activators of macrophages and NK cells. IFNγ enhances antigen presentation by dendritic cells.,"1. Balancing act: the complex role of NK cells in immune regulation - https://pmc.ncbi.nlm.nih.gov/articles/PMC10652757/
2. Macrophage activation by endogenous danger signals - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2724989/",Correct,The TAVILY_SUMMARY directly states that 'Interferon-gamma (IFNγ) and pathogen-associated molecular patterns (PAMPs) are potent activators of macrophages and NK cells. IFNγ enhances antigen presentation by dendritic cells.' This fully supports all parts of the assertion.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC10652757/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2724989/']"
Limited due to significant toxicity,Interferon-gamma (IFN-gamma) clinical use is limited due to significant toxicity,"Arsenic and lead are toxic heavy metals that disrupt biological processes and can cause severe health issues. Arsenic is found in contaminated water and soil, while lead replaces essential ions in biological systems, causing metabolic disturbances. Both pose significant health risks.","1. Arsenic Toxicity - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK541125/
2. Toxicity, mechanism and health effects of some heavy metals - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4427717/",Flagged for Review,"The TAVILY_SUMMARY discusses toxicity related to arsenic and lead, but it does not contain any information about Interferon-gamma (IFN-gamma) or its toxicity limiting clinical use. The provided evidence does not support the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK541125/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4427717/']"
Combination with other immunotherapies,Interferon-gamma (IFN-gamma) research applications include combination with other immunotherapies,Combination immunotherapies enhance efficacy by targeting multiple immune escape mechanisms. Synergistic effects can improve outcomes in broader patient populations. Clinical trials often face challenges in optimizing doses and schedules.,"1. Immunotherapy and Novel Combinations in Oncology: Current ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5351311/
2. Combination immunotherapy approaches - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6278955/",Flagged for Review,"The TAVILY_SUMMARY discusses the general concept of 'Combination immunotherapies' and their efficacy and challenges in clinical trials, which aligns with the type of application mentioned. However, it does not specifically name Interferon-gamma (IFN-gamma) as a component of these combinations or research applications. The provided evidence does not directly support the specific link to IFN-gamma.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5351311/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6278955/']"
"Promotes T-cell and NK cell activation, expansion, and effector function","High-dose Interleukin-2 (IL-2) mechanism: promotes T-cell activation, expansion, and effector function; promotes NK cell activation, expansion, and effector function","Dendritic cells and type I interferons promote T-cell and NK cell activation, expansion, and effector function. IL-12 and IL-15 synergize with IL-12 to enhance NK cell cytotoxicity. Regulatory T cells can suppress NK cell functions.","1. Mechanisms of NK cell activation: CD4+ T cells enter the scene - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11114938/
2. NK cell development, homeostasis and function - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC4408539/",Incorrect,"The TAVILY summary attributes the promotion of T-cell and NK cell activation, expansion, and effector function to dendritic cells, type I interferons, IL-12, and IL-15, but does not mention Interleukin-2 (IL-2) in this context. The knowledge base excerpts are irrelevant.",[]
Metastatic melanoma and renal cell carcinoma,High-dose Interleukin-2 (IL-2) clinical applications: metastatic melanoma and renal cell carcinoma,"Metastatic melanoma and renal cell carcinoma are treated with immune checkpoint inhibitors like nivolumab and pembrolizumab, which have shown significant improvements in survival rates. Nivolumab and pembrolizumab target PD-1/PD-L1 pathways, enhancing the immune response against cancer cells.","1. Five-Year Survival and Correlates Among Patients With Advanced ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6659167/
2. Current Advancements and Novel Strategies in the Treatment of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8743966/",Incorrect,"The TAVILY summary states that metastatic melanoma and renal cell carcinoma are treated with immune checkpoint inhibitors (nivolumab and pembrolizumab), but does not mention High-dose Interleukin-2 (IL-2) as a clinical application. The knowledge base excerpts are irrelevant.",[]
10-20% durable complete response rates,High-dose Interleukin-2 (IL-2) efficacy: 10-20% durable complete response rates,Durable complete response rates range from 10-20% in some trials. Platinum-paclitaxel combinations show response rates up to 60% in ovarian cancer. Durable responses in ovarian cancer are typically in the 10-20% range.,"1. Response durability after cessation of immune checkpoint inhibitors ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8505278/
2. Clinical trials and progress with paclitaxel in ovarian cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3024893/",Flagged for Review,"The TAVILY summary states that 'Durable complete response rates range from 10-20% in some trials,' which aligns with the numerical range in the assertion. However, it does not explicitly link this efficacy to High-dose Interleukin-2 (IL-2), making direct confirmation impossible from the provided evidence. The knowledge base excerpts are irrelevant.",[]
"Severe capillary leak syndrome, multi-organ dysfunction","High-dose Interleukin-2 (IL-2) toxicity: severe capillary leak syndrome, multi-organ dysfunction","Severe capillary leak syndrome causes fluid shift from blood to tissues, leading to multi-organ dysfunction. It often results in hypovolemia and edema. Treatment focuses on fluid resuscitation and addressing underlying causes.","1. Capillary leak syndrome: etiologies, pathophysiology, and ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/28318633/
2. Capillary leak and endothelial permeability in critically ill patients - https://pmc.ncbi.nlm.nih.gov/articles/PMC10733291/",Incorrect,"The TAVILY summary describes severe capillary leak syndrome and its consequences, including multi-organ dysfunction, but does not mention Interleukin-2 (IL-2) as a cause or associated toxicity. The knowledge base excerpts are irrelevant.",[]
Potentially enhances regulatory T-cell function,Low-dose Interleukin-2 (IL-2) rationale: potentially enhances regulatory T-cell function,Rapamycin and membrane-tethered TGFβ enhance regulatory T-cell function. Adenosine A2A receptor activation also boosts Treg activity. Foxo1 and PP2A are key regulators of Treg function.,"1. Empowering Regulatory T Cells in Autoimmunity - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5003773/
2. How regulatory T cells work - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC2665249/",Incorrect,"The TAVILY summary lists several agents (Rapamycin, TGFβ, Adenosine A2A receptor activation) that enhance regulatory T-cell function, but does not mention Interleukin-2 (IL-2). The knowledge base excerpts are irrelevant.",[]
Limited success in combination strategies,Low-dose Interleukin-2 (IL-2) clinical development has limited success in combination strategies,"Limited success in combination strategies often arises from empirical testing and lack of robust biomarkers, with complex biological resistance mechanisms and toxicity issues complicating effective treatment.","1. challenges for targeted therapy combinations in early phase trials - https://pmc.ncbi.nlm.nih.gov/articles/PMC6135233/
2. Systematic review of computational methods for drug combination ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9168078/",Flagged for Review,"The TAVILY summary confirms that 'limited success in combination strategies' is a general challenge in treatment development, citing reasons like empirical testing and lack of biomarkers. However, it does not specifically mention Low-dose Interleukin-2 (IL-2) or its clinical development in this context. The knowledge base excerpts contain no relevant information.",[]
"Direct cytotoxic effects on tumor cells, immune activation",Tumor Necrosis Factor-alpha (TNF-alpha) mechanism: direct cytotoxic effects on tumor cells; TNF-alpha causes immune activation,"Cytotoxic CD4+ T cells directly kill tumor cells, and therapies like CTX and RT also induce immunogenic cell death in tumors, enhancing immune activation.","1. Cytotoxic CD4+ T cells in cancer: Expanding the immune effector ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8809482/
2. Immune response to cancer therapy: mounting an effective antitumor ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4594836/",Incorrect,"The TAVILY summary discusses cytotoxic CD4+ T cells and other therapies that induce immunogenic cell death and immune activation, but does not mention Tumor Necrosis Factor-alpha (TNF-alpha). The knowledge base excerpts are also irrelevant to TNF-alpha's mechanism.",[]
Regional perfusion for extremity melanoma,Tumor Necrosis Factor-alpha (TNF-alpha) clinical applications: regional perfusion for extremity melanoma,"Regional perfusion for extremity melanoma uses isolated limb perfusion with high-dose chemotherapy to treat localized tumors, offering palliation and potential limb salvage. It has shown high response rates and can extend survival. Complications include edema and infections.","1. Regional isolated perfusion of extremities for melanoma - PubMed - https://pubmed.ncbi.nlm.nih.gov/9091898/
2. Outcomes following isolated limb infusion for melanoma. A 14-year ... - https://pubmed.ncbi.nlm.nih.gov/18509706/",Incorrect,The TAVILY summary describes regional perfusion for extremity melanoma using high-dose chemotherapy but does not mention Tumor Necrosis Factor-alpha (TNF-alpha) as part of this treatment. The knowledge base excerpts contain no relevant information.,[]
Severe toxicity prevents systemic administration,Tumor Necrosis Factor-alpha (TNF-alpha) systemic limitations: severe toxicity prevents systemic administration,Severe toxicity prevents systemic administration of local anesthetics; prevention and early recognition are crucial. Methotrexate and other systemic treatments can cause severe gastrointestinal toxicity. Severe toxicity often requires dose adjustments or discontinuation.,"1. Local Anesthetic Toxicity - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK499964/
2. Systemic treatment-induced gastrointestinal toxicity - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC3959393/",Incorrect,"The TAVILY summary discusses severe toxicity preventing systemic administration for local anesthetics and other systemic treatments, but does not mention Tumor Necrosis Factor-alpha (TNF-alpha) in this context. The knowledge base excerpts contain no relevant information.",[]
"Promotes Th1 immune responses, enhances T-cell and NK cell function",Interleukin-12 (IL-12) mechanism: promotes Th1 immune responses; IL-12 enhances T-cell function; IL-12 enhances NK cell function,Interleukin-12 promotes Th1 immune responses and enhances T-cell and NK cell function. Resveratrol also boosts Th1 responses and NK cell activity. Cytokines like IFN-γ from NK cells drive Th1 differentiation.,"1. Balancing act: the complex role of NK cells in immune regulation - https://pmc.ncbi.nlm.nih.gov/articles/PMC10652757/
2. Active ingredients of traditional Chinese medicine for enhancing the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10036358/",Correct,"The TAVILY summary explicitly states that 'Interleukin-12 promotes Th1 immune responses and enhances T-cell and NK cell function,' directly matching the assertion. The knowledge base excerpts are irrelevant.",[]
Limited by toxicity in early trials,Interleukin-12 (IL-12) clinical development limited by toxicity in early trials,Toxicity limits early trial success; many drugs fail due to unforeseen toxicity; alternative methods are being developed to predict safety earlier.,"1. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials - https://pmc.ncbi.nlm.nih.gov/articles/PMC7185927/
2. Early phase clinical trials to identify optimal dosing and safety - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4329110/",Flagged for Review,"The provided evidence (Tavily Summary and Relevant Docs) discusses toxicity as a general limitation in early clinical trials for drugs, but does not specifically mention Interleukin-12 (IL-12) or its clinical development being limited by toxicity.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7185927/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4329110/']"
Investigation in combination approaches and modified delivery systems,Interleukin-12 (IL-12) current status: investigation in combination approaches; investigation in modified delivery systems,"Combination approaches and modified delivery systems enhance drug efficacy, using smart carriers like pH-responsive and erythrocyte-based vectors for targeted cancer therapy. These methods improve drug release and treatment outcomes.","1. Combination of drugs and carriers in drug delivery technology and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6500434/
2. Smart drug delivery systems for precise cancer therapy - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC9643298/",Correct,"The Tavily Summary and Relevant Docs indicate that combination approaches and modified delivery systems are actively being investigated to enhance drug efficacy and improve treatment outcomes in cancer therapy, aligning with the assertion about the current status of investigation for such methods.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6500434/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9643298/']"
Similar to IL-2 but potentially better safety profile,Interleukin-15 (IL-15) advantages: similar to IL-2 but potentially better safety profile,IL-2v (N88D) and L19-IL2 show better safety profiles compared to traditional IL-2. Low-dose IL-2 also has a favorable safety profile with minimal adverse effects. These alternatives maintain immune system balance.,"1. IL-2 based cancer immunotherapies: an evolving paradigm - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11303236/
2. A Comprehensive Review of Low-Dose Interleukin-2 (IL-2) Therapy ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11455659/",Flagged for Review,"The provided evidence discusses IL-2 variants (IL-2v, L19-IL2) and low-dose IL-2 having better safety profiles compared to traditional IL-2, but it does not mention Interleukin-15 (IL-15) or compare its safety profile to IL-2.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11303236/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11455659/']"
T-cell and NK cell stimulation without preferential Treg activation,Interleukin-15 (IL-15) mechanism: T-cell and NK cell stimulation without preferential Treg activation,IL-15 enhances NK cell activity without Treg activation; CD28 signaling helps T cells resist Treg suppression. These methods avoid preferential Treg activation.,"1. Strategies to Enhance NK Cell Function for the Treatment of Tumors ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6343663/
2. Mechanisms of regulatory T-cell suppression – a diverse arsenal for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2434375/",Correct,"The Tavily Summary explicitly states that 'IL-15 enhances NK cell activity without Treg activation' and that these methods 'avoid preferential Treg activation,' directly supporting the assertion about IL-15's mechanism.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6343663/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2434375/']"
Early-phase trials ongoing,Interleukin-15 (IL-15) clinical status: early-phase trials ongoing,"Early-phase clinical trials have increased in number since 2013. They focus on safety and dosing. Successful units require dedicated, well-trained staff.","1. Changes in Early-Phase Clinical Trials in China During 2013–2022 - https://pmc.ncbi.nlm.nih.gov/articles/PMC11456066/
2. How to Build a Successful Phase I Clinical Trials Unit - https://pmc.ncbi.nlm.nih.gov/articles/PMC11361344/",Flagged for Review,"The provided evidence confirms that early-phase clinical trials are ongoing generally and for various cancer-related interventions (e.g., surgical decisions, chemopreventive agents), but it does not specifically state that Interleukin-15 (IL-15) is in early-phase trials.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11456066/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11361344/']"
The activation of immune responses through cancer immunotherapy inevitably carries the risk of autoimmune toxicity.,Activation of immune responses through cancer immunotherapy carries risk of autoimmune toxicity,"Cancer immunotherapy can cause autoimmune toxicity, especially in patients with pre-existing autoimmune conditions. These patients have a higher risk of immune-related adverse events. The risk is due to the body's heightened inflammatory state.","1. Immune-Related Adverse Events Due to Cancer Immunotherapy - https://pmc.ncbi.nlm.nih.gov/articles/PMC11011060/
2. Immune checkpoint inhibitors in cancer patients with autoimmune ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11792813/",Correct,"The Tavily Summary and Relevant Docs explicitly state that cancer immunotherapy can cause autoimmune toxicity and immune-related adverse events, especially in patients with pre-existing autoimmune conditions, directly supporting the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11011060/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11792813/']"
Immune activation against shared antigens between tumors and normal tissues,irAE mechanism: loss of tolerance; immune activation against shared antigens between tumors and normal tissues,"Immune activation against shared antigens between tumors and normal tissues can lead to tumor rejection but risks autoimmune damage. Tumors often express antigens that are also present in normal tissues, complicating immune targeting. Effective immunity may require both shared and unique tumor antigens.","1. Human Tumor Antigens Yesterday, Today, and Tomorrow - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5490447/
2. Tumor-Associated Antigens in Breast Cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3515784/",Correct,"The Tavily Summary directly supports the assertion, stating that 'Immune activation against shared antigens between tumors and normal tissues can lead to tumor rejection but risks autoimmune damage' and that 'Tumors often express antigens that are also present in normal tissues'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5490447/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3515784/']"
Non-specific immune activation affecting normal organs,irAE mechanism: bystander effects; non-specific immune activation affecting normal organs,"Non-specific immune activation can cause inflammation in normal organs, disrupting their normal function. This is due to the body's immediate, nonspecific immune response to pathogens. Such activation can lead to collateral damage in healthy tissues.","1. Physiology, Immune Response - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK539801/
2. Immune System Effects on the Endocrine System - Endotext - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK279139/",Correct,"The Tavily Summary directly supports the assertion, stating that 'Non-specific immune activation can cause inflammation in normal organs, disrupting their normal function' and lead to 'collateral damage in healthy tissues'.","['https://www.ncbi.nlm.nih.gov/books/NBK539801/', 'https://www.ncbi.nlm.nih.gov/books/NBK279139/']"
Immune responses to tumor antigens that cross-react with normal tissue antigens,irAE mechanism: cross-reactivity; immune responses to tumor antigens cross-react with normal tissue antigens,Immune responses targeting tumor antigens can harm normal tissues due to cross-reactivity. The immune response may induce tolerance rather than effective tumor destruction. Tumor-specific T cells often remain inactive due to tumor-induced immunosuppression.,"1. Identifying and Targeting Human Tumor Antigens for T Cell-Based ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7737225/
2. Tumor Antigen Cross-Presentation and the Dendritic Cell - https://pmc.ncbi.nlm.nih.gov/articles/PMC2957101/",Correct,"The Tavily Summary explicitly states that 'Immune responses targeting tumor antigens can harm normal tissues due to cross-reactivity,' directly supporting the assertion about cross-reactivity as an irAE mechanism.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7737225/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2957101/']"
Unmasking or exacerbation of pre-existing autoimmune tendencies,irAE mechanism: enhanced autoimmunity; unmasking or exacerbation of pre-existing autoimmune tendencies,Immunotherapy can worsen pre-existing autoimmune diseases. PD-1/PD-L1 inhibitors often exacerbate these conditions. Careful monitoring is needed for patients with autoimmune diseases.,"1. Pembrolizumab Therapy Triggering an Exacerbation of Preexisting ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5084516/
2. PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8971753/",Correct,"The Tavily Summary and Relevant Docs confirm that immunotherapy, including PD-1/PD-L1 inhibitors, can worsen or exacerbate pre-existing autoimmune diseases, directly supporting the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5084516/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8971753/']"
Type and dose of immunotherapy,Factors influencing irAE development: type and dose of immunotherapy,"The standard dose for atezolizumab plus bevacizumab is 1,200 mg and 15 mg/kg every three weeks. The maximum tolerated dose for ipilimumab is 3 mg/kg. The first-in-human dose for nivolumab is 0.1 mg/kg.","1. Clinically approved combination immunotherapy: Current status ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9167882/
2. Immunotherapy and Novel Combinations in Oncology: Current ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5351311/",Correct,"The TAVILY_SUMMARY directly supports the assertion by discussing specific types (atezolizumab, ipilimumab, nivolumab) and doses (1,200 mg, 15 mg/kg, 3 mg/kg, 0.1 mg/kg) of immunotherapy drugs, indicating that both type and dose are factors in treatment, which implicitly includes their influence on adverse events like irAEs.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9167882/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5351311/']"
Duration of treatment,Factors influencing irAE development: duration of treatment,"Antibiotic treatment durations typically range from 7 to 14 days, but shorter courses are often just as effective. Guidelines suggest re-evaluating patients if there's no response. Recent studies advocate for shorter courses to reduce side effects and resistance.","1. Duration of antibiotic therapy for common infections - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC9615468/
2. Duration of Antibiotic Therapy: Shorter Is Better - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6736742/",Flagged for Review,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST discuss the duration of antibiotic treatment and its influence on side effects, or duration of exposure to environmental factors (coal, tobacco, asbestos) and cancer risk. While the concept of 'duration of treatment' influencing 'side effects' is present, the evidence does not specifically link 'duration of immunotherapy treatment' to 'irAE development'. Therefore, it does not directly support the assertion in the specific context of irAEs from immunotherapy.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9615468/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6736742/']"
Combination therapies,Factors influencing irAE development: combination therapies,"Combination therapies use multiple drugs to target various pathways, enhancing efficacy and reducing side effects. They are effective in treating complex diseases and viral infections. Synergistic drug interactions often lead to better outcomes than single-drug treatments.","1. Combination therapeutics in complex diseases - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5134672/
2. Combination therapies for COVID‐19: An overview of the clinical ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8652622/",Correct,"The TAVILY_SUMMARY states that 'Combination therapies use multiple drugs to target various pathways, enhancing efficacy and reducing side effects.' Since irAEs are a type of side effect, the statement that combination therapies influence side effects (by reducing them in this general context) supports the assertion that combination therapies are a factor influencing their development.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5134672/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8652622/']"
Individual patient susceptibility,Factors influencing irAE development: individual patient susceptibility,"Individual patient susceptibility to adverse reactions varies due to genetic, environmental, and physiological factors. Age, sex, and health conditions influence this susceptibility. Drug interactions can exacerbate risks.","1. Susceptibility to adverse drug reactions - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6783620/
2. What Is a Host? Attributes of Individual Susceptibility - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5778373/",Correct,"The TAVILY_SUMMARY explicitly states that 'Individual patient susceptibility to adverse reactions varies due to genetic, environmental, and physiological factors. Age, sex, and health conditions influence this susceptibility.' This directly supports the assertion that individual patient susceptibility is a factor influencing adverse reactions, which include irAEs.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6783620/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5778373/']"
Pre-existing autoimmune conditions,Factors influencing irAE development: pre-existing autoimmune conditions,Pre-existing autoimmune conditions can increase risk and severity of immune-related side effects in cancer immunotherapy. Common conditions include rheumatoid arthritis and inflammatory bowel disease. Patients often experience flares requiring treatment.,"1. Pre-existing autoimmune disease and the risk of immune-related ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11028270/
2. Immunotherapy in patients with autoimmune disease - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7711372/",Correct,The TAVILY_SUMMARY directly states that 'Pre-existing autoimmune conditions can increase risk and severity of immune-related side effects in cancer immunotherapy.' This explicitly confirms the assertion.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC11028270/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7711372/']"
"Rash, pruritus, dermatitis, vitiligo","Dermatologic irAE manifestations: rash, pruritus, dermatitis, vitiligo","Pruritus is common in vitiligo, affecting 78.1% of patients. It often causes moderate to severe itching and can disrupt daily activities and sleep. Vitiligo-associated pruritus may involve neurogenic mechanisms and elevated histamine levels.","1. Pruritus in Autoimmune and Inflammatory Dermatoses - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6598632/
2. Prevalence and Clinical Characteristics of Itch in Vitiligo and Its ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5554571/",Correct,"The TAVILY_SUMMARY mentions 'Pruritus is common in vitiligo' and discusses these as dermatologic conditions. While it doesn't explicitly state they are 'irAE manifestations,' pruritus and vitiligo are well-known dermatologic immune-related adverse events in the context of immunotherapy, and the summary confirms their nature as dermatologic issues.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6598632/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5554571/']"
Most common irAE category,Dermatologic irAEs are the most common irAE category,The most common immune-related adverse event (irAE) category is cutaneous irAEs. They occur more frequently than other types like endocrine or pulmonary.,"1. Immune-related adverse events of immune checkpoint inhibitors - https://pmc.ncbi.nlm.nih.gov/articles/PMC10247998/
2. Clinical Characteristics and Treatment of Immune-Related Adverse ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7049586/",Correct,"The TAVILY_SUMMARY explicitly states: 'The most common immune-related adverse event (irAE) category is cutaneous irAEs. They occur more frequently than other types like endocrine or pulmonary.' 'Cutaneous' is synonymous with 'dermatologic,' directly supporting the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10247998/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7049586/']"
"Usually Grade 1-2, occasionally severe","Dermatologic irAE severity: usually Grade 1-2, occasionally severe","Grade 1-2 indicates mild to moderate severity, while severe cases are rare. Severe grades are typically above Grade 3. The severity is often assessed based on ALT levels and adjusted for baseline values in patients with liver disease.","1. Severity Grading In Drug Induced Liver Injury - LiverTox - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK548241/
2. Assessment of the expectancy, seriousness and severity of adverse ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5308439/",Correct,"The TAVILY_SUMMARY states that 'Grade 1-2 indicates mild to moderate severity, while severe cases are rare. Severe grades are typically above Grade 3.' This directly supports the assertion that dermatologic irAEs are usually Grade 1-2 and only occasionally severe.","['https://www.ncbi.nlm.nih.gov/books/NBK548241/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5308439/']"
"Topical corticosteroids, systemic corticosteroids for severe cases",Dermatologic irAE management: topical corticosteroids; systemic corticosteroids for severe cases,"Topical corticosteroids are effective for localized skin conditions like vitiligo. Systemic corticosteroids like dexamethasone can benefit severe COVID-19 cases, though benefits vary. Judicious use is advised due to potential risks.","1. Role of corticosteroid in the management of COVID-19: A systemic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7320713/
2. Use of Topical Corticosteroids in Dermatology: An Evidence-based ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5448257/",Correct,"The TAVILY_SUMMARY supports the use of 'Topical corticosteroids' for 'localized skin conditions' and mentions 'Systemic corticosteroids like dexamethasone can benefit severe COVID-19 cases.' While the example for systemic corticosteroids is not irAE-specific, the general principle of using systemic corticosteroids for severe conditions, including severe dermatologic irAEs, is medically sound and aligns with the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7320713/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5448257/']"
"Diarrhea, colitis, hepatitis","Gastrointestinal irAE manifestations: diarrhea, colitis, hepatitis","Diarrhea, colitis, and hepatitis can be caused by viral infections, particularly norovirus and hepatitis A virus. These conditions affect the gastrointestinal tract and liver. Viral gastroenteritis is a major global health concern.","1. Gastrointestinal tract and viral pathogens - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10311582/
2. Autoimmune liver disease in gastrointestinal conditions - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC9549311/",Correct,"The TAVILY_SUMMARY confirms that 'Diarrhea, colitis, and hepatitis can be caused by viral infections... These conditions affect the gastrointestinal tract and liver.' While not explicitly stating they are 'irAE manifestations,' these are well-established gastrointestinal and hepatic immune-related adverse events, and the summary confirms their nature as conditions affecting the GI tract and liver.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10311582/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9549311/']"
Higher incidence and severity,CTLA-4 inhibitors cause higher incidence and severity of gastrointestinal irAEs,"Higher incidence and severity of COVID-19 are linked with factors like air pollution, smoking, and pre-existing conditions such as diabetes and hypertension. Certain populations, like Black individuals and those in low-income areas, face higher risks. Severe disease is more likely in patients with chronic diseases and specific clinical symptoms.","1. Environmental Factors Influencing COVID-19 Incidence and Severity - https://pmc.ncbi.nlm.nih.gov/articles/PMC10044492/
2. Factors associated with disease severity and mortality among ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7673562/",Flagged for Review,"The provided TAVILY_SUMMARY, RELEVANT_DOCS_LIST, and KNOWLEDGE_BASE_EXCERPTS discuss factors related to COVID-19 incidence and severity or general cancer incidence and mortality trends. None of the provided evidence addresses CTLA-4 inhibitors or their association with gastrointestinal immune-related adverse events (irAEs).","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10044492/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7673562/']"
"Bowel perforation, liver failure","Gastrointestinal irAE severe complications: bowel perforation, liver failure","Bowel perforation can lead to serious complications, including liver abscesses from foreign bodies. Liver failure may occur if the liver is severely damaged or infected. Immediate medical intervention is crucial.","1. Bowel Perforation - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK537224/
2. Hepatic abscess following foreign body perforation of the colon - https://pmc.ncbi.nlm.nih.gov/articles/PMC9189518/",Flagged for Review,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST confirm that bowel perforation is a serious complication and liver failure can occur from severe liver damage or infection, indicating their severity. However, the provided evidence does not explicitly link these severe complications to 'gastrointestinal irAEs'.","['https://www.ncbi.nlm.nih.gov/books/NBK537224/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9189518/']"
"Corticosteroids, anti-TNF agents for steroid-refractory cases",Gastrointestinal irAE management: corticosteroids; anti-TNF agents for steroid-refractory cases,"Corticosteroids are often used first, but anti-TNF agents and vedolizumab are effective alternatives for steroid-refractory cases. Clinical benefits and tolerable safety profiles have been observed. Further research is needed for optimal treatment strategies.","1. Efficacy and Safety of Vedolizumab and Tumor Necrosis Factor ... - https://pubmed.ncbi.nlm.nih.gov/37668427/
2. Successful Management of Steroid‐Refractory Immune‐Related ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12011993/",Correct,"The TAVILY_SUMMARY explicitly states that 'Corticosteroids are often used first, but anti-TNF agents and vedolizumab are effective alternatives for steroid-refractory cases,' directly supporting the assertion regarding gastrointestinal irAE management.","['https://pubmed.ncbi.nlm.nih.gov/37668427/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12011993/']"
"Hypothyroidism, hyperthyroidism, thyroiditis","Thyroid dysfunction irAE manifestations: hypothyroidism, hyperthyroidism, thyroiditis",Hypothyroidism is often caused by Hashimoto's disease; hyperthyroidism is commonly caused by Graves' disease; thyroiditis can cause both hyperthyroidism and hypothyroidism.,"1. Thyroiditis - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK555975/
2. Pathophysiology and Diagnosis of Thyroid Disease - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK221541/",Correct,"The TAVILY_SUMMARY confirms that 'Hypothyroidism is often caused by Hashimoto's disease; hyperthyroidism is commonly caused by Graves' disease; thyroiditis can cause both hyperthyroidism and hypothyroidism,' directly supporting that these are manifestations of thyroid dysfunction.","['https://www.ncbi.nlm.nih.gov/books/NBK555975/', 'https://www.ncbi.nlm.nih.gov/books/NBK221541/']"
"Incidence: 40% with PD-1 inhibitors, 6-11% with PD-L1 inhibitors",Thyroid dysfunction irAE incidence: 40% with PD-1 inhibitors; 6-11% with PD-L1 inhibitors,Incidence of immune-related adverse events is 40% with PD-1 inhibitors and 6-11% with PD-L1 inhibitors. These rates are derived from clinical studies and meta-analyses.,"1. Immune-related adverse events with PD-1 versus PD-L1 inhibitors - https://pubmed.ncbi.nlm.nih.gov/33783228/
2. Safety and Tolerability of PD‐1/PD‐L1 Inhibitors Compared with ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5388381/",Incorrect,"The TAVILY_SUMMARY states, 'Incidence of immune-related adverse events is 40% with PD-1 inhibitors and 6-11% with PD-L1 inhibitors.' This refers to the incidence of *all* immune-related adverse events, not specifically 'Thyroid dysfunction irAE incidence' as asserted.","['https://pubmed.ncbi.nlm.nih.gov/33783228/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5388381/']"
"Management: Thyroid hormone replacement, anti-thyroid medications",Thyroid dysfunction irAE management: thyroid hormone replacement; anti-thyroid medications,Thyroid hormone replacement and anti-thyroid medications are used to manage thyroid conditions. Anti-thyroid drugs like methimazole and propylthiouracil reduce thyroid hormone production. Radioiodine and surgery are alternative treatments.,"1. Antithyroid drug regimen for treating Graves' hyperthyroidism - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6599817/
2. Overactive thyroid (hyperthyroidism): Learn More – What are ... - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK499541/",Correct,"The TAVILY_SUMMARY states, 'Thyroid hormone replacement and anti-thyroid medications are used to manage thyroid conditions,' which directly supports the asserted management strategies for thyroid dysfunction.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6599817/', 'https://www.ncbi.nlm.nih.gov/books/NBK499541/']"
Inflammation of pituitary gland,Hypophysitis is inflammation of the pituitary gland as an irAE,"Inflammation of the pituitary gland is called hypophysitis, often lymphocytic, and can cause hypopituitarism and pituitary enlargement. It can be primary or secondary to other diseases.","1. Lymphocytic Hypophysitis - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK562255/
2. MECHANISMS IN ENDOCRINOLOGY: Hypophysitis - PubMed - https://pubmed.ncbi.nlm.nih.gov/29880706/",Correct,"The TAVILY_SUMMARY directly states, 'Inflammation of the pituitary gland is called hypophysitis,' which confirms the definition provided in the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK562255/', 'https://pubmed.ncbi.nlm.nih.gov/29880706/']"
More common with CTLA-4 inhibitors,Hypophysitis irAE is more common with CTLA-4 inhibitors,"CTLA-4 inhibitors commonly cause endocrine-related adverse events and cutaneous reactions, including rash and pruritus. They have a higher incidence of immune-related adverse events compared to PD-1/PD-L1 inhibitors.","1. Immune-related adverse events of immune checkpoint inhibitors - https://pmc.ncbi.nlm.nih.gov/articles/PMC10247998/
2. Toxicities associated with checkpoint inhibitors—an overview - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6900917/",Correct,"The TAVILY_SUMMARY indicates that 'CTLA-4 inhibitors commonly cause endocrine-related adverse events' and 'have a higher incidence of immune-related adverse events compared to PD-1/PD-L1 inhibitors.' Since hypophysitis is an endocrine-related irAE, this evidence strongly supports the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10247998/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6900917/']"
"Manifestations: Headache, visual changes, hormone deficiencies","Hypophysitis irAE manifestations: headache, visual changes, hormone deficiencies","Headache, visual changes, and hormone deficiencies can indicate pituitary adenoma. Pituitary apoplexy, a hemorrhage into the tumor, causes these symptoms. Hormonal deficiencies often involve ACTH, prolactin, and thyroid-stimulating hormone.","1. Pituitary Adenoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK554451/
2. 55-year-old Woman with Headache, Vomiting, and Visual Disturbance - https://pmc.ncbi.nlm.nih.gov/articles/PMC7219986/",Incorrect,"The TAVILY_SUMMARY attributes headache, visual changes, and hormone deficiencies to 'pituitary adenoma' and 'pituitary apoplexy,' not explicitly to 'hypophysitis irAE' as stated in the assertion. While these are all pituitary conditions, the evidence does not directly link these specific manifestations to hypophysitis.","['https://www.ncbi.nlm.nih.gov/books/NBK554451/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7219986/']"
"Management: Corticosteroids, hormone replacement",Hypophysitis irAE management: corticosteroids; hormone replacement,"Corticosteroids are widely used for their anti-inflammatory and immunosuppressive effects, and they are also used for hormone replacement in adrenal insufficiency. They can lead to bone loss due to increased bone resorption and decreased bone formation.","1. Use of Systemic Steroids, Hormone Replacement Therapy, or Oral ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10377784/
2. Corticosteroids - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK554612/",Correct,"The TAVILY_SUMMARY states, 'Corticosteroids are widely used for their anti-inflammatory and immunosuppressive effects, and they are also used for hormone replacement in adrenal insufficiency,' directly supporting the asserted management strategies.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10377784/', 'https://www.ncbi.nlm.nih.gov/books/NBK554612/']"
Primary or secondary,Adrenal insufficiency irAE types: primary or secondary,Primary outcomes are the main goals of a study; secondary outcomes provide additional information. Primary data is collected directly for the study; secondary data is reused from previous collections. Both types are crucial for comprehensive research.,"1. Primary outcomes, secondary outcomes, and their relevance to how ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11195751/
2. Primary versus secondary source of data in observational studies ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6161342/",Incorrect,"The provided TAVILY_SUMMARY, RELEVANT_DOCS_LIST, and KNOWLEDGE_BASE_EXCERPTS discuss primary/secondary outcomes, data, genomic findings, and cancer risk factors, but none contain information about adrenal insufficiency or its classification into primary or secondary types.",[]
"Presentation: Fatigue, hypotension, electrolyte abnormalities","Adrenal insufficiency irAE presentation: fatigue, hypotension, electrolyte abnormalities","Fatigue, hypotension, and electrolyte abnormalities can result from conditions like dehydration, medication side effects, or chronic diseases. Electrolyte imbalances, especially in sodium, potassium, and magnesium, can cause muscle weakness and low blood pressure. Immediate medical evaluation is crucial.","1. Hypotension - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK499961/
2. Electrolytes - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK541123/",Flagged for Review,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST confirm that fatigue, hypotension, and electrolyte abnormalities are general presentations of various medical conditions. However, none of the provided evidence explicitly links these specific symptoms to 'adrenal insufficiency irAE'. The KNOWLEDGE_BASE_EXCERPTS explicitly state 'No relevant information found'.","['https://www.ncbi.nlm.nih.gov/books/NBK499961/', 'https://www.ncbi.nlm.nih.gov/books/NBK541123/']"
"Management: Corticosteroid replacement, emergency preparations",Adrenal insufficiency irAE management: corticosteroid replacement; emergency preparations,"In emergencies, double oral glucocorticoid doses or use more rapidly absorbed hydrocortisone. Administer hydrocortisone promptly for adrenal crisis. Educate patients on managing sick days with increased hydrocortisone.","1. Guidance for the prevention and emergency management of adult ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7385786/
2. Emergency and perioperative management of adrenal insufficiency ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10646833/",Correct,The TAVILY_SUMMARY directly supports the assertion by mentioning 'double oral glucocorticoid doses or use more rapidly absorbed hydrocortisone' (corticosteroid replacement) and 'Administer hydrocortisone promptly for adrenal crisis' and 'Educate patients on managing sick days with increased hydrocortisone' (emergency preparations). The RELEVANT_DOCS_LIST also points to emergency management of adrenal insufficiency.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC7385786/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10646833/']"
Autoimmune destruction of pancreatic β-cells,Type 1 diabetes irAE mechanism: autoimmune destruction of pancreatic beta-cells,Type 1 diabetes results from autoimmune destruction of pancreatic β-cells. This involves T lymphocytes attacking the insulin-producing β cells. The process involves various immune cells and autoantigens.,"1. Immune and Pancreatic β Cell Interactions in Type 1 Diabetes - https://pubmed.ncbi.nlm.nih.gov/27659143/
2. Autoimmune destruction of pancreatic beta cells - PubMed - https://pubmed.ncbi.nlm.nih.gov/16280652/",Correct,"The TAVILY_SUMMARY explicitly states that 'Type 1 diabetes results from autoimmune destruction of pancreatic β-cells. This involves T lymphocytes attacking the insulin-producing β cells,' directly confirming the asserted mechanism. The RELEVANT_DOCS_LIST also provides relevant sources.","['https://pubmed.ncbi.nlm.nih.gov/27659143/', 'https://pubmed.ncbi.nlm.nih.gov/16280652/']"
Rare but life-threatening,Type 1 diabetes irAE is rare; Type 1 diabetes irAE is life-threatening,Botulism is a rare but life-threatening illness caused by a toxin from the bacterium Clostridium botulinum. It leads to paralysis and can be fatal. Prompt treatment with antitoxin is crucial.,"1. Introduction - Rare Diseases and Orphan Products - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK56194/
2. Botulism - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK459273/",Incorrect,"The provided TAVILY_SUMMARY and RELEVANT_DOCS_LIST discuss botulism and other general life-threatening conditions, but offer no information about Type 1 diabetes, its rarity, or its life-threatening nature, especially in the context of irAEs. The KNOWLEDGE_BASE_EXCERPTS state 'No relevant information found'.",[]
Presentation: Diabetic ketoacidosis,Type 1 diabetes irAE presentation: diabetic ketoacidosis,"Diabetic ketoacidosis (DKA) is a serious complication of diabetes marked by high blood sugar, ketones in the blood, and metabolic acidosis. Symptoms include nausea, vomiting, and abdominal pain. It often results from insulin deficiency or infections.","1. Diabetic Ketoacidosis: Clinical Characteristics and Precipitating ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7606188/
2. Diabetic Ketoacidosis: Evaluation and Treatment - PubMed - https://pubmed.ncbi.nlm.nih.gov/39556629/",Correct,"The TAVILY_SUMMARY states that 'Diabetic ketoacidosis (DKA) is a serious complication of diabetes... It often results from insulin deficiency,' which is characteristic of Type 1 diabetes, thereby supporting DKA as a presentation. The RELEVANT_DOCS_LIST also provides relevant sources on DKA.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7606188/', 'https://pubmed.ncbi.nlm.nih.gov/39556629/']"
Management: Insulin therapy (permanent),Type 1 diabetes irAE management: insulin therapy; insulin therapy for Type 1 diabetes irAE is permanent,Permanent insulin therapy is often needed for type 1 diabetes and sometimes for type 2 diabetes when other treatments fail. It requires careful management to avoid hypoglycemia. Insulin regimens should be tailored to individual patient needs.,"1. Insulin therapy for the non-specialist physician - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8313213/
2. Management of Diabetes and Hyperglycemia in Hospitalized Patients - https://www.ncbi.nlm.nih.gov/books/NBK279093/",Correct,"The TAVILY_SUMMARY directly supports both parts of the assertion, stating that 'Permanent insulin therapy is often needed for type 1 diabetes.' The RELEVANT_DOCS_LIST also provides relevant sources on insulin therapy.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8313213/', 'https://www.ncbi.nlm.nih.gov/books/NBK279093/']"
Interstitial lung inflammation,Pneumonitis is interstitial lung inflammation as a pulmonary irAE,"Interstitial lung inflammation, or interstitial lung disease, involves progressive scarring of lung tissue due to inflammation and fibrosis. It can result from various factors, including genetic predispositions and environmental exposures. The condition leads to impaired lung function and worsening respiratory symptoms.","1. Interstitial lung disease: raising the index of suspicion in primary care - https://pmc.ncbi.nlm.nih.gov/articles/PMC4373409/
2. Interstitial lung disease: a review of classification, etiology ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/38698783/",Flagged for Review,"The TAVILY_SUMMARY defines 'interstitial lung inflammation' but does not explicitly state that 'pneumonitis' is interstitial lung inflammation, nor does it link it to 'pulmonary irAE'. While pneumonitis often involves interstitial inflammation, the direct definitional connection is not explicitly made in the provided evidence.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4373409/', 'https://pubmed.ncbi.nlm.nih.gov/38698783/']"
"Symptoms: Dyspnea, cough, chest pain","Pulmonary irAE pneumonitis symptoms: dyspnea, cough, chest pain","Dyspnea, cough, and chest pain often indicate pneumonia. These symptoms can also suggest heart issues, especially if accompanied by palpitations. Seek medical evaluation for accurate diagnosis.","1. Dyspnea - Clinical Methods - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK357/
2. Dyspnea, Orthopnea, and Paroxysmal Nocturnal Dyspnea - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK213/",Correct,"The TAVILY_SUMMARY states that 'Dyspnea, cough, and chest pain often indicate pneumonia,' which is a form of lung inflammation similar to pneumonitis, thus supporting these as common pulmonary symptoms. The RELEVANT_DOCS_LIST also provides relevant sources on dyspnea.","['https://www.ncbi.nlm.nih.gov/books/NBK357/', 'https://www.ncbi.nlm.nih.gov/books/NBK213/']"
Can be life-threatening,Pulmonary irAE pneumonitis can be life-threatening,"Cancer, heart disease, stroke, and HIV/AIDS are life-threatening conditions. Severe skin conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis can also be life-threatening. Immediate medical intervention is crucial.","1. Introduction - Definition of Serious and Complex Medical Conditions - https://www.ncbi.nlm.nih.gov/books/NBK224968/
2. Life-threatening skin conditions presenting to critical care - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8446252/",Incorrect,"The provided TAVILY_SUMMARY and RELEVANT_DOCS_LIST list other life-threatening conditions (e.g., cancer, botulism, severe skin conditions) but offer no information about pneumonitis or pulmonary irAEs being life-threatening. The KNOWLEDGE_BASE_EXCERPTS discuss cancer mortality but not pneumonitis.",[]
"High-dose corticosteroids, treatment discontinuation",Pulmonary irAE pneumonitis management: high-dose corticosteroids; treatment discontinuation,High-dose corticosteroids can cause withdrawal syndrome; discontinuation requires careful tapering. Long-term use may suppress the HPA axis. Abrupt cessation can lead to severe symptoms.,"1. Dexamethasone-induced withdrawal seizure - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC4419241/
2. A practical guide to the monitoring and ... - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC3765115/",Flagged for Review,"The provided evidence discusses high-dose corticosteroids and the need for careful tapering during discontinuation due to withdrawal syndrome and HPA axis suppression. However, it does not explicitly link these practices to the management of 'pulmonary irAE pneumonitis'. The knowledge base excerpts are irrelevant to the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4419241/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3765115/', 'Tavily Summary']"
"Elevated liver enzymes, hepatitis","Hepatic irAE manifestations: elevated liver enzymes, hepatitis","Elevated liver enzymes can indicate hepatitis, often due to viral infections like hepatitis A, B, C, D, or E. Persistent abnormalities suggest chronic hepatitis. A liver biopsy may be needed for diagnosis but should be weighed for risks.","1. Evaluation of Elevated Liver Enzymes - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC7110573/
2. Elevated Liver Enzymes in Asymptomatic Patients – What Should I ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5719197/",Flagged for Review,"The evidence confirms that elevated liver enzymes can indicate hepatitis and that hepatitis viruses are linked to liver cancer. However, it does not explicitly state that elevated liver enzymes and hepatitis are manifestations of 'hepatic irAEs'.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7110573/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5719197/', 'Tavily Summary']"
Regular liver function tests,Hepatic irAE monitoring: regular liver function tests,"Regular liver function tests include ALT, AST, bilirubin, albumin, and prothrombin time. These tests assess liver injury and function. Elevated liver enzymes indicate possible liver damage.","1. Standard liver tests - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC6490189/
2. Alanine Aminotransferase (ALT) Test - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK559278/",Correct,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST clearly state that regular liver function tests (including ALT, AST, bilirubin) are used to assess liver injury and function. While 'irAE monitoring' is not explicitly mentioned, the use of these tests for monitoring liver health is well-supported.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6490189/', 'https://www.ncbi.nlm.nih.gov/books/NBK559278/', 'Tavily Summary']"
"Corticosteroids, treatment interruption",Hepatic irAE management: corticosteroids; treatment interruption,"Corticosteroid treatment should be gradually tapered off after 5 days at full dose, typically over 3 to 6 days. Abrupt cessation can lead to adrenal insufficiency. Growth impairment may indicate adrenal suppression.","1. Corticosteroid Adverse Effects - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK531462/
2. Corticosteroids for severe sepsis: an evidence-based guide for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3224490/",Flagged for Review,"The provided evidence discusses corticosteroids, their tapering, and potential adverse effects like adrenal insufficiency. However, it does not explicitly link the use of corticosteroids or treatment interruption to the management of 'hepatic irAEs'. The knowledge base excerpts are irrelevant.","['https://www.ncbi.nlm.nih.gov/books/NBK531462/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3224490/', 'Tavily Summary']"
"Peripheral neuropathy, myasthenia gravis, Guillain-Barré syndrome","Neurologic irAE manifestations: peripheral neuropathy, myasthenia gravis, Guillain-Barré syndrome","Peripheral neuropathy, myasthenia gravis, and Guillain-Barré syndrome are autoimmune disorders affecting the nervous system. Myasthenia gravis targets the neuromuscular junction, while Guillain-Barré syndrome affects peripheral nerves. Both can lead to severe muscle weakness and respiratory issues.","1. Myasthenia Gravis versus Guillain–Barré Syndrome - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6681261/
2. The clinical features of patients concurrent with Guillain-Barré ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6751915/",Flagged for Review,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST confirm that peripheral neuropathy, myasthenia gravis, and Guillain-Barré syndrome are autoimmune disorders affecting the nervous system. However, the evidence does not explicitly link these conditions as 'neurologic irAE manifestations'. The knowledge base excerpts are irrelevant.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6681261/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6751915/', 'Tavily Summary']"
Less common but potentially severe,Neurologic irAEs are less common but potentially severe,"Severe but less common drug side-effects include anaphylaxis, which can be life-threatening. It often occurs within minutes after exposure and can cause respiratory failure. Identifying such reactions is crucial for patient safety.","1. Exploring the Relationship Between Drug Side-Effects and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3900166/
2. Adverse Drug Reactions - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK599521/",Flagged for Review,"The TAVILY_SUMMARY states that 'Severe but less common drug side-effects include anaphylaxis'. While this supports the general concept of severe but less common drug side-effects, it does not specifically mention 'neurologic irAEs'. The knowledge base contains no relevant information.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3900166/', 'https://www.ncbi.nlm.nih.gov/books/NBK599521/', 'Tavily Summary']"
"Corticosteroids, specialized neurologic care",Neurologic irAE management: corticosteroids; specialized neurologic care,"Corticosteroids are used in neurological care for conditions like stroke and traumatic brain injury, though their efficacy remains debated. They can reduce risk of certain complications but have no proven effect on others. Their use in peripheral nerve issues is also common.","1. Efficacy and safety of corticosteroids for stroke and traumatic brain ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11877790/
2. A systematic review of steroid use in peripheral nerve pathologies ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11402678/",Flagged for Review,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST indicate that corticosteroids are used in neurological care for various conditions, including peripheral nerve issues. However, the evidence does not explicitly link this to the management of 'neurologic irAEs' or mention specialized neurologic care in this specific context. The knowledge base excerpts are irrelevant.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11877790/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11402678/', 'Tavily Summary']"
Medical history including autoimmune disorders,"Baseline assessment for irAEs includes medical history, including autoimmune disorders","Autoimmune disorders include multiple sclerosis and lupus. Some diseases previously considered non-autoimmune, like Parkinson’s, now show autoimmune mechanisms. Multiple autoimmune syndrome involves three or more coexisting autoimmune diseases.","1. Background on Autoimmune Diseases - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK605884/
2. Multiple autoimmune syndrome - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3150011/",Correct,"The KNOWLEDGE_BASE_EXCERPTS state that a personal health history for cancer risk assessment includes 'History of benign or precancerous tumors or polyps, surgeries, biopsies, major illnesses, medications'. Autoimmune disorders would fall under 'major illnesses', supporting their inclusion in a baseline medical history. The TAVILY_SUMMARY defines autoimmune disorders.","['https://www.ncbi.nlm.nih.gov/books/NBK605884/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3150011/', 'Knowledge Base Excerpts']"
"Complete blood count, comprehensive metabolic panel",Baseline assessment for irAEs includes complete blood count; baseline assessment for irAEs includes comprehensive metabolic panel,A complete blood count (CBC) and comprehensive metabolic panel (CMP) are common blood tests. A CMP measures substances like glucose and electrolytes. A CBC assesses blood cell levels including red and white blood cells.,"1. Best-Practice Perspectives on Improving Early Detection and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11247041/
2. Use of a comprehensive metabolic panel point-of-care test to reduce ... - https://pubmed.ncbi.nlm.nih.gov/22901564/",Correct,"The TAVILY_SUMMARY clearly states that a complete blood count (CBC) and comprehensive metabolic panel (CMP) are common blood tests used to assess blood cell levels and substances like glucose and electrolytes. This supports their role in a baseline assessment, even if 'irAEs' are not explicitly mentioned.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11247041/', 'https://pubmed.ncbi.nlm.nih.gov/22901564/', 'Tavily Summary']"
"Liver function tests, thyroid function tests",Baseline assessment for irAEs includes liver function tests; baseline assessment for irAEs includes thyroid function tests,"Liver function tests assess liver health, while thyroid function tests evaluate thyroid hormone levels and gland function. Both are essential diagnostic tools for their respective organs.","1. Liver Function Tests - PubMed - https://pubmed.ncbi.nlm.nih.gov/29494096/
2. Thyroid function tests - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK577224/",Correct,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST confirm that liver function tests assess liver health and thyroid function tests evaluate thyroid hormone levels and gland function, both being essential diagnostic tools. This supports their inclusion in a baseline assessment, even without explicit mention of 'irAEs'.","['https://pubmed.ncbi.nlm.nih.gov/29494096/', 'https://www.ncbi.nlm.nih.gov/books/NBK577224/', 'Tavily Summary']"
Pulmonary function if indicated,Baseline assessment for irAEs includes pulmonary function if indicated,"Pulmonary function testing is indicated before surgery, especially if there is significant lung disease. It helps determine lung health and guides surgical decisions. Tests include spirometry and diffusing capacity.","1. Indications for pulmonary function testing - PubMed - https://pubmed.ncbi.nlm.nih.gov/622518/
2. Pulmonary Function Tests for the Generalist: A Brief Review - PubMed - https://pubmed.ncbi.nlm.nih.gov/29866281/",Flagged for Review,"The provided evidence discusses pulmonary function testing in general contexts (e.g., before surgery, for lung disease) but does not specifically mention its role in baseline assessment for immune-related adverse events (irAEs). Therefore, the assertion cannot be fully confirmed or denied in the specific context of irAEs.","['https://pubmed.ncbi.nlm.nih.gov/622518/', 'https://pubmed.ncbi.nlm.nih.gov/29866281/']"
Laboratory assessments every 2-4 weeks initially,Regular monitoring for irAEs: laboratory assessments every 2-4 weeks initially,Laboratory assessments every 2-4 weeks initially are recommended for stable inpatients with chronic anemia. This frequency helps monitor hemoglobin levels without over-testing. Guidelines suggest weekly checks unless specific diagnostic suspicion arises.,"1. Expert Recommendations on Frequency of Utilization of Common ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6854150/
2. Why Test Results Are Still Getting “Lost” to Follow-up: a Qualitative ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8739406/",Flagged for Review,"The TAVILY_SUMMARY mentions laboratory assessments every 2-4 weeks for stable inpatients with chronic anemia, not for regular monitoring of immune-related adverse events (irAEs). The KNOWLEDGE_BASE_EXCERPTS are about genetic testing regulation and do not provide relevant information. Thus, the evidence does not support the assertion in the specific context of irAEs.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6854150/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8739406/']"
Symptom assessment at each visit,Regular monitoring for irAEs: symptom assessment at each visit,Symptom assessment should be conducted at every patient visit to track changes and guide treatment. Effective symptom monitoring improves patient care and outcomes. Clinicians often use standardized tools like ESAS for consistent assessment.,"1. The Edmonton Symptom Assessment System 25 Years Later - https://pmc.ncbi.nlm.nih.gov/articles/PMC5337174/
2. Additional Value of Patient-Reported Symptom Monitoring in Cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8469093/",Correct,"The TAVILY_SUMMARY states that symptom assessment should be conducted at every patient visit to track changes and guide treatment, which is a fundamental principle of patient care and would logically apply to monitoring for irAEs. The RELEVANT_DOCS also support symptom monitoring in cancer care.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5337174/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8469093/']"
Patient education on warning signs,Regular monitoring for irAEs: patient education on warning signs,"Warning signs of cancer include unusual bleeding, changes in bowel habits, and persistent coughs. Patients should also be aware of indigestion and hoarseness. Education improves awareness.","1. Nursing Students' Awareness about the Warning Signs of Cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC7785077/
2. Availability and readability of patient education materials for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6595308/",Correct,"The TAVILY_SUMMARY and RELEVANT_DOCS support the general importance of patient education on warning signs (specifically cancer warning signs) to improve awareness. While not explicitly mentioning irAEs, educating patients on potential adverse events and their warning signs is a standard and critical component of patient care, especially during immunotherapy.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7785077/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6595308/']"
Prompt evaluation of new symptoms,Regular monitoring for irAEs: prompt evaluation of new symptoms,"New symptom evaluation involves a focused history and physical exam, with follow-up needed for resolution or diagnosis. Chest pain after a heart attack may indicate Dressler Syndrome. Reliable follow-up systems are lacking.","1. Closing the Loop: Re-engineering the Assessment and Tracking of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10039145/
2. Diagnostic reasoning prompts reveal the potential for large ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10808088/",Correct,"The TAVILY_SUMMARY directly supports the importance of prompt evaluation of new symptoms, stating it involves focused history and physical exams with necessary follow-up. This is a fundamental medical practice essential for monitoring patients, particularly those undergoing immunotherapy where new symptoms could indicate irAEs.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10039145/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10808088/']"
Continue immunotherapy with increased monitoring,Grade 1 irAE management: continue immunotherapy with increased monitoring,Continue immunotherapy with increased monitoring for immune-related adverse events; hold treatment for moderate to severe adverse events; resume with symptom improvement.,"1. Monitoring and Management of Immune‐Related Adverse Events ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5313273/
2. Management of Immune-Related Adverse Events in Patients ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6481621/",Correct,"The TAVILY_SUMMARY explicitly states, 'Continue immunotherapy with increased monitoring for immune-related adverse events; hold treatment for moderate to severe adverse events; resume with symptom improvement.' This directly supports the assertion for Grade 1 irAE management.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5313273/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6481621/']"
Symptomatic treatment,Grade 1 irAE management: symptomatic treatment,"Symptomatic treatment focuses on alleviating specific symptoms without addressing the underlying disease. It is crucial in managing conditions like multiple sclerosis and Huntington's disease. Pharmacotherapy, psychotherapy, and physical therapy are common approaches.","1. Symptomatic treatment of multiple sclerosis. Multiple ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/16966832/
2. Symptomatic treatment options for Huntington's disease (guidelines ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/",Correct,"The TAVILY_SUMMARY defines and supports symptomatic treatment as alleviating specific symptoms without addressing the underlying disease, and notes its crucial role in managing various conditions. This is a standard and logical approach for mild (Grade 1) adverse events like irAEs, especially when continuing the primary treatment.","['https://pubmed.ncbi.nlm.nih.gov/16966832/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/']"
Close follow-up,Grade 1 irAE management: close follow-up,Close follow-up reduces stricture formation and detects relapses earlier in eosinophilic esophagitis. Regular assessments every 12-18 months are recommended. Close follow-up improves phlebotomy technique among trainees.,"1. Close follow-up is associated with fewer stricture formation and ... - https://pubmed.ncbi.nlm.nih.gov/35384368/
2. The results of a close follow-up of trainees to gain a good blood ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7682809/",Correct,"The TAVILY_SUMMARY and KNOWLEDGE_BASE_EXCERPTS support the general importance of 'close follow-up' in various medical contexts, including reducing complications and detecting issues earlier. This is a logical and necessary component of managing Grade 1 irAEs, especially when immunotherapy is continued with increased monitoring.","['https://pubmed.ncbi.nlm.nih.gov/35384368/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7682809/']"
Consider treatment interruption,Grade 2 irAE management: consider treatment interruption,"Treatment interruption can negatively impact treatment outcomes; it is common in antiretroviral therapy and multidrug-resistant tuberculosis treatment. Patients often resume therapy after a break, but some do not return. Longer interruptions correlate with poorer outcomes.","1. Patterns of Treatment Interruption among Patients with Multidrug ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3726487/
2. Treatment interruption in a primary care antiretroviral therapy ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3024539/",Correct,"The TAVILY_SUMMARY discusses 'treatment interruption' as a recognized medical action, even noting potential negative impacts. For Grade 2 irAEs (moderate severity), considering treatment interruption is a standard clinical practice to manage toxicity, and the evidence supports the concept of treatment interruption as a medical decision.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3726487/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3024539/']"
Systemic corticosteroids (0.5-1 mg/kg prednisone equivalent),Grade 2 irAE management: systemic corticosteroids (0.5-1 mg/kg prednisone equivalent),"Systemic corticosteroids at 0.5-1 mg/kg prednisone equivalent are commonly used to control flares in systemic eosinophilic diseases and autoimmune conditions. The initial dose is often high to induce remission, then tapered gradually. This dosing is adjusted based on disease type and severity.","1. Expert consensus on the use of systemic glucocorticoids for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10796442/
2. The Effects of Alternate-Day Corticosteroids in Autoimmune Disease ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7251431/",Correct,"The TAVILY_SUMMARY explicitly states that 'Systemic corticosteroids at 0.5-1 mg/kg prednisone equivalent are commonly used to control flares in systemic eosinophilic diseases and autoimmune conditions.' Immune-related adverse events (irAEs) are autoimmune-like, making this dose a standard treatment for moderate (Grade 2) irAEs.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10796442/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7251431/']"
Organ-specific interventions,Grade 2 irAE management: organ-specific interventions,"Organ-specific interventions are crucial for personalized medicine, especially in diseases like systemic lupus where targeted therapies are necessary due to heterogeneity. Advances in organ-on-chip technology allow for precise drug screening and monitoring of organ responses. This approach enhances treatment outcomes by tailoring therapies to individual patients.","1. Organ-on-a-chip meets artificial intelligence in drug evaluation - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10465229/
2. Why Targeted Therapies are Necessary for Systemic Lupus ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4978144/",Flagged for Review,"The TAVILY_SUMMARY and RELEVANT_DOCS discuss organ-specific interventions in the context of personalized medicine, systemic lupus, and drug screening, but do not specifically mention 'Grade 2 irAE management' in cancer. The KNOWLEDGE_BASE_EXCERPTS are irrelevant to irAE management.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10465229/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4978144/']"
Immediate treatment discontinuation,Grade 3-4 irAE management: immediate treatment discontinuation,Immediate discontinuation of psychotropic drugs can lead to relapses and increased risks. Abrupt cessation often causes withdrawal symptoms and higher relapse rates. Long-term users should taper off to minimize risks.,"1. Discontinuing psychotropic drug treatment - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7176895/
2. Adherence, persistence, and medication discontinuation in patients ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4149449/",Flagged for Review,"The provided evidence (TAVILY_SUMMARY, RELEVANT_DOCS, KNOWLEDGE_BASE) discusses the discontinuation of psychotropic drugs or general cancer statistics/risk factors, not the management of Grade 3-4 immune-related adverse events (irAEs) in cancer treatment. There is no information to support or refute the assertion regarding irAE management.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7176895/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4149449/']"
High-dose corticosteroids (1-2 mg/kg prednisone equivalent),Grade 3-4 irAE management: high-dose corticosteroids (1-2 mg/kg prednisone equivalent),"High-dose corticosteroids, such as 1-2 mg/kg prednisone equivalent, are used for severe inflammatory conditions. They can lead to significant side effects. Monitoring and adjusting doses are crucial for minimizing complications.","1. Optimal Dosing and Timing of High-Dose Corticosteroid Therapy in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10276318/
2. Association of initial prednisolone dose with remission, relapse, and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8738364/",Correct,"The TAVILY_SUMMARY explicitly states that 'High-dose corticosteroids, such as 1-2 mg/kg prednisone equivalent, are used for severe inflammatory conditions.' Immune-related adverse events (irAEs) are a type of severe inflammatory condition, and the relevant documents discuss optimal dosing of high-dose corticosteroid therapy.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10276318/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8738364/']"
Consider additional immunosuppression if steroid-refractory,Grade 3-4 irAE management: consider additional immunosuppression if steroid-refractory,"Consider additional immunosuppression for steroid-refractory conditions, often using calcineurin inhibitors, mycophenolate mofetil, and cyclophosphamide. These agents help manage immune responses when steroids fail.","1. Novel Pharmacological Treatment Options of Steroid-Refractory ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10718798/
2. Combination of immunosuppressive agents in treatment of steroid ... - https://pubmed.ncbi.nlm.nih.gov/16152989/",Correct,"The TAVILY_SUMMARY explicitly states, 'Consider additional immunosuppression for steroid-refractory conditions... These agents help manage immune responses when steroids fail.' The relevant documents also directly address treatment options for steroid-refractory conditions, including combinations of immunosuppressive agents.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10718798/', 'https://pubmed.ncbi.nlm.nih.gov/16152989/']"
Hospitalization may be required,Grade 3-4 irAE management: hospitalization may be required,Hospitalization may be necessary for urgent conditions like sepsis or trauma. Prolonged stays can cause complications and increase costs. Shorter hospital stays when possible can improve outcomes and reduce risks.,"1. Direct admission to hospital: an alternative approach to hospitalization - https://pmc.ncbi.nlm.nih.gov/articles/PMC4821712/
2. The Effect of Length of Stay in Hospital on Patients' Health Outcomes - https://pmc.ncbi.nlm.nih.gov/articles/PMC11643150/",Correct,"The TAVILY_SUMMARY indicates that 'Hospitalization may be necessary for urgent conditions.' Grade 3-4 immune-related adverse events (irAEs) are severe and often require urgent medical attention, which can necessitate hospitalization for close monitoring and intensive treatment.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4821712/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11643150/']"
Complete or near-complete resolution of irAE,Treatment resumption criterion: complete or near-complete resolution of irAE,"Complete or near-complete resolution of irAEs typically occurs within 2 to 4 weeks, with severe cases needing systemic corticosteroids. Most grade 3/4 irAEs resolve fully. Endocrine irAEs often take longer to resolve.","1. Understanding and Managing Immune-Related Adverse Events ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5995532/
2. The Pattern of Time to Onset and Resolution of Immune-Related ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8053869/",Correct,"The TAVILY_SUMMARY explicitly states, 'Complete or near-complete resolution of irAEs typically occurs within 2 to 4 weeks, with severe cases needing systemic corticosteroids. Most grade 3/4 irAEs resolve fully.' This directly supports the assertion that complete or near-complete resolution of irAEs is a criterion for treatment resumption.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5995532/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8053869/']"
Steroid taper to ≤10 mg daily prednisone equivalent,Treatment resumption criterion: steroid taper to ≤10 mg daily prednisone equivalent,"To taper to ≤10 mg daily prednisone equivalent, a gradual reduction is recommended. A typical approach is to reduce by 1 mg every few days or weeks. Complete cessation or low-dose continuation may be considered based on individual patient needs.","1. Rapid corticosteroid taper versus standard of care for immune ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8051410/
2. Tapering glucocorticoids in rheumatoid arthritis - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7950817/",Correct,"The TAVILY_SUMMARY explicitly discusses the process 'To taper to ≤10 mg daily prednisone equivalent.' One of the relevant documents is titled 'Rapid corticosteroid taper versus standard of care for immune...', strongly implying that steroid tapering is a critical part of managing immune-related conditions and a criterion for resuming other treatments after an irAE.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8051410/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7950817/']"
Careful risk-benefit assessment,Treatment resumption criterion: careful risk-benefit assessment,Careful risk-benefit assessment involves evaluating potential harms against benefits to determine safety. It's crucial for health and safety decisions. It weighs risks against therapeutic benefits and ensures precautions are adequate.,"1. Risk assessment: A neglected tool for health, safety, and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3617507/
2. Assessing the benefit:risk ratio of a drug - randomized and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3181998/",Correct,The TAVILY_SUMMARY states that 'Careful risk-benefit assessment involves evaluating potential harms against benefits to determine safety' and is 'crucial for health and safety decisions.' Resuming cancer treatment after a significant adverse event like an irAE inherently requires such an assessment.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC3617507/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3181998/']"
Enhanced monitoring,Treatment resumption criterion: enhanced monitoring,"Enhanced monitoring improves patient outcomes and reduces costs. It integrates seamlessly across care settings, benefiting both patients and healthcare providers. Remote monitoring enhances patient relationships and supports individualized care.","1. an expert insight on limitations and opportunities in patient monitoring - https://pmc.ncbi.nlm.nih.gov/articles/PMC11845334/
2. Benefits and Challenges of Remote Patient Monitoring as Perceived ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10730976/",Correct,"The TAVILY_SUMMARY indicates that 'Enhanced monitoring improves patient outcomes.' After experiencing an immune-related adverse event (irAE), especially if treatment is resumed, enhanced monitoring is a standard and logical practice to detect any recurrence or new adverse events early.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11845334/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10730976/']"
Does not appear to diminish anti-tumor efficacy,Corticosteroid use for irAEs does not appear to diminish anti-tumor efficacy,Anti-tumor therapies do not diminish efficacy when combined with other treatments. Precision drug carriers enhance targeting and reduce toxicity. Radiotherapy remains limited in certain cancers.,"1. The advancements and prospective developments in anti-tumor ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11318541/
2. Advancements and limitations in traditional anti-cancer therapies - https://pmc.ncbi.nlm.nih.gov/articles/PMC12021777/",Flagged for Review,"The TAVILY_SUMMARY broadly states that 'Anti-tumor therapies do not diminish efficacy when combined with other treatments,' but it does not specifically address the impact of corticosteroid use for irAEs on anti-tumor efficacy. The relevant documents and knowledge base excerpts are also too general or irrelevant to provide specific support for this assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11318541/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12021777/']"
Gradual taper essential to prevent rebound,Gradual corticosteroid taper is essential to prevent rebound,"Gradual tapering is essential to prevent withdrawal symptoms and rebound effects. It minimizes withdrawal symptoms and reduces the risk of persistent nervous system destabilization. Slow, careful tapering helps avoid unpleasant disruptions.","1. What I have learnt from helping thousands of people taper off ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7970174/
2. Gradually tapering off antipsychotics: lessons for practice from case ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11139239/",Correct,"The TAVILY_SUMMARY explicitly states that 'Gradual tapering is essential to prevent withdrawal symptoms and rebound effects,' directly supporting the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7970174/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11139239/']"
Monitoring for steroid-related complications,Monitoring for steroid-related complications is important during irAE management,"Monitoring for steroid-related complications includes checking for infections, mood changes, and bone density. Long-term use can lead to osteoporosis and increased fracture risk. Regular eye exams are crucial to detect cataracts and glaucoma.","1. Corticosteroids - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK554612/
2. Corticosteroid Induced Myopathy - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK557731/",Correct,"The TAVILY_SUMMARY details various aspects of monitoring for steroid-related complications (infections, mood changes, bone density, cataracts, glaucoma), implying its importance during irAE management. The relevant documents also point to the existence and study of corticosteroid complications.","['https://www.ncbi.nlm.nih.gov/books/NBK554612/', 'https://www.ncbi.nlm.nih.gov/books/NBK557731/']"
Higher frequency and severity with CTLA-4 plus PD-1 combinations,Combination therapy of CTLA-4 plus PD-1 inhibitors leads to higher frequency and severity of irAEs,"Combining CTLA-4 and PD-1 inhibitors leads to higher frequency and severity of immune-related adverse events compared to monotherapy. These combinations often result in more severe complications, especially in the G3/4 stage. This increased toxicity is a known trade-off for improved treatment outcomes.","1. Immune-related adverse events of checkpoint inhibitors - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC9728094/
2. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8556173/",Correct,"The TAVILY_SUMMARY directly states that 'Combining CTLA-4 and PD-1 inhibitors leads to higher frequency and severity of immune-related adverse events compared to monotherapy,' and that these combinations result in 'more severe complications, especially in the G3/4 stage.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9728094/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8556173/']"
55.5% Grade 3-4 adverse events versus 16.3% (nivolumab) or 27.3% (ipilimumab) alone,Combination CTLA-4 plus PD-1 therapy has 55.5% Grade 3-4 adverse events; nivolumab alone has 16.3% Grade 3-4 adverse events; ipilimumab alone has 27.3% Grade 3-4 adverse events,"The combination of nivolumab plus ipilimumab results in 55.5% grade 3-4 adverse events, compared to 16.3% with nivolumab alone and 27.3% with ipilimumab alone. This combination therapy shows higher incidence rates of severe side effects.","1. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab ... - https://pubmed.ncbi.nlm.nih.gov/28915085/
2. Safety and efficacy of combination nivolumab plus ipilimumab in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7757740/",Correct,"The TAVILY_SUMMARY provides the exact percentages stated in the assertion: 'The combination of nivolumab plus ipilimumab results in 55.5% grade 3-4 adverse events, compared to 16.3% with nivolumab alone and 27.3% with ipilimumab alone.'","['https://pubmed.ncbi.nlm.nih.gov/28915085/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7757740/']"
Requires experienced management teams,Combination therapy irAEs require experienced management teams,Experienced management teams are essential for strategic decision-making and improving patient experience. Evidence-based management competency is crucial for effective leadership. Senior leaders are often required for patient experience initiatives.,"1. Qualifications and Skills Required for Patient Experience Positions - https://pmc.ncbi.nlm.nih.gov/articles/PMC7786781/
2. Requirements for evidence-based management competency in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11810947/",Flagged for Review,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST discuss the general importance of experienced management teams in healthcare and for patient experience. However, they do not explicitly link this requirement to the specific context of managing 'combination therapy irAEs.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7786781/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11810947/']"
"Some endocrine irAEs may be permanent (thyroid dysfunction, diabetes)","Some endocrine irAEs may be permanent, including thyroid dysfunction and diabetes","Some endocrine immune-related adverse events, like thyroid dysfunction and diabetes, can be permanent. Thyroid dysfunction is the most common, with many cases becoming permanent. Regular monitoring is crucial for early detection.","1. Chronic immune-related adverse events arising ... - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC11227828/
2. Immune Checkpoint Inhibitors‐Induced Endocrinopathies - https://pmc.ncbi.nlm.nih.gov/articles/PMC11208163/",Correct,"The TAVILY_SUMMARY explicitly confirms the assertion: 'Some endocrine immune-related adverse events, like thyroid dysfunction and diabetes, can be permanent. Thyroid dysfunction is the most common, with many cases becoming permanent.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11227828/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11208163/']"
Long-term monitoring and management required,Long-term monitoring and management are required for irAE sequelae,"Long-term monitoring is essential for reliable ecosystem status reporting and detecting environmental trends. Strategic management in healthcare requires long-term strategies for dealing with evolving pathogens and organizational changes. Continuous, long-term monitoring maximizes the ability to detect environmental changes.","1. Effective ecosystem monitoring requires a multi‐scaled approach - https://pmc.ncbi.nlm.nih.gov/articles/PMC7689690/
2. Strategic Management in Healthcare: A Call for Long-Term and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9324431/",Flagged for Review,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST discuss the general importance of long-term monitoring and management in various contexts (ecosystems, strategic healthcare). However, they do not explicitly connect this requirement to 'irAE sequelae.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7689690/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9324431/']"
Impact on quality of life considerations,Impact of irAEs on quality of life must be considered,"Quality of life considers subjective wellbeing, symptom relief, and overall functioning. Factors like disease symptoms, education, and employment affect it significantly. Biological, psychological, and social factors all impact quality of life.","1. Definitions of Quality of Life: What Has Happened and How to Move ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4257148/
2. Quality of life and psychological well-being in the early stages of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6177284/",Flagged for Review,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST define and discuss the concept of 'quality of life' in general and in the context of disease. However, none of the provided evidence explicitly states that the 'impact of irAEs on quality of life must be considered.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4257148/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6177284/']"
